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2 Guidance for Psychological Therapists
BACP has been proud to be part of this 
important project to produce much-
needed guidance for our members.
The increase in the prescription of 
psychiatric drugs means many of our 
members are working with clients who 
are taking or withdrawing from them, 
and this can have an impact on their 
work.
We know from a recent survey of 
practising therapists that the majority 
feel ill-equipped to deal with these 
issues in a therapeutic setting.
This work will provide our members 
with up-to-date evidence and relevant 
guidance to help clients deal with the 
issues around taking or withdrawing 
from such drugs and understand the 
impact on clients and therapy.
We fully support the guidance and 
recommend it as a resource for our 
members and training providers.
Hadyn Williams  
Chief Executive Officer, BACP
The BPS fully endorses this guidance 
and is proud to have produced this 
in collaboration with our partner 
organisations.
We believe the official recognition 
of the increasing numbers of people 
being prescribed psychiatric drugs, 
and the difficulties withdrawing from 
them, is a positive step in helping both 
patients and psychological therapists.
Our members have consistently told us 
that they need guidance, information 
and training to help them work more 
confidently with clients either taking or 
withdrawing from prescribed drugs.
The evidence reviewed in this guidance 
provides an up-to-date summary of the 
main effects, adverse consequences 
and possible withdrawal reactions for 
each of the main classes of psychiatric 
drug.
We strongly recommend this guidance 
as a resource for our members. 
Sarb Bajwa  
Chief Executive, BPS
We are absolutely delighted to 
endorse this guidance document, 
which will be an invaluable resource 
to countless therapists both now and 
for years to come. It’s commonplace 
for UKCP members to be working 
with individuals taking psychiatric 
medication, yet many don’t feel 
properly equipped to discuss this 
in therapy. This guidance not only 
provides therapists with deeper 
knowledge of these medications, but 
will enable them to discuss confidently 
issues that are often central to the 
emotional distress that people they 
are working with are experiencing. 
The importance of this cannot be 
underestimated. It constitutes yet 
another important step in improving 
the care for the alarming number of 
people currently being prescribed 
psychiatric medication.




As a network led by people who 
experience long-term mental 
distress, during the creation of this 
guidance NSUN helped to provide the 
perspective of people directly affected 
by prescribed drug dependence. 
This guidance is needed more than 
ever, given the widescale prescribing 
of psychiatric drugs continues to 
increase.
It is vitally important to support 
the prevention of drug harms and 
dependency by offering practitioners 
crucial information about withdrawal 
management, the monitoring of 
symptoms, while supporting regular 
medication review and the limiting of 
unnecessary long term use. Above all 
people should have a choice about 
whether to take medication or not and 
have information and access to a range 
of alternatives.
NSUN welcomes the guidance 
and hopes it will help to reduce 
unnecessary long term use of 
psychiatric medication, while taking  




The National Counselling Society fully 
support this guidance, and commend 
the authors and organisatons involved 
in its compostion. The increase in 
psychiatric drug prescriptions should 
be viewed through a critical lens. The 
research laid out in this guidance 
clearly indicates an urgent need for 
more education on the impact of 
such prescribing, as well as critical 
evaluation of the paradigm by which 
it is enabled. As medication is being 
used in a wide variety of mental health 
settings, our members will have 
experienced the impact of these drugs 
upon clients and therapy. In many 
cases, therapists may be unaware 
how medication, and psychaitric 
drug withdrawal itself, can subtly yet 
significantly impact the therapeutic 
process. We would ideally like to see 
all therapists and allied professionals 
develop greater awareness of the 
potential impact of prescribed drug 
dependency. We strongly encourage 
our members and training providers 
to familiarise themselves with this 
guidance.
Vicky Parkinson  
Chief Executive Officer, NCS
I am delighted that the APPG for 
Prescribed Drug Dependence has 
brought together the leading therapy 
organisations and relevant experts to 
produce this guidance, which will help 
to tackle the problem of prescribed 
drug dependence highlighted by Public 
Health England’s recent report. It is 
clear that many people end up taking 
unnecessary and potentially harmful 
psychoactive drugs for years, and that 
there has been inadequate recognition 
of the problem and very little support 
for those wishing to withdraw. This 
guidance, along with the other 
recommendations from PHE such as a 
national helpline, are therefore part of 
an overdue response to this important 
public health issue.
Sir Oliver Letwin MP  
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1. Introduction
 Dr  James Davies, Professor Rosemary Rizq & Dr Anne Guy 
In September 2017 the All-Party Parliamentary 
Group for Prescribed Drug Dependence (APPG 
for PDD) met senior representatives from Public 
Health England (PHE) to present data and research 
(including work undertaken by the British Medical 
Association, 20161) revealing the mounting 
social and individual problems associated with 
prescribed drug dependency and withdrawal.  
As a result, Steve Brine MP, then Under Secretary 
of State for Public Health and Primary Care, 
commissioned PHE to undertake the largest review 
to date into prescribed drug dependency and 
withdrawal. This comprehensive review has now 
been published and has called for the following: 
■■ A 24-hour national helpline and associated 
website to provide advice and support for 
those adversely affected by prescribed drug 
dependency and withdrawal.
■■ Updated clinical guidance and improved  
doctor training. 
■■ Provision for better patient-information about 
drug risks and benefits, as well as alternatives 
such as therapy and social prescribing.
■■ Further research into the nature and severity of 
withdrawal and its successful treatment.
■■ Appropriate support from the NHS for patients, 
including dedicated support services.2
In May 2019 the Royal College of Psychiatrists 
issued a new position statement on antidepressant 
withdrawal,3 following new research4,5 and 
campaigning by people who have been harmed by 
psychiatric drugs, (also known as the prescribed-
harm community), the Council for Evidence-based 
Psychiatry (CEP) and the APPG for PDD. The 
Royal College’s statement acknowledged that 
antidepressant withdrawal is more widespread 
than previously thought and can be more severe 
and protracted than our current clinical guidelines 
acknowledge.6 Joining the campaigners, the 
Royal College also called for NICE to update its 
guidelines to better reflect the evidence base. 
In October 2019, NICE heeded calls by CEP, the 
APPG for PDD and the RCPsych to remove its 
previous advice that antidepressant withdrawal 
is usually mild, self-limiting and resolving over 
1-week, and acknowledge that, while many people 
may experience only mild withdrawal, there is 
‘substantial variation’ in people’s experience ‘with 
symptoms lasting much longer (sometimes months 
or more) and being more severe for some patients’.7
While these changes largely relate to 
antidepressants (and, in the case of PHE, 
benzodiazepines, Z-drugs, GABA-ergic medicines 
and opioid pain medications), they demonstrate 
that thinking around psychiatric drug withdrawal 
has shifted considerably since early 2018. Today, 
in the UK, it is now widely acknowledged that 
we previously underestimated the incidence, 
severity and duration of withdrawal effects and 
the extent to which those people affected need 
support. Relevant organisations are therefore 
now considering how best to support people who 
have suffered harm. PHE has recommended a 
helpline, better training for doctors on appropriate 
withdrawal management, and more support for 
GPs; recommendations now supported by the Royal 
College of General Practitioners, the Royal College 
of Psychiatrists , the British Medical Association and 
all the organisations involved in either the creation 
and/or endorsement of this current document (i.e. 
the APPG for PDD, CEP, the British Association for 
Counselling and Psychotherapy (BACP), United 
Kingdom Council for Psychotherapy (UKCP), 
the British Psychological Society (BPS), and the 
National Counselling Society (NCS)).8
In endorsing this document these organisations 
are taking their share of responsibility for 
addressing the withdrawal problem, by equipping 
psychological therapists with the information and 
guidance necessary to help them better inform 
and support clients who are either taking or 
withdrawing from psychiatric drugs. 
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1.1 What are the aims of this guidance?
Psychiatric drugs such as antidepressants and 
antipsychotics are more prescribed today than at 
any other time in our profession’s history. Around a 
quarter of the UK adult population was prescribed 
a psychiatric drug last year, with around 16% being 
prescribed antidepressants (2016–17) (DHSC 2018).9 
The steep rise in prescriptions (which have broadly 
doubled in the last 20 years10) means that most 
therapists now work with clients who have either 
taken or are taking psychiatric drugs. These drugs will 
produce effects that may or may not be experienced as 
positive by the individual in question. These drugs can 
also produce adverse effects, while many clients will 
struggle to reduce or withdraw from them. To date, the 
lack of summarised evidence, information and training 
for therapists who work with such clients, constitutes 
a growing problem for therapists whatever their 
modality or setting in which they work. 
This lack of knowledge and training is reflected in 
data gathered from a 2018 survey of approximately 
1,200 practising therapists – all members of BPS, 
UKCP or BACP. While 96.7% of the therapists 
reported that they currently work with at least 
one client who is taking a psychiatric drug (e.g. 
an antidepressant, anxiolytic or antipsychotic), 
only 7.3% reported that their training equipped 
them ‘very well’ in responding to questions about 
withdrawing from or taking psychiatric drugs. 
Additionally, 42.5% of therapists reported feeling 
a lack of confidence in knowing where to find 
appropriate information (or ethical or professional 
guidance) on how to work in the most therapeutic 
way with people taking or withdrawing from 
psychiatric drugs. This lack of support, training 
and information may well explain why 93.1% of 
the therapists surveyed reported they would find it 
either ‘useful’ or ‘very useful’ to have professional 
guidance to help them work more competently and 
confidently with such clients.
It is therefore now essential for the therapeutic 
professions to respond jointly to this growing need 
for clear guidance about how best to work with and 
support clients either taking or withdrawing from 
psychiatric drugs. This guidance seeks to provide 
such support in two distinct ways: 
Firstly, it aims to support therapists in deepening 
their knowledge and reflection on working with 
the said client group. The evidence reviewed in 
this guidance means that therapists will now 
have access to an up-to-date summary of the 
main effects, adverse consequences and possible 
withdrawal reactions for each of the main classes 
of psychiatric drug. Using this evidence base, the 
guidance aims to empower therapists to talk about 
prescribed drugs with their clients (and where 
appropriate with prescribers) as well as to identify 
and work with the impact that psychiatric drugs 
may exert on the process of therapy itself. 
Secondly, it invites therapists to familiarise 
themselves with core issues relating to the role 
of psychiatric drugs in therapy. Many therapists 
prefer to avoid discussing the client’s relationship 
to prescribed psychiatric drugs, assuming any 
consideration or discussion of this relationship 
is best left to prescribers. This preference may 
be rooted in feelings of anxiety about navigating 
alternative views on psychiatric drugs, not 
having sufficient knowledge to engage other 
professionals, or feeling uncertain about managing 
the boundaries of one’s professional competence 
or role. Indeed, while this guidance agrees that it is 
not the role of the therapist to tell a client either to 
take, continue to take or withdraw from psychiatric 
drugs, nor to decide when, if or what drugs need to 
be withdrawn, this guidance actively encourages 
therapists to support clients in whatever 
decisions they reach with their prescribers. It also 
encourages them to engage with the views and 
perspectives of other professionals whilst at the 
same time honouring the distinctive and important 
contributions therapists can make in supporting 
a client through withdrawal from psychiatric 
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drugs. Finally, it is also important to note that this 
guidance does not aim to disrupt or comment on 
the NICE guidelines as used by medical doctors, 
which, for example, recommend drugs for many 
conditions in addition to psychological therapies. 
However, it is also important to note that NICE’s 
recommendations are continually being updated 
in the light of new debates, disputes, interests and 
evidence. For example, at the time of writing the 
guideline on depression (CG90) is undergoing an 
additional period of consultation in response to 
criticisms from a coalition of stakeholders, which 
includes many therapy organisations.
1.2 Who is this guidance for?
This guidance aims to be relevant to a wide variety 
of theoretical models as well as professional and 
personal positions held by members of the main 
accrediting bodies. These are: BPS, BACP and UKCP 
and NCS. It is clear that therapists’ professional 
training as well as their personal and therapeutic 
experience means there are likely to be significant 
differences in how they think about and work with 
the various issues relating to prescribed drugs. Many 
therapists will be highly critical of their use whilst 
others may believe prescribing privileges should 
be extended to therapists.11 It is also important to 
note that, in addition to holding different views, 
therapists also operate within a variety of settings. 
These may include NHS primary care, secondary 
care and specialist services; statutory or third sector 
services; private practice and other private sector 
services and agencies. Different professional settings 
will shape therapists’ decision-making as well as 
the opportunities available to them for working 
collaboratively with other healthcare professionals. 
Given this rich diversity of professional 
backgrounds, trainings and settings, this guidance 
does not aim to be prescriptive nor attempt to offer 
a set of therapeutic ‘competences’ or ‘guidelines’. 
Rather, by using the available evidence base, 
therapists of all persuasions will be invited to 
consider a number of key questions and concerns 
relevant to their therapeutic work with clients who 
are either taking or withdrawing from prescribed 
psychiatric drugs. 
Therapists will also be invited to reflect on their 
own professional background and training, their 
personal and practice-based experiences as well 
as their relationship to and understanding of the 
‘medical model’ and its associated interventions. 
While this guidance is therefore written for 
therapists, much that is included may be of 
professional interest to those working in allied 
helping professions (e.g. nursing; occupational 
therapy; social work; and those in relevant caring 
and medical roles). It is therefore hoped that allied 
professions might be able to make use of some 
or all of these materials in ways that will serve 
their clients’ interests while at the same time best 
honouring their own professional and ethical values.
1.3 The medical model and the emerging crisis
Whatever an individual’s view regarding the best 
model with which to understand and respond to 
emotional and mental distress, it is clear that since 
the mid-2000s there has been growing professional 
and public criticism of the utility and validity of the 
‘biomedical’ model and associated interventions – a 
model in which distress has been assumed by some 
to be rooted in an underlying disease mechanism 
or organic pathology. It is important to note, 
however, that such criticism has been advanced 
not only by non-medical professionals. Indeed, 
many of its proponents stem from the medical and 
psychiatric community itself, where today there is 
a diversity of views regarding the utility and validity 
of this model. In short, the lines of debate cut 
through all mental health disciplines, and so can 
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no longer be framed in disciplinary polarised ways. 
Furthermore, such debates now resonate beyond 
the disciplines themselves, in ever larger sections 
of the academic, political, media and service-user 
communities, and similarly stem from increasing 
concern that our mental health services are not 
just failing due to lack of investment, but owing 
to peoples’ emotional and behavioural difficulties 
being over, unduly and unhelpfully medicalised. 
It has been argued that over-medicalisation has 
led, in turn, to the consequent over-prescribing of 
psycho-pharmaceuticals,12,13 rising mental health 
stigma,14 the proliferation of unnecessary and 
harmful long-term prescribing, and the crowding 
out of effective alternatives that people both need 
and want.15,16 These arguments have dovetailed with 
others that pertain to the medical model, such as 
the value or otherwise of psychiatric diagnosis more 
broadly17–21; the role of conflicts of interest between 
the pharmaceutical industry, prescribers and drug-
researchers22–24; the lack of biomarkers for ‘mental 
disorders’ or evidence for the chemical imbalance 
theory of mental distress 25,15; the evidence that 
antidepressants may yield no clinically significant 
benefits over placebos for most people despite ever-
rising prescriptions30–33; the expanding knowledge 
of withdrawal problems34,4,5, and the growing 
understanding that long-term use of psychiatric 
drugs is often associated with poor outcomes and 
increased harms3. These concerns, criticisms and 
areas of debate have been articulated, advanced and 
engaged with not only by psychologists, academics 
and therapists, but also by many psychiatrists 
who have seen in the psychiatric perspectives and 
treatments once championed in the 1990s, many 
promises left unrealised.  
Each individual involved in the composition of 
this guidance will have a particular view on these 
separate debates and criticisms, as will its readers. 
As no guidance can ever be written in a vacuum, 
and as many contributors have been involved 
in some of the above debates, it is important to 
be explicit about how these criticisms may have 
informed the content of this guidance.
The first obvious influence is that this guidance 
departs from the increasingly contested belief, both 
within psychiatry and beyond, that psychiatric drugs 
‘cure’ mental ‘illnesses’ that are rooted in brain 
pathologies. Rather, it takes the view that psychiatric 
drugs, like all other psychoactive substances, alter 
states of mind in ways that may or may not be 
experienced as helpful by the individual in question. 
Also, like many other psychoactive substances, 
psychiatric drugs can cause side, adverse and 
withdrawal effects that can complicate a person’s 
recovery, certainly if not acknowledged as such.
The second influence concerns the language used 
in this guidance. Medical terms such as ‘illness’, 
‘disorder’, ‘pathology’ and ‘dysfunction’ do not 
merely describe the suffering they depict but shape 
how it is understood, managed and perceived. 
Medical language imports meanings that may 
not always accord with how many psychological 
therapists frame distress. A common view in the 
psychological community is that medical language 
broadly assumes what it should rather demonstrate: 
that the suffering it describes is in fact medical 
‘illness’, ‘disorder’ or ‘pathology’. Rather than seeing 
suffering as an illness, many therapists would 
understand it as a rational reaction to hurt, trauma 
or impairment. In many cases it may be a call for 
change or an instance of what may be termed ‘social 
suffering’ – namely, a non-pathological, distressing, 
yet understandable human response to harmful 
social, political, relational and environmental 
conditions (past or present). 
Given that medical language carries meanings 
that extend well beyond the way in which many 
therapists understand psychological distress, 
including meanings that assume, rather than 
demonstrate the biological causes of mental 
distress, this guidance will avoid medical 
terminology where possible. Instead, it will 
adopt non-medical descriptors, such as those 
recommended by the British Psychological 
Society.36 There are occasions, however, where 
the meaning of alternative words is not clear 
and so some language has been retained for the 
sake of simplicity and readability, but this should 
not be taken as an acceptance of its full medical 
implications. Quotation marks have been used in 
some places to denote a disputed term.
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1.4 Glossary
In this guidance the terms below will be preferred 
and used for the following reasons:
■■ Therapists – this term is used to denote the 
range of different psychological therapists 
represented by the bodies endorsing this 
guidance (e.g. counsellors, clinical and 
counselling psychologists, psychotherapists, 
psychoanalysts). This term is used simply for the 
matter of convenience, and its usage in no way 
intends to minimise or overlook the differences 
that may exist between different therapeutic 
professionals and modalities. 
■■ Psychiatric drugs – this term is used 
throughout to refer to all prescribed psycho-
pharmaceuticals including antidepressants, 
antipsychotics, stimulants, tranquilisers, 
anxiolytics etc. regardless of who has  
prescribed them.
■■ Client: this term is used throughout this 
guidance to refer to anybody meeting a 
therapist for therapy.
■■ Dependence – this term is used throughout this 
guidance to denote physical dependence on a 
drug. This is not to deny the relevance of meanings 
and beliefs and the psychological effects of 
taking and stopping psychiatric drugs, but only to 
specify that the research covered in the evidence 
sections of this guidance predominately relates to 
dependence in its physical form.
Also, this guidance draws the distinctions between 
the following terms:
■■ ‘Dependence’ rather than ‘addiction’ – this 
distinction is drawn for two reasons: the 
term ‘addiction’ is generally associated with 
dependence on non-prescribed substances 
(such as illicit drugs and alcohol). As such it may 
be read, rightly or wrongly as having negative 
connotations. In contrast, ‘dependence’ largely 
avoids those connotations, which is why the 
prescribed-harm community, in general, prefers 
the term, as it better captures the experience of 
becoming dependent by following a prescriber’s 
recommendations. Secondly, and following 
Public Health England’s preferred language, 
dependence refers to an adaptation to the 
repeated exposure to a drug. This is usually 
characterised by tolerance and withdrawal, 
(though tolerance may not occur with some 
drugs).2
■■ Psychiatric ‘drugs’ rather than psychiatric 
‘medication’ – this distinction is drawn since 
the term ‘medication’ is defined as a substance 
that is used to cure or treat a disease or 
medical condition, or to alleviate symptoms of 
an illness.37 As it is contestable as to whether 
psychiatric drugs either ‘cure’ or ‘treat’ a 
‘disease’ or a ‘medical’ condition or ‘illness’, the 
term ‘drugs’ is preferred, in particular as the 
definition for drugs (i.e. ‘a substance which has 
a physiological effect’38), better captures the 
evidence-base for how psychopharmaceuticals 
work.
■■ Drug-Centred vs Disease-Centred model of 
drug action – this distinction is drawn to clarify 
how psychiatric drugs work: the disease model 
assumes psychiatric drugs work by reversing or 
partially reversing an underlying ‘disease’, while 
the drug-centred model asserts that psychiatric 
drugs work by producing physiological and 
psychological effects, as all psychoactive 
substances do, which may or may not be 
experienced as beneficial. This guidance prefers 
the drug-centred over the disease-centred 
model, as it better captures the evidence-base 
as to how psychopharmaceuticals work. This is 
further expanded on in section 2.
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1.5 Scope
This guidance relates to psychiatric drugs that have 
been prescribed in the course of clinical practice. 
It does not tackle illicit or recreational drug use 
(nor prescribed painkiller/opioid use) and any 
associated problems. Naturally, such hard and fast 
distinctions may belie clinical complexity, given 
some clients may present with multiple prescribed 
and non-prescribed dependencies. 
A further area beyond scope is first, the impact 
of other physical health conditions on both drug 
and talking therapy, and conversely, the impact 
of prescribed psychiatric drugs on physical 
health (beyond those problems associated with 
dependence and withdrawal). As important as 
these areas are, the number of variables involved 
renders making any general statements unfeasible, 
beyond recommending that such adverse reactions 
must always be discussed with the prescriber. 
Finally, systemic, child and family therapies, as 
well as social prescribing are not discussed in 
this guidance, although we clearly recognise the 
vital contribution they make in this area. The 
parameters of a project must be drawn somewhere, 
and ours reflect pragmatic constraints rather than 
any implied grading of the relative importance of 
the topics omitted.
1.6 How to use the guidance 
It is suggested that the sections giving general 
information should where possible be read in full, 
whilst readers might selectively read information 
relating to specific classes of drugs in sections 4 
and 5, depending on which they are most likely to 
encounter, or on an as-needed basis.
This guidance aims to empower and support 
conversations often already taking place 
between therapists and their clients. Therapists 
will need to decide for themselves whether, and 
to what extent, they wish to use this guidance 
in the context of their therapeutic work. These 
decisions will depend on their theoretical 
modality, practice setting and the individual 
needs of the client. The client’s agency, as 
always, should be supported and respected 
at all times. Clients should be encouraged to 
discuss withdrawal from prescribed psychiatric 
drugs with a knowledgeable prescriber who 
can give medical advice, oversee and manage 
any withdrawal process appropriately. While 
this guidance advocates the importance 
of informed client choice based on full 
information about potential benefits and risks, 
it does not advocate therapists telling their 
clients to take, not take, stay on or withdraw 
from psychiatric drugs. These matters should be 
left to the prescriber and client to decide.
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2.  Introduction for therapists on how 
psychiatric drugs work
  Professor Joanna Moncrieff & Dr Tom Stockmann 
2.1 The place of prescribed drugs in Mental Health Services
Drugs have been the mainstay of psychiatric 
treatment since the 1950s. Nowadays, most people 
who receive specialist psychiatric services are 
prescribed one sort of psychiatric drug, and often 
several. General practitioners prescribe such drugs 
to millions of other people.
Before the 1950s, drugs, especially sedatives, 
were used extensively in psychiatric hospitals 
and prescribed to outpatients. However, they 
received little attention because they were 
generally regarded simply as a means of chemical 
restraint.1,2 However, during the 1950s and 
1960s new ranges of drugs were introduced 
into psychiatry. Views about how they worked 
gradually transformed: they came to be seen 
not simply as inducing useful but crude states of 
sedation and passivity, like the older style drugs, 
but as acting to reverse underlying psychiatric 
diseases. 
The naming of psychiatric drugs reflects this 
assumption; so ‘antipsychotics’ are thought to 
act on the biological abnormality that produces 
symptoms of psychosis or ‘schizophrenia’, 
‘antidepressants’ are thought to reverse the basis 
of depressive symptoms, ‘mood stabilisers’ are 
thought to help rectify the process that gives rise to 
abnormal fluctuations of mood and ‘anxiolytics’ are 
thought to address the biological mechanism that 
creates anxiety. 
2.2 How do psychiatric drugs work?
The assumption that the major types of drug 
used in psychiatry work by reversing or partially 
reversing the underlying disease process may 
be termed the ‘disease-centred’ model of drug 
action. There is little evidence to support this 
model, however. An alternative ‘drug-centred’ 
model states that psychiatric drugs produce 
a global state characterised by a range of 
physiological and psychological alterations, 
which are superimposed on, and interact with, the 
‘symptoms’ of mental ‘disorders’ in ways that may 
or may not be perceived as beneficial.
2.2.1 The disease-centred model
The disease-centred model has been imported 
from general medicine, where most modern drugs 
are correctly understood in this way. Although 
most medical treatments do not reverse the 
original disease process, they generally act on the 
physiological processes that produce symptoms, 
or on specific physiological targets to reduce 
symptoms via an identified mechanism. Thus, 
chemotherapeutic agents counteract the abnormal 
cell division that occurs in cancer, while analgesics 
act on the physiological processes that produce 
pain. Some anti-hypertensives (medications for 
high blood pressure) relax blood vessels by acting 
on specific receptors to lower blood pressure, 
even though the cause of the hypertension may be 
unknown. 
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The disease-centred model of drug action is closely 
related to theories that mental health conditions 
are caused by abnormalities in particular brain 
chemicals, or a ‘chemical imbalance’. Chemicals 
that facilitate or inhibit the transmission of nervous 
impulses with the brain are called ‘neurotransmitters’. 
Following the observation that psychiatric drugs 
act on neurotransmitter systems, it started to be 
proposed that an abnormality in these systems might 
be the cause of psychiatric disorders. The best-known 
example of this way of thinking is the dopamine 
hypothesis of ‘schizophrenia’, which followed from the 
discovery that early antipsychotics reduce dopamine 
activity (dopamine is a brain-based neurotransmitter). 
The idea that depression is caused by a deficiency 
of the neurotransmitters serotonin or noradrenalin 
is another example sometimes referred to as the 
‘monoamine theory’ of depression (serotonin and 
noradrenalin are both classified as monoamine-type 
brain chemicals or neurotransmitters). 
Some researchers still support the dopamine 
hypothesis of ‘schizophrenia’3, and some 
antipsychotic drugs certainly affect dopamine 
transmission, although others have only weak 
effects on dopamine. However, evidence that 
there are dopamine abnormalities in people with 
psychosis or ‘schizophrenia’ prior to starting drug 
treatment is inconsistent.4,5 Few people now accept 
the idea that depression is caused by a serotonin or 
noradrenaline abnormality, and again the evidence 
is highly inconsistent.6 
In fact, despite decades of intensive research on 
all sorts of aspects of biological science including 
various neurotransmitters, genetics and neural 
networks, definitive causes of mental health 
difficulties have not been established. Recently, 
the former head of the US National Institute of 
Mental Health admitted that $20 billion of funding 
for investigating the neuroscience and genetics 
of mental disorders, had produced no benefit to 
people suffering from mental health difficulties.7 
There is also little evidence that drugs that are 
meant to have specific effects in certain conditions, 
according to the disease-centred model, are 
better than other sorts of drugs.8,9 For example, 
numerous drugs that are not considered to 
be antidepressants have been shown to have 
equivalent effects to antidepressants in people 
with depression, including anti-anxiety drugs like 
diazepam (Valium), stimulants and antipsychotics. 
Antipsychotics are not clearly distinguished from 
other sedatives in studies of people diagnosed 
with psychosis or schizophrenia10, and lithium is 
not superior to other drugs in studies in people 
diagnosed with acute bipolar or manic states.11 In 
addition, two studies that attempted to distinguish 
between the effects of lithium and antipsychotics 
in people with different diagnoses (bipolar or 
affective disorder versus non-affective psychosis or 
schizophrenia) failed to do so.12,13 
Even if the mechanisms of mental health difficulties 
could be identified, however, we would still be 
uncertain whether or not psychiatric drugs impact 
symptoms by affecting those mechanisms. This is 
because to draw this conclusion, we somehow need 
to discount the effect of the general mental and 
behavioural alterations that these drugs are known 
to cause in anyone, regardless of whether or not they 
have an identified neurochemical abnormality. 
The drug-centred model of drug action suggests it 
is these alterations that are significant. 
2.2.2 The drug-centred model
This model highlights that psychiatric drugs can 
be considered to be ‘psychoactive’ drugs in the 
sense that they are substances that cross the 
blood/brain barrier and affect brain functioning. 
By doing so they produce an altered global 
state characterised by a range of physiological, 
psychological and behavioural changes. There is 
no essential distinction, according to this view, 
between drugs used for psychiatric treatment and 
recreational psychoactive drugs like alcohol and 
cocaine. All psychoactive drugs produce altered 
physical and mental states that can influence the 
way people think, feel and act, with different sorts 
of substances having different sorts of effects. 
The effects of recreational drugs are experienced 
as desirable by at least some people, but some 
drugs produce mental and physical changes that 
are generally experienced as unpleasant (e.g. 
antipsychotics and lithium). The drug-centred 
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model suggests that it is these psychoactive 
properties that explain the changes seen when 
drugs are given to people with mental health 
difficulties. Drugs like benzodiazepines and alcohol, 
for example, reduce arousal and induce a usually 
pleasant state of calmness and relaxation. This 
state may be experienced as a relief for someone 
who is intensely anxious or agitated. But taking 
a drug like this does not return the individual to 
‘normal’, or to their ‘pre-symptom’ state. The drug-
induced state is superimposed on the ‘symptoms’ 
and is found to be preferable, either by the sufferer 
themselves, or by others.
In psychiatry, an accepted example of a drug-
centred treatment is the recognised benefits of 
alcohol in social anxiety (also referred to as social 
phobia). Alcohol can help people with social 
anxiety because a state of mild intoxication is 
associated with a lessening of social inhibitions. 
Rather than reversing an underlying biochemical 
imbalance, alcohol works because it substitutes the 
alcohol-induced behavioural and emotional state, 
with its characteristic lessening of inhibitions, for 
the previous anxious state. 
The brain reacts to the presence of a drug in various 
ways, and often adapts to the drug in ways that 
counteract the drug’s effects. Therefore, the effects 
that a drug has when it is first taken may wear off 
and increasing doses may be required to sustain 
the initial effects. Sometimes this is referred to as 
‘tolerance’. Biological adaptations to the presence 
of a drug are also responsible for withdrawal 
symptoms. When a drug that has been taken for 
some time is stopped, the body’s adaptations are 
no longer opposed by the presence of the drug 
and can give rise to unpleasant and debilitating 
sensations and experiences. 
Whereas the disease-centred model assumes that 
psychiatric drugs help to restore normal brain 
functioning, the drug-centred model stresses that 
taking a drug creates an abnormal biological state. 
Some effects associated with this altered state may be 
perceived as worthwhile in certain situations. Often 
however, by distorting normal bodily function, drugs 
have an adverse impact. They may therefore do more 
harm than good, particularly in the long term.
Much of the material in this section is a condensed 
and updated version of material contained in A 
Straight Talking Introduction to Psychiatric Drugs by 
Joanna Moncrieff, published by PCCS Books, and 
used with the publisher’s kind permission.
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3. Implications for therapeutic practice
  Professor Rosemary Rizq, with Professor Tim Bond,  
Dr Anne Guy, Dr David Murphy, Paul Sams,  
Professor Marcantonio Spada & Georgina Whitney
Having introduced the broader context and the 
different ways of viewing prescribed psychiatric 
drugs in sections 1 and 2 of this guidance, this 
section considers the implications for therapeutic 
practice. It invites therapists to reflect on their 
own position in relation to the biomedical 
paradigm and to consider a number of key issues 
in relation to prescription psychiatric drugs. 
Practice-related guidance includes suggestions 
for working with clients at different stages of 
their prescribed drug journey: those who are 
considering taking prescribed drugs; those who 
are considering withdrawing; and those who are 
already withdrawing and who may be experiencing 
withdrawal reactions. For ease of reference, brief 
summaries of the evidence presented in sections 4, 
5 and 6 are included.
3.1 The biomedical paradigm and its relationship to 
different therapeutic modalities 
From the outset, it is important to acknowledge 
some of the tensions that exist between the 
biomedical model currently dominating healthcare 
and the psychological paradigm adopted by 
therapists working with those in emotional distress. 
As stated in the introduction, the growing 
medicalisation of distress in society reflects the 
widespread assumption that mental illness exists 
in the same way as physical illness and can be 
diagnosed and treated like flu or a virus. The idea 
that psychological distress may be understood as 
the symptom of an underlying disease process or 
organic abnormality, to be treated with prescribed 
psychiatric drugs, reflects a disease-centred model 
of practice in line with the biomedical approach to 
science, policy and practice currently dominating 
mental health services.
Of course, the prevalence of the biomedical 
approach does not exclude mental health services 
advocating better access to psychological therapies, 
particularly where therapy is assumed to be 
complementary to the use of psychiatric drugs. 
However, the majority of psychological therapists 
hold a framework for understanding emotional 
pain that conflicts with the prevailing disease-
centred model of practice. Therapists from all 
professional backgrounds draw from paradigms 
that predominantly emphasise the psychological 
and psychosocial aspects of experience thought 
to underpin mental suffering, rather than on 
models that emphasise notions of deficit, 
symptomatology and medicalisation. Indeed, there 
has been a growing professional movement in 
the psychotherapeutic field away from a disease-
centred model of practice and the use of prescribed 
psychiatric drugs. For example, there have been 
recent attempts to offer alternative ways of 
understanding mental distress (e.g. the Power Threat 
Meaning Framework1). The BPS2, too, has stated that 
‘clients and the general public are negatively affected 
by the continued and continuous medicalisation 
of their natural and normal responses to their 
experiences; responses…which do not reflect illnesses 
so much as normal individual variation…This misses 
the relational context of problems and the undeniable 
social causation of many such problems’ (p2). 
Underpinning these and other critiques lies the call 
for a ‘paradigm shift’ within mainstream psychiatry3 
that takes account of the complex interplay of social, 
cultural, economic and psychological forces that are 
thought to result in much mental distress today.
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However, the continuing cultural dominance 
of the biomedical approach means that it 
is likely to shape the attitudes, beliefs and 
values of therapists from all psychotherapeutic 
backgrounds and to pervade their practice in 
both explicit and implicit ways. Whilst Elkins 
(2009)4 suggests that the ‘medical model’ in the 
psychological therapies is essentially an analogy: 
‘a descriptive schema borrowed from the practice 
of medicine and superimposed on the practice of 
psychotherapy’ (pp67–71), it is clear that different 
psychotherapeutic disciplines will understand, 
take up and respond to it in different ways. For 
example, some have argued that the field of 
applied psychology is significantly permeated by 
a biomedical perspective5, whilst others prefer 
to adopt a critical position in relation to notions 
of ‘pathology’, ‘illness’ and ‘disorder’.6 Within 
the different theoretical traditions too there is 
considerable variation in philosophical stance 
and attitude, reflective of different tensions and 
discourses within the field. Although therapists 
principally draw from psychological paradigms 
that differ from the biomedical approach, it 
is clear some psychotherapeutic frameworks 
actively recruit the ‘medical model’ by analogy, 
borrowing language and classificatory systems 
that give rise to an apparent alignment in practice.
In the face of these and other complex debates 
and professional differences, therapists using this 
guidance will need to consider carefully the degree 
to which they think a biomedical perspective 
currently influences their practice. Clearly there will 
be considerable differences here, depending on each 
therapist’s professional background, professional 
training, work context and personal preference. For 
example, there will be some therapists whose work 
setting privileges a biomedical framework, requiring 
them to use the language of psychiatric classification 
and to incorporate standardised assessments 
and manualised ‘clinical’ techniques into their 
therapeutic work. By contrast, others may work in 
settings that allow them to reject the language of 
medicalisation and symptomatology entirely and 
to focus instead on the therapeutic relationship and 
client self-determination. There are many possible 
configurations here and many possible variations 
in the extent to which therapists feel they can or 
must adhere to a biomedical perspective. For this 
reason, it is important for therapists to reflect on the 
personal and professional ways in which they relate 
to and engage with the ‘medical model’, as this is 
likely to influence significantly, if implicitly, their 
attitude towards people who are taking prescribed 
drugs, prescribers and the drugs themselves.
How do the main modalities relate 
to the medical model?
The authority of the medical model means that 
many therapists consider issues of prescribed 
psychiatric drugs to be the exclusive remit of 
doctors, psychiatrists and neurologists. However, 
the specialist training of therapists means they 
all subscribe to a conceptual system of mental 
distress that is primarily psychological rather than 
biomedical. They are therefore well placed to help 
their clients in ways that are additional to and 
distinctive from medication.
The next section offers a brief summary of how the 
three main therapeutic modalities traditionally 
position themselves in relation to the biomedical 
model of practice. It is clear that such a summary 
cannot be exhaustive, nor can it do justice to 
the variations that exist within and between 
theoretical orientations. Rather, it aims to offer 
a starting-point of reference for therapists who 
wish to locate their practice on the continuum 
discussed above. 
3.1.1 Humanistic models of training 
and practice, including person-centred, 
experiential, existential and Gestalt approaches are 
concerned with notions of subjective experience, 
personal meaning and the development of potential, 
with therapy seen as inherently relational. The 
client’s potential for actualisation, uniqueness, 
autonomy and authenticity contrasts with the 
medical model’s focus on ‘illness’, ‘disorder’ 
‘psychopathology’ and its use of standardised 
assessments, ‘objective’ outcome measures 
and the specificity of ‘clinical’ techniques. 
Psychological distress is considered to be the 
result of thwarted actualisation due to sub-optimal 
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social/environmental conditions. Humanistic 
therapists seek to develop a therapeutic relationship 
characterised by authenticity and transparency 
rather than by hidden agendas or ‘expert’ positions, 
instead emphasising emotional engagement, 
collaborative work, responsibility for the self and 
the client’s freedom to self-direct. The fundamental 
call for humanistic therapists to ‘be with’ rather 
than ‘do to’ the client means they do not direct or 
actively encourage clients to make changes in their 
lives. Instead, they prefer to support clients in taking 
responsibility for themselves through a spirit of 
collaborative, empathic enquiry, exploration and 
acceptance. 
3.1.2 Psychodynamic models of 
training and practice range from long-
term psychoanalytic and relational psychotherapy 
through to shorter term models such as brief, 
psychodynamically oriented counselling and 
Dynamic Interpersonal Therapy (DIT). Whilst 
there are important differences between the 
various psychoanalytic schools of thought, all 
approaches emphasise the centrality of unconscious 
mechanisms and processes in relationships and 
tend to focus on the emergence of transferential 
and countertransferential material within therapy. 
The client is seen as ‘divided’, and therapeutic work 
aims to bring unconscious material to the surface, 
allowing it to be experienced safely and to become 
available for thought and processing with the 
therapist. Psychodynamic therapists, like humanistic 
therapists, tend to reject the ‘expert’ position 
characteristic of biomedical approaches, although 
some schools of psychoanalytic thought adhere to 
diagnostic classifications that are closely linked with 
medical psychiatry. Most therapists prefer to adopt a 
‘neutral’ stance that allows the client to project on to 
the therapist feelings and fantasies deriving from his 
or her early relationships. The traditional injunction 
to keep the therapeutic space free for transferential 
work means that psychodynamic therapists may 
vary in their willingness to offer direction or advice 
to clients, and they are likely to consider carefully 
the unconscious implications of the therapist’s 
contact with prescribers or other people involved in 
the client’s care. 
3.1.3 Cognitive-behavioural models 
of training and practice cover a number of 
approaches including Beckian cognitive-behavioural 
therapy (CBT), dialectical behaviour therapy (DBT) and 
rational-emotive behaviour therapy (REBT) as well as 
those that would be considered under the heading of 
‘third wave’ approaches such as mindfulness-based 
CBT (MBCBT), compassion-focused therapy (CFT) and 
acceptance and commitment therapy (ACT). These 
are all structured, focused approaches emphasising 
the use of specific techniques and strategies to 
promote measurable change. Whilst there is some 
debate about the extent to which its proponents align 
themselves with the ‘expert’ position characteristic of 
the biomedical model, the therapist stance endorsed 
by most CBT practitioners is collaborative, seeking 
to develop a helpful therapeutic alliance, a shared 
formulation and therapy goals. Psychoeducation and 
self-monitoring may be used to help clients identify 
unhelpful patterns of thought, behaviour and action 
that are seen as maintaining their current psychological 
difficulties. This may be followed by therapeutic work 
aimed at addressing underlying issues such as the 
impact of trauma. CBT is a common approach within 
public sector services, where therapists routinely work 
within a multi-disciplinary team. 
In concluding this section, it can be seen that the 
different perspectives outlined above all carry very 
different assumptions about the nature of emotional 
suffering. The biomedical paradigm sees much of 
mental distress as an unproductive ‘disorder’ or 
‘symptom’ that is best removed with the help of 
prescription psychiatric drugs. Within the humanistic 
and psychodynamic traditions, however, suffering is 
conceptualised as having potential value and purpose 
rather than something that is merely ‘pathological’ or 
otherwise useless. Therapists from these traditions 
tend to see emotional distress as a signal that 
there is something wrong in the individual’s life: 
suffering represents an opportunity for change and 
transformation if it can be explored and managed 
productively. By contrast, in approaches such as 
cognitive-behavioural therapy, the main focus is on 
removing symptoms of distress by altering patterns 
of cognition, emotion and behaviour that are 
understood to maintain emotional suffering. 
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3.2 Key issues for therapists to consider when working with 
clients who are taking or withdrawing from prescribed 
psychiatric drugs
A general principle emerging from the evidence 
base in this guidance is that there is little to 
support a ‘disease-centred’ model of drug action. 
Prescription psychiatric drugs act on the brain to 
alter mood and consciousness. In general, they 
control reactions to emotional distress by numbing, 
tranquilising or sedating a person, thereby 
producing subjective states that may or may not 
be experienced as helpful to the individual. Where 
psychiatric drugs produce effects experienced as 
helpful, they are best thought of as a temporary 
tool or coping mechanism that can be a helpful 
precursor to psychological change.  
In the instances where prescribed psychiatric drugs 
produce short-term relief, they do not change the 
underlying causes of psychological distress and 
may do some harm in the long term. It should 
also be remembered, however, that psychiatric 
drugs can be prescribed for physical conditions 
such as migraine. As we will see from the evidence 
presented in sections 4–7, all prescription 
psychiatric drugs come with withdrawal costs to 
some people. What follows is a brief summary of 
that evidence.
Evidence box A: Summary of adverse effects and withdrawal reactions to broad classes of prescribed 
psychiatric drugs 
(For full details, including references, see sections 4 and 5)
Benzodiazepines (e.g. Diazepam) have sedative properties and are generally prescribed for anxiety and sleep disturbance. They 
carry a significant risk of dependence if used for more than a month and for this reason should be prescribed for no longer than 
that. Adverse effects include drowsiness and impaired cognitive ability and, at higher doses, slurring of speech, loss of balance 
and confusion. Withdrawal effects are often severe and generally include an acute period over two weeks to two months with 
symptoms such as anxiety, agitation, insomnia and muscle stiffness. There can also be tingling, numbness, electric shock-type 
feelings, hallucinations, delusions and nightmares. Some people will experience longer-term withdrawal symptoms lasting a 
year or more. 
Antidepressants come in two main classes: Tricyclic antidepressants which are sedating, resulting in slowed reaction time, 
drowsiness and emotional indifference. In high doses they can also cause heart arrhythmias; SSRIs/SNRIs can cause nausea, 
drowsiness, but also sometimes insomnia. They usually have sedative effects and appear to numb emotions but may sometimes 
cause anxiety and agitation. There is also some evidence that SSRIs may increase suicidal impulses and possibly also violent 
behaviour in children and young people. Withdrawal effects can include nausea, dizziness, anxiety, depression, ‘brain zaps’, 
insomnia, hallucinations, vivid dreams, agitation and confusion. These symptoms typically last a few weeks but may continue 
for up to a year and occasionally for several years.
Stimulants (e.g. Ritalin) are generally prescribed for behavioural problems in children (and now often adults). They increase 
arousal and improve attention in the short-term, but suppress interest, spontaneity and emotional responsiveness. Insomnia is 
common. An important adverse effect for children is growth suppression. There may be rebound effects on withdrawal as well as 
tearfulness, irritability and emotional lability (rapid often exaggerated changes in mood).
Mood stabilisers (e.g. Lithium) are most commonly prescribed for those who have been given a diagnosis of bipolar disorder. All 
have a sedative effect, suppressing physical activity and reducing or flattening emotional responses. There is decreased ability 
to learn new information, prolonged reaction times, poor memory, loss of interest and reduced spontaneous action. Weight gain 
is common. Withdrawal from Lithium does not result in the physical withdrawal symptoms typical of other drugs but can cause a 
relapse of mania if undertaken too quickly.
Anti-psychotics (e.g. Olanzepine) all produce a sedative effect, dampening or restricting emotional reactions and making it 
difficult to take the initiative. There are a number of adverse neurological and metabolic adverse effects, including muscle 
stiffness, tremors, slowness in movement and thought, and akathisia (restlessness). Weight gain, increased risk of diabetes and 
cardiovascular disease are also common, and long-term use leads to shortened life span. Suicidality and sexual dysfunction 
are common adverse effects. Tardive dyskinesia or involuntary movements of the face, tongue, arms and legs is common, and 
may become evident, or be exacerbated, after withdrawal, reduction or switching medication. Withdrawal effects typically start 
within four days and may include symptoms such as nausea, headache, tremor, insomnia, decreased concentration, anxiety, 
irritability, agitation, aggression and depression. Rebound psychosis may also occur.
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For ease of reference, the following table 
summarises the main adverse effects and 
withdrawal reactions for each class of prescribed 
psychiatric drug. For fuller lists and a review of the 
evidence (including references), please see sections 
4 and 5.
Evidence box B: Summary of psychiatric drug effects by class.
Drug class Effects that may be perceived as adverse Possible withdrawal reactions
Benzodiazepines and Z-drugs




■■ Significant risk of dependence
■■ Drowsiness and impaired cognitive ability
■■ Sweating, nausea, dizziness, 
abdominal cramps
■■ Anxiety, agitation, insomnia, 
muscle stiffness 
■■ Tingling, electric shock type 
feelings. Risk of epilepsy






■■ SSRIs/SNRIs: nausea, drowsiness, insomnia
■■ Sexual dysfunction 












■■ Growth suppression in children
■■ Rebound effects, including 






■■ Drowsiness, tremor, lethargy, decreased ability 
to learn new information, prolonged reaction 
time, poor memory, reduced spontaneity
■■ Weight gain
■■ Reduced emotional responses
■■ Toxic state: levels have to be regularly 
monitored
■■ No physical withdrawal effects






■■ Dampened emotional responses and 
motivation
■■ Dizziness, sexual dysfunction, weight gain
■■ Cardiovascular effects 
■■ Akathisia and extra-pyramidal effects 
■■ Tardive dyskinesia




■■ Nausea, headache, tremor 
■■ Sleep disturbance, irritability, 
aggression, depression. 
■■ Possibility of ‘supersensitivity’, 
psychosis, particularly when 
withdrawing from clozapine
■■ Rebound psychosis.
For fuller lists of possible drug effects and withdrawal reactions, please refer to sections 4 and 5.
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3.2.1 Potential effects of taking 
prescribed psychiatric drugs on 
therapeutic work
The evidence detailed in section 4 suggests that 
research aimed at demonstrating the superiority 
of a combination of psychiatric drugs and 
psychotherapy over either intervention alone is 
not conclusive. Indeed, given the predominantly 
sedative effects of many prescribed psychiatric 
drugs, it is not unrealistic to suggest they can 
significantly and unhelpfully affect therapeutic 
work.7 Therapists may find that prescribed 
psychiatric drugs act in ways that limit their 
emotional access to clients and the problems for 
which they are seeking help. Clients may feel ‘out 
of reach’ or emotionally cut off and their difficulties 
may seem vague or difficult to define. In addition, 
prescription psychiatric drugs have the potential 
to significantly alter the way clients think, feel and 
behave. 
Effects on thinking may include: loss of memories; 
poor recall; poor concentration; confusion; losing 
track of ideas; difficulties in making links; difficulties 
in structuring thought; problems staying focused; 
and an inability to retain insights over time. 
Effects on feeling may include: emotional 
withdrawal; being uninvolved, distanced or ‘not 
really there’; inability to reconnect with feelings 
relating to past experiences; suppressed anger, 
sadness or fear; and a lack of emotional congruence. 
Effects on behaviour may include: passivity with 
the therapist; passivity outside therapy sessions; 
uncooperativeness or over-compliance; denial 
of responsibility; absences due to lateness, 
cancellations or missed appointments; apparently 
poor motivation; repetitive speech or behaviour; 
and disengagement from work or social activities. 
These effects will vary according to the particular 
drug, its dosage and the period of time over which 
it has been taken as well as the individual taking it. 
A picture will build up over time of how and in what 
way the client’s life has been affected and shaped by 
taking prescription psychiatric drugs, bearing in mind 
that no-one is likely to display all of the above signs. 
Given the above evidence for a range of effects 
and adverse reactions to taking or withdrawing 
from prescription psychiatric drugs, therapists 
may wish to consider a number of key issues 
when working with those who are currently 
taking, have previously taken or have now been 
advised to take these drugs. The following section 
invites therapists to consider questions relating to 
reflexivity, evidence, context and ethics.
3.2.2 Reflexivity: where am I in this?
Therapists will need to consider their personal 
position in relation to the medical model, reflecting 
on their own beliefs, values and attitudes towards 
prescribed psychiatric drugs together with any 
relevant personal or professional experiences 
that might have contributed to their stance. A 
complicating factor is that the widespread use 
of prescription drugs means it is possible, even 
likely, that therapists themselves will have been 
prescribed psychiatric drugs at some point in 
their lives. They may also have witnessed family 
members, partners or friends taking psychiatric 
drugs. Where this is the case, they may also 
wish critically to reflect on their own and others’ 
experiences of such drugs and to consider how 
and to what extent this might impact on their 
therapeutic stance.
Question box 1: What do I feel about 
prescribed psychiatric drugs? 
■■ What do I understand by the term ‘medical 
model’?
■■ How does the medical model ‘sit’ with my 
preferred therapeutic modality?
■■ What position do I take up in relation to the 
medical model? Where do I locate myself?
■■ How does my professional training and 
clinical experience influence the way I 
understand and work with issues relating 
to taking or withdrawing from prescribed 
psychiatric drugs?
■■ Do I have any experience of taking 
prescribed psychiatric drugs myself? Am 
I aware of any family members or friends 
who have taken prescribed drugs?
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■■ If so, what do I think and/or feel about 
these drugs, based on my own knowledge 
and experience? 
■■ How might this facilitate or hinder a 
discussion with the client?
■■ Do I need to reflect on any of these issues 
in my own personal therapy? Do I need to 
discuss in supervision?
3.2.3 Evidence: what do I know?
Therapists will find it helpful to develop a basic 
understanding of the evidence relating to the 
possible effects of the main classes of psychiatric 
drugs, together with their withdrawal effects. This 
includes being aware of general information about 
tapering, such as the need to avoid any sudden 
cessation of psychiatric drugs when withdrawing. 
They may also find it useful to understand the 
likely impact of prescribed drugs on therapeutic 
work and how some withdrawal reactions can 
be mistaken for relapse back into psychological 
distress.
Question box 2: What evidence do I need to 
consider?
■■ Which drugs do I most commonly hear 
about from my clients?
■■ Am I familiar with the main classes of 
psychiatric drugs and what they are used 
for? (See section 4).
■■ Am I familiar with their common effects and 
withdrawal symptoms? (See sections 4  
and 5). 
■■ What do I know about the evidence for the 
impact of prescribed psychiatric drugs on 
therapy? (See section 4 per drug, and 3.2.1).
■■ Do I understand the importance of slow 
withdrawal or tapering strategies?  
(See section 5.4).
■■ What knowledge and skills do I need to best 
support my client?
3.2.4 Context: what are the key 
influences on my work and me?
Other issues will need to be considered in the light 
of each therapist’s theoretical framework, work 
setting and personal and professional judgment. 
It is important that therapists use the evidence 
base included in this guidance to develop their 
therapeutic understanding and skills in the light 
of their particular modality and professional 
context, as well as the particular needs of the 
client. As an example, therapists working within 
public sector services such as the NHS are likely 
to be expected to liaise where appropriate with 
prescribers, other mental health professionals and 
in some cases with partners, carers and relatives as 
well. Therapists working in independent practice 
may have less opportunity for such collaboration. 
Different theoretical models will also take diverse 
perspectives on the likely impact of collaboration 
on the therapeutic relationship. In these and other 
situations, therapists may wish to draw on the 
evidence-base to tailor their support of clients in 
ways that are appropriate to the particular model 
and context within which they are working.
Question box 3: What contextual issues do I 
need to consider? 
■■ How does my preferred theoretical 
framework enable me to think about the 
role and function of prescribed drugs in my 
client’s life?
■■ Given my preferred therapeutic model, 
what position do I take up in relation to 
working with other health professionals if 
requested by the client? 
■■ Should I consider liaising with the client’s 
prescriber? Given my current workplace, 
what are the possible channels of 
communication with other people involved 
in the care of my client? 
■■ How does my preferred framework 
influence whether I signpost information 
where this is in the best interests of the 
client?
24 Guidance for Psychological Therapists
■■ Might it be helpful to find out more about 
multidisciplinary models of work in cases 
of prescribed psychiatric drug withdrawal? 
(See section 6.2)
■■ What is the likely impact of contact 
or collaboration with others on the 
therapeutic relationship?
■■ Should I consider signposting the client to 
further relevant information or evidence 
about their drugs? 
■■ Should I consider referring the client 
to specialist agencies or other forms of 
support? 
■■ What is the likely impact of such a referral 
on the therapeutic relationship?
3.2.5 Ethics: what are the principles 
that might apply to this issue?
Finally, working with issues of prescribed drug 
dependence raises legal and ethical questions 
relating to the importance of therapists working 
within the boundaries of their professional 
competence and role. It may be useful here 
to clearly distinguish between medical advice 
and medical information. Whilst it is clear that 
psychological therapists are neither trained to 
issue medical diagnoses nor to prescribe medical 
or pharmacological treatment, they may frequently 
be asked by clients for medical information. 
Discussing facts, scientific evidence or information 
where appropriate with clients differs substantially 
from offering a diagnosis, prescribing drugs or 
advising withdrawal. It is important to be clear 
about this distinction with clients. 
Let us consider the difference between offering 
information to clients (sometimes called psycho-
education) and giving them advice. As therapists, 
we may prefer to talk with clients about the 
common features of – and helpful reactions to – a 
panic attack rather than telling them what they 
should or should not do. The former is a common 
therapeutic strategy that enables therapists to 
help clients think about and understand the range 
of options available. It allows the client to decide 
what they feel is best or most helpful for them.  
The latter places the therapist in the position of 
‘expert’ and may risk undermining the client’s 
autonomy and decision-making capacity. In 
the same way, the therapist who offers general 
information about the effects of psychiatric drugs is 
not offering any specific advice about ‘what to do’ 
but is rather providing information on the ethical 
basis of ‘informed consent’. Clients can then decide 
for themselves how best to proceed. 
Clearly, this process is not always straightforward, 
and will be dependent on a number of factors:
■■ The skill of the therapist in engaging the client 
in ways that support them to make informed 
decisions i.e. decisions based on understanding 
the benefits and risks of any proposed 
psychiatric drug treatment. 
■■ The capacity of the client to engage in decision-
making processes, which will vary according 
to their personal circumstances, history of 
psychological problems and current level of 
distress. 
■■ The tendency of clients to favour interventions 
that claim immediate relief for their emotional 
distress, rather than longer-term interventions 
whose future outcome may appear less certain. 
This bias arguably skews the entire informed 
consent process, no matter how conscientiously 
implemented.
■■ Additional processes and care will be required 
where a client lacks the mental ability to make 
informed decisions about what is best for them.
It remains the case that there is currently no 
specific legal or ethical guidance on how therapists 
should respond to issues relating to taking or 
withdrawing from prescribed psychiatric drugs. 
This means that general ethical principles provided 
by all the main professional accrediting bodies 
will remain an important touchstone for their 
therapeutic practice and therapists may need 
to consider which principles are likely to be 
particularly relevant when working with those 
who are taking or withdrawing from prescribed 
psychiatric drugs. 
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For example, BACP’s Ethical Framework (2018)8 
covers the following areas: 
■■ Working on the basis of informed consent. 
Helping the client to understand the potential 
impact of their prescribed psychiatric drugs 
on the therapeutic process can be seen to be 
part of the therapist’s responsibility to ensure 
the client’s informed consent within therapy. 
This should be clearly distinguished from the 
prescriber’s responsibility to inform the client 
about the physiological and psychological 
effects of their prescribed drugs. However, 
it may be helpful for therapists to support 
this process where appropriate, for example 
by directing clients to relevant sources of 
information. 
■■ Respecting the client’s best interests. This 
includes supporting the client to take action, 
or where necessary, for therapists to consider 
doing so themselves, in order to prevent 
significant harm to the client or others. 
■■ Keeping knowledge and skills up to date. 
This may include therapists referring to the 
evidence-base included in this guidance and 
supplementing their competence in the areas 
proposed. 
■■ Demonstrating accountability and candour. This 
includes being open and honest with clients 
about the potential problems or risks associated 
with dependence on or withdrawal from 
prescribed psychiatric drugs.
■■ Working respectfully with colleagues. Whilst it 
is important that therapists do not undermine 
a client’s relationship with other colleagues or 
prescribers, they may need to be prepared to 
support clients where they have had unhelpful 
experiences or advice.
Although the ethical frameworks of the UKCP, BPS 
and NCS also endorse these ethical principles, 
therapists will need to reflect on and apply them 
to their own particular therapeutic practice and 
professional work setting, as well as taking any 
associated organisational policies into account.
All psychological therapists should be aware 
that working with issues of prescribed drug 
dependence is becoming an increasingly 
contested and fast-moving field of practice. The 
rapid growth of scientific knowledge can make 
it difficult for professional guidance, including 
medical guidelines, to keep pace with the speed 
of change, leading to the potential for significant 
differences of opinion between those who are 
caring for the client. Where therapists disagree 
with a prescriber’s medical advice to the client 
(e.g. which they believe to rest on erroneous or 
out-dated medical information), they may, with 
client consent where possible, consider contacting 
the prescriber to raise their concerns. However, 
differences in professional expertise, as well as 
variations in how a patient presents can also 
lead to well-founded disagreements within or 
across teams and disciplinary divides and practice 
settings. Therapists will need to be mindful of the 
need to communicate thoughtfully, sensitively 
and courteously with other professionals whilst 
prioritising the best interests of the client at all 
times (see Note in 4.3 below).
Question box 4: What ethical and legal issues 
do I need to consider?
■■ Am I aware of the distinction between 
medical advice and medical information? 
■■ How might I ensure that my client does not 
interpret any information giving as advice?
■■ Am I aware of the relevant principles 
and ethics of professional practice 
recommended within my current 
professional accrediting body? E.g.:
■– working on the basis of the client’s 
informed consent
■– respecting the client’s best interests 
■– taking steps to keep my knowledge  
and skills up to date 
■– demonstrating accountability  
and candour
■– respecting the client’s autonomy  
and self-determination.
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3.3 Practice-related guidance for therapists
It is not possible for this guidance to address all the 
possible implications of taking or withdrawing from 
prescribed psychiatric drugs, for all therapeutic 
practice, in all contexts. Rather, the intention is to 
promote critical thinking and awareness of the impact 
of prescribed psychiatric drugs, and for therapists 
to extend their competence by considering issues 
particular to their own clients and practice settings. 
This part of the guidance is divided into three 
main sections for ease of reference. Each section 
addresses issues that are relevant to the client’s 
drug ‘journey’, i.e. where the client is in relation to 
taking prescribed psychiatric drugs. The sections 
are as follows: a) clients who are considering a 
prescription for psychiatric drugs; b) clients who 
are already taking prescribed psychiatric drugs; c) 
clients who are considering withdrawing from their 
prescribed drugs; and, d) clients who are currently 
withdrawing from prescribed drugs and who may 
be experiencing withdrawal effects. 
In each section, a number of key information areas 
are highlighted alongside links to relevant sections 
in the guidance that provide further material, 
resources and/or evidence for therapists to consult. 
Implications for the client and for therapy are also 
discussed. At the end of each section there are a 
number of practice-related questions for therapists 
to consider. These are designed to help therapists 
think critically about their therapeutic work and 
its particular context, and are not necessarily to be 
asked of clients. Given the considerable differences 
within and between theoretical frameworks, these 
questions are intentionally broad, aiming to help 
therapists reflect on their personal knowledge, 
skills and experience in working with clients who 
have issues relating to taking or withdrawing from 
prescribed psychiatric drugs. 
Note 1: Working with prescribers 
and family members or carers
Throughout the guidance, therapists are encouraged 
to consider if, when and how it might be appropriate 
to contact prescribers. It is clear that there can be 
no hard and fast rules here about the best course 
of action where therapists are concerned about 
a client’s use of or withdrawal from prescribed 
psychiatric drugs, and in many cases therapists may 
decide against such contact. The decision to get in 
touch with a prescriber will inevitably be a function 
of multiple, overlapping factors: whether contact 
is at the request of and in the best interests of the 
client; whether the client has consented to the 
therapist making contact; the therapist’s preferred 
therapeutic model and rationale for communicating 
– or not – with the prescriber concerned; the work 
context in which therapy is taking place; and 
the therapist’s own confidence in and previous 
experience of initiating contact with prescribers and 
other medical professionals. 
Where contact with the prescriber is considered 
appropriate and where the client has given consent, a 
short email to request a discussion or meeting can be 
helpful, followed up where necessary by a telephone 
call or message. For therapists working in public 
sector services like the NHS, such communications 
are usually straightforward, particularly where 
therapists are working side-by-side with prescribers. 
Where it proves difficult to contact prescribers, it 
may be necessary for the therapist to discuss their 
concerns with colleagues and/or supervisors. Where 
appropriate, they may wish to consider bringing 
their concerns to a multidisciplinary team meeting 
for discussion (details of models for supporting 
withdrawal in multidisciplinary teams can be found 
in 6.2). In other settings such as independent practice, 
communication with prescribers is frequently 
more complex and will be dependent on therapists 
obtaining the GP or prescriber contact details. Where 
possible, therapists can email or write to request a 
conversation or meeting, indicating their professional 
qualifications and role together with their reasons 
for being concerned about the client. Following 
initial contact, therapists may need to be prepared to 
maintain communication particularly where the client 
is withdrawing from prescribed drugs. 
Therapists are also encouraged to consider whether 
it might be appropriate, with the client’s consent, 
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to be in contact with carers or family members such 
as partners or other relatives. In the case of some 
older adults, or those with learning disabilities or 
communication difficulties, carers, partners and 
families are likely to be involved in supporting 
the client. In some work settings, particularly 
within public sector services, collaboration with 
family members and carers is seen as a relatively 
straightforward element in therapeutic work. In other 
settings, such as independent practice, there is less 
opportunity or need for contact and collaboration. 
Therapists will need to consider carefully, from the 
perspective of their preferred therapeutic framework 
and practice setting, the range of issues and 
implications associated with contacting and working 
with carers and/or family members. 
Note 2: Working with the beliefs 
clients hold about prescribed 
psychiatric drugs 
Therapists may also wish to explore the beliefs 
clients hold about taking prescription psychiatric 
drugs, as well as the psychological ‘message’ that a 
pharmacological intervention inevitably carries. For 
example, some people believe, or have been told, 
that depression, anxiety and other psychological 
problems are caused by biochemical changes to 
the brain, while others believe there are genetic 
factors underlying their emotional distress. In these 
cases, prescription psychiatric drugs carry a strong 
psychological message for the individual that they 
are ‘ill’ and require medical ‘treatment’ in order to 
manage. Indeed, where clients believe that they are 
‘weak’ or have failed to live up to social expectations 
and norms, it may be preferable for them to treat 
what they believe to be the physical or biochemical 
causes of their distress rather than to explore painful 
life experiences or interpersonal dynamics that may 
be contributing to the problem. Clients may also 
believe that it is not good for them to experience 
strong feelings of distress, and that prescribed 
psychiatric drugs will quickly and effortlessly get 
rid of feelings of sadness or anger. In these and 
many other situations, therapists will need to take 
into account the beliefs and meanings held by the 
client, exploring any unrealistic or over-optimistic 
expectations about prescribed psychiatric drugs 
that prevent the client from accepting an alternative 
view of their difficulties, which would in turn enable 
therapy to be of more benefit. 
The relationship that clients have with their 
prescribed psychiatric drugs becomes more 
complex where drugs are taken as a consequence 
of being detained under the Mental Health Act 
or being treated under a Community Treatment 
Order (CTO). In these circumstances, therapists 
will need to be alert to the way in which 
pharmacological treatments are likely to impact 
on the therapeutic relationship, working with 
clients to support them within the limitations 
imposed by legal frameworks. Difficulties are also 
likely to arise where clients rely on prescription 
psychiatric drugs to demonstrate eligibility 
for benefits such as Employment and Support 
Allowance (ESA). In these situations, therapists 
will need to explore sensitively and with care the 
extent to which anxiety about any possible loss 
of benefits underpins the client’s understanding 
of the causes of their emotional distress and 
drives any decision about withdrawing from 
prescribed psychiatric drugs. Therapists should 
also bear in mind the extensive debates in the 
field about the overprescribing of psychiatric 
drugs in marginalised groups, including those 
from black and ethnic minority backgrounds. For 
further information about this, it may be helpful to 
consult the British Psychological Society’s (2017) 
Understanding Psychosis document. 
3.3.1 Working with clients who 
are considering a prescription for 
psychiatric drugs
Useful information for therapists to know:
■■ Main effects of the proposed psychiatric drug 
(section 4).
■■ The potential risks of drug dependence 
(sections 4 and 5).
■■ The likely impact of the proposed prescribed 
drug on therapy (section 4 by drug and 3.2.1 
above).
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a) Implications for the client
■■ Based on the principle of informed consent, 
therapists may wish to enquire whether the 
client’s prescriber has discussed with them the 
possible effects of or potential for dependence 
on the proposed psychiatric drug. If not, they 
can encourage the client to discuss this further 
with their prescriber. Therapists may also need 
to ensure the client is aware of the potential 
impact of taking the proposed drug on the 
process and progress of therapeutic work.
■■ Therapists should be aware of the implications 
of prescribed psychiatric drugs for working with 
particular groups of clients. For example, older 
adults who have diminished physical or cognitive 
capacities may be at increased risk of falling whilst 
taking prescribed drugs. Clients who are pregnant 
or planning a pregnancy may incur risks to the 
unborn child. In these and other cases, therapists 
are well-placed to encourage the client, where 
appropriate, to discuss the potential impact of 
prescribed psychiatric drugs with their prescriber 
in order to ensure they are making an informed 
choice about the use of such drugs. 
b) Implications for therapy
■■ Therapists will need to explore sensitively and 
with care the client’s perception of his or her 
psychological problems. It is important to judge 
whether the client wishes, or is ready, to talk 
about any issues associated with their planned 
use of prescribed psychiatric medication. 
■■ Therapists should consider whether and to what 
extent the client’s planned use of prescription 
psychiatric drugs is likely to affect therapy. Where 
possible, it is helpful to address issues around 
psychiatric drug use at an early point in the 
therapeutic relationship in order to better assess 
its likely impact on successful therapeutic work.
■■ Where clients directly ask therapists for advice 
concerning prescribed drugs, therapists will need 
to ensure they do not offer any personalised 
suggestions about the advisability or otherwise of 
taking prescription psychiatric drugs. They should 
not be drawn into discussions about the type, 
dosage or frequency of any drugs that the client’s 
prescriber has recommended, and should always 
refer the client back to their prescriber for medical 
advice, remaining alert to any reluctance on the 
part of the client to question their prescriber. Acting 
on the principle of informed consent, therapists 
may wish to explore any concerns the client may 
have about their prescribed drugs and where 
appropriate direct them to relevant available 
sources of information (e.g. BNF) or evidence in a 
sensitive and non-leading manner (see 3.2.5). 
c) Practice-related questions for therapists to 
consider 
Question box 5
■■ What does the client think and feel about 
taking prescribed psychiatric drugs?
■■ Why might the client wish, or feel they 
need, to accept (or not) a prescription? 
■■ What is the likely impact of the proposed 
drug on the client’s ability to engage in 
psychological therapy?
■■ Is the client directly requesting advice 
about drugs? If so, can I support their 
agency in relation to the prescription?  
Do they need more information?
■■ How can I best support the client’s choice 
either to start their prescribed drugs or 
to revisit the GP/prescriber to consider 
alternatives to drugs?
■■ Is therapy appropriate for the client  
at this time, or is referral to another  
service required?
3.3.2 Working with clients who 
have already started taking 
prescribed psychiatric drugs
Useful information for therapists to know:
■■ Main effects of client’s prescribed psychiatric 
drug (see section 4).
■■ Impact of prescribed drugs on therapy (section 
4 by drug and 3.2.1 above).
■■ Risks of abrupt discontinuation, reduction or 
switching prescribed drugs.
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a) Implications for the client
■■ Clients may experience a range of effects whilst 
taking their prescribed psychiatric drugs. If 
therapists are familiar with some of the adverse 
effects of the main classes of psychiatric drugs 
(e.g. benzodiazepines and antidepressants) they 
may be able to help the client identify if and 
when they might be experiencing them. 
■■ Taking prescribed psychiatric drugs may have 
significant implications for the client’s partner, 
family, carers or other people involved in their 
care. This may be of particular relevance for 
older adults and those with learning disabilities 
or communication problems. Therapists will 
need to consider carefully, from the perspective 
of their work setting and preferred therapeutic 
framework, the range of issues associated with 
contacting and working with carers and/or 
family members (see Note 1, 3.3).
b) Implications for therapy
■■ Therapists will need to explore sensitively and 
with care the extent to which the client wishes, or 
is ready, to talk about any issues associated with 
their use of prescribed psychiatric drugs. In some 
cases, therapists may decide that it is not in the 
client’s best interests to start therapy and instead 
may choose to refer the client to alternative 
sources of help and support. However, given the 
lack of currently available services, therapists 
should remain cautious about assuming other 
professionals are better able to offer emotional 
or psychological care. Depending on the type and 
level of prescription psychiatric drugs taken by 
the client, therapists are generally well-placed 
to offer support, though it may be necessary to 
adjust therapeutic expectations of what kind of 
work will be possible.
■■ Clients may make a ‘late reveal’ in therapy that 
they are or have been taking prescribed drugs 
for some time but have not previously been able 
or willing to discuss this. In some cases where 
the client’s prescription drug use is known 
but has not been discussed, the therapist may 
make a decision to raise it as an issue where 
previously it had not been part of the work,  
if in the interest of the therapy.
c) Practice-related questions for therapists  
to consider
Question box 6
■■ If the client’s prescribed drug use was not 
raised at the start of therapy, why has it been 
raised now? 
■■ Why might the issue of prescribed drugs 
be significant within the therapy at this 
particular time?
■■ What are the implications of taking 
prescribed drugs for the progress of therapy? 
■■ What is the client’s relationship with their 
prescriber?
■■ How can I support the client to contact 
their GP, psychiatrist or other prescriber? 
Might it be helpful for me to do so?
■■ Does the client want me to contact any 
family members, carers or others who may 
be involved in the client’s care? What are 
the implications of this for the therapeutic 
relationship?
3.3.3 Working with clients who 
are considering withdrawing from 
prescribed psychiatric drugs
This guidance aims to empower and support 
conversations often already taking place 
between therapists and their clients. Therapists 
will need to decide for themselves whether, and 
to what extent, they wish to use this guidance 
in the context of their therapeutic work. These 
decisions will depend on their theoretical 
modality, practice setting and the individual 
needs of the client. The client’s agency, as 
always, should be supported and respected 
at all times. Clients should be encouraged to 
discuss withdrawal from prescribed psychiatric 
drugs with a knowledgeable prescriber who 
can give medical advice, oversee and manage 
any withdrawal process appropriately. While 
this guidance advocates the importance 
of informed client-choice based on full 
information about potential benefits and risks, 
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it does not advocate therapists telling their 
clients to take, not take, stay on or withdraw 
from psychiatric drugs. These matters should 
be left to the prescriber and client to decide.
During the course of therapeutic work, clients may 
consider withdrawing from their psychiatric drugs 
and either moving to therapy alone or ending all 
interventions if they are feeling better. In these 
cases, it will be helpful if therapists are aware of  
the following:
■■ The process and possible experiences of 
withdrawing from prescribed psychiatric drugs.
■■ Awareness of the importance of planning for 
withdrawal: preparation, timing, knowledge  
and support.
■■ Understanding the likelihood of withdrawal effects.
■■ Understanding the potential impact of withdrawal 
on the client’s family and other social networks.
■■ Understanding the importance of the client 
having informed medical support and 
supervision during withdrawal.
■■ Key definitions about relapse and withdrawal.
Box C: Evidence summary – useful information for therapists to know
Although there is a lack of formal research into the effectiveness of therapeutic strategies aimed at supporting withdrawal, the 
theoretical, experiential and anecdotal evidence from those working in this field nonetheless offers useful suggestions. What 
follows is a summary of the ‘combined wisdom’ from these sources (for full details, including references, see section 6). 
There are five relevant factors that have been found to be helpful in supporting withdrawal. These are:
1. Access to accurate information about withdrawal.
2. The involvement of a knowledgeable prescriber to devise, help monitor and manage, a tapering programme that is tolerable 
and agreeable to the client.
3. Access to client-centred, non-authoritarian support.
4. Access to information about and help with engaging with useful coping strategies and/or supportive lifestyle changes.
5. Awareness of the need to suspend customary assumptions about sources of distress and their associated interventions  
(i.e. emotional processing or analysis) for the duration of withdrawal.
The ‘combined wisdom’ approach
The combined wisdom of those therapists who have worked in depth with this client group describes three stages of support:
Stage 1: Preparation before withdrawal is started 
Preparation is essential to successful withdrawal. Understanding the withdrawal process, alongside a stance of non-judgmental 
acceptance, allows the therapist to engage the client in a discussion about the advantages and disadvantages of withdrawal.  
Ten areas to consider reviewing with the client are:
■■ Exploring whether a client feels ready to begin the withdrawal process. 
■■ Exploring who is going to provide medical support, and their relationship with their prescriber.
■■ Signposting and discussing relevant information on withdrawal (*see list of examples below).
■■ Discussing the possibility and general nature of withdrawal effects so clients know what to look for. 
■■ Clarifying the high-level definitions of relapse, rebound, recurrence and withdrawal and how they might be mistaken (e.g. 
adverse withdrawal reactions that result from reducing or discontinuing a drug might be mistaken as ‘relapse’, a term which 
refers to the gradual return of the original issue, at the same intensity, for which the drug was initially taken – see 5.4.2).
■■ Addressing any potential fears about the withdrawal process.
■■ Identifying possible ways the attempt might be inadvertently sabotaged. 
■■ Identifying potential support networks.
■■ Discussing the idea of the client using a diary or log to keep track of drug reductions and experiences.
■■ Discussing the availability of extra sessions or other contact if needed in between scheduled meetings, being clear about the 
limits of what can be provided. 
* Examples of information about withdrawal that may be shared with the client if appropriate (see 5.4.1 for fuller information):
■■ Withdrawal from prescribed psychiatric drugs should be carefully planned and carried out under the supervision of an 
informed prescriber.
■■ Withdrawal should never be sudden or abrupt; people’s experience can vary significantly, with some experiencing no 
withdrawal reactions whilst others can experience severe and protracted withdrawal. 
■■ Schedules should be flexible and the reduction rate based on the individual’s withdrawal reactions, intensity of reactions, 
their ability to cope and whether there is sufficient support available. Drugs may need to be tapered very slowly over months 
or beyond.
■■ Where reactions to withdrawal are severe, it is sometimes possible for a client to get a liquid prescription from the GP/
prescriber. This helps to ensure accuracy in making small reductions to the prescribed drug. 
Further details about the ‘combined wisdom’ approach, including references, can be found in section 6.
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a) Implications for the client
■■ Clients may not have considered the possibility 
of withdrawal reactions, nor of the need to 
prepare for withdrawing from their prescribed 
psychiatric drugs. Indeed, where clients are 
planning to finish therapy and subsequently to 
withdraw from their prescribed drugs because 
they feel better, they may not have considered 
how a therapist could support them in the 
withdrawal.
■■ Withdrawing from prescribed psychiatric 
drugs may have significant implications for 
the client’s partner, family, carers or other 
people involved in their care. This may be of 
particular relevance for older adults and those 
with learning disabilities or communication 
problems. 
b) Implications for therapy
In addition to reviewing the information outlined in 
box C:
■■ Therapists should be aware that withdrawing 
from prescribed drugs requires planning and 
preparation and may take some time. The 
process of withdrawal itself can take months 
or years, not days or weeks. A rushed or 
unplanned withdrawal process is less likely  
to succeed.
■■ While it is beyond the professional remit 
of psychological therapists to give direct, 
personalised withdrawal or tapering advice, 
therapists may wish to consider in advance 
their position on giving or signposting relevant 
information to clients. This may be particularly 
important if the relationship between client and 
prescriber is problematic or has broken down.
■■ Adopting a stance of non-judgmental 
acceptance allows the therapist to engage the 
client in a discussion about the advantages and 
disadvantages of withdrawal. 
■■ Where relevant, therapists will need to consider 
carefully, from the perspective of their work 
setting and preferred therapeutic framework, 
the range of issues associated with contacting 
and working with carers and/or family members 
(see 3.3, note 1).
c) Practice-related questions for therapists  
to consider
Question box 7
■■ If the client wishes to withdraw from their 
prescribed drugs, why now? What has 
precipitated their decision?
■■ Has the client discussed their decision to 
withdraw with his or her prescriber?
■■ What is the client’s relationship with their 
prescriber?
■■ Does the client have a plan for withdrawal?
■■ How can I support the client to contact 
their GP, psychiatrist or other prescriber? 
Might it be helpful for me to do so?
■■ Does the client want me to contact any 
family members, carers or others who may 
be involved in the client’s care? What are 
the implications of this for the therapeutic 
relationship?
3.3.4 Working with clients who 
are currently withdrawing from 
prescribed psychiatric drugs
Clients may already have started to withdraw from 
their prescribed drugs before starting work with 
a therapist. Some may not wish to tell a therapist 
that they are doing so. In these cases, it may be 
useful for the therapist to consider the following, 
in addition to the information given in section 3.3.3:
a) Implications for the client
■■ If a client has chosen to start withdrawing 
without talking to a prescriber or researching 
how to taper, any information given may come 
as a surprise. Discussing the helpfulness of 
informed medical support and supervision 
during withdrawal will need to be done in such a 
way as to not undermine the client’s agency.
■■ Clients may have a range of experiences when 
withdrawing from prescribed psychiatric drugs 
(summarised in section 3.2, full information in 
section 5). Withdrawal reactions such as anxiety, 
agitation or insomnia, especially those that 
continue past the acute stages are commonly 
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assumed by clients and their prescribers to signal 
a return of the client’s psychological problems 
and to require further medication. In such cases, 
therapists will need to work with clients to help 
them understand their experiences of withdrawal 
as physiological rather than psychological 
in origin, and to agree what is realistic 
therapeutically during the process.
■■ If a client experiences protracted or severe 
withdrawal reactions they will naturally need 
to adjust their expectations of the withdrawal 
process and how long it might take. They may 
also need to consider more fully what support 
is available to them from family and friends, or 
from a continued relationship with a therapist. 
■■ Withdrawing from prescribed psychiatric drugs 
may have significant implications for the client’s 
partner, family, carers or other people involved 
in his or her care. 
■■ Where clients have been sedated and inactive 
due to long periods of drug use, they may 
need to find new and more satisfying ways of 
occupying themselves.
b) Implications for therapy
In addition to those elements described in Box 
D, and always dependent on the therapist’s 
theoretical framework, therapists should also 
consider the following elements that may form part 
of therapeutic work over the withdrawal period:
■■ If there was no opportunity to work with the 
client to prepare for withdrawal, therapists 
should consider the list of 10 areas listed in Box 
C to see if any would be still helpful to address.
■■ If clients experience ‘waves and windows’ 
during the withdrawal process (see Box D) 
where reactions fluctuate over time, therapists 
can help monitor the course of these episodes if 
they happen, providing the client with support 
and information and tailoring therapeutic work 
appropriately. 
■■ Whilst it is clear from Box D that any reactions 
that emerge during the transition should be 
treated as a result of withdrawal unless proven 
otherwise, it is possible that new emotions 
may also emerge. The therapist may need to 
Evidence box D: Summary – useful information for therapists to know
The ‘combined wisdom’ approach
As introduced in 3.3.3 the combined wisdom of those therapists who have worked in depth with this client group describes three 
stages of support. The second and third stages are as follows:
Stage 2: During withdrawal – support 
Therapists are likely to have more regular contact with a client than a prescriber. They are therefore in a strong position to offer 
the client ongoing support for the withdrawal process. Possible areas for therapeutic work may include:
■■ Helping clients to identify withdrawal reaction and offering reassurance that they will pass. It is important to assume that 
any reactions that emerge during the transition are due to withdrawal unless proven otherwise. 
■■ Encouraging clients to make sense of their experiences and to accept them as normal to the withdrawal process. For 
example, clients may experience intense anxiety and fluctuating levels of physical and mental pain.
■■ Helping clients to manage withdrawal reactions that can come and go. This is sometimes referred to as ‘waves’ and 
‘windows’, where the ‘waves’ of reaction slowly decrease in intensity, interspersed with ‘windows’ of reduced or very limited 
reactions. Some clients may only experience ‘waves’ within ‘waves’.
■■ Helping clients to identify supportive practices which enable them to manage and tolerate withdrawal experiences while 
they last. These may include coping strategies such as: acceptance; maintaining a non-resisting attitude to withdrawal 
experiences, or breathing exercises. (For the full range of potential coping tools, see 6.1.1.1).
Stage 3: After withdrawal is complete 
■■ At the end of withdrawal, therapists may find it useful to review the client’s experience and to determine with them what 
further therapeutic needs they have. In addition:
■■ If the client has experienced any cognitive problems as a part of their withdrawal experience it may take a while for 
confidence in decision making to rebuild (including the ability to say ‘no’ to others).
■■ If the clients’ withdrawal was experienced as traumatic this might need to be considered in any further therapeutic work.
■■ Both client and therapist should be aware that post-withdrawal reactions can occur for some time after stopping taking 
prescribed psychiatric drugs. 
Working in multidisciplinary teams 
■■ There are examples in the theoretical and research literature of psychiatrist-led models to support withdrawal that may be 
of interest for further reading if a therapist has an opportunity to suggest this in a multidisciplinary team setting (see 6.2).
Further details about withdrawing from prescribed psychiatric drugs, including references, can be found in sections 5 and 6.
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consider these feelings carefully together with 
the client, deciding whether they are further 
material for therapeutic work and if so, when 
they might be best addressed.
■■ Where the client is unable to process emotional 
material due to high levels of anxiety or 
physical/mental pain or discomfort, it will 
be necessary for the therapist to revisit any 
previously agreed therapeutic aims in order to 
provide support, guidance and reassurance. 
■■ The therapist will need to anticipate, discuss 
and work through potential problems, feelings 
or setbacks with the client. It is important to 
maintain an accepting and non-judgmental 
therapeutic stance, identifying risks in the event 
of the client becoming emotionally unsafe.
■■ If there are concerns about prolonged or adverse 
reactions during withdrawal, therapists should 
consider discussing with the client the advantages 
and disadvantages of seeking advice from the 
prescriber and/or other mental health professional. 
■■ Therapists will need to encourage the client’s 
sense of responsibility and autonomy whilst 
remaining clear about the support they are able 
to provide. 
■■ As for 3.3.3, therapists will need to consider 
carefully, from the perspective of their work 
setting and preferred therapeutic framework, 
the range of issues that arise when asked to 
contact and work with carers and/or family 
members (see 3.3, note 1).
c) Practice-related questions for therapists  
to consider
Question box 8
■■ Am I aware of the ‘combined wisdom’ 
approach in relation to withdrawal 
strategies? (Boxes C & D).
■■ Does the client want me to contact his or 
her GP, psychiatrist or other prescriber?
■■ It may not be possible to distinguish 
between withdrawal symptoms and any 
re-emergence of the client’s presenting 
psychological problem. Can I tolerate my 
own and the client’s uncertainty about this?
■■ Is the client aware of the potential impact 
of withdrawal from drugs on existing 
relationships such as family, partners and 
colleagues? 
■■ What might I need to do or change in my 
therapeutic practice to accommodate the 
client’s withdrawal reaction distress? 
■■ What additional relevant tools or strategies 
might be helpful, and how might these 
impact the therapeutic relationship? 
Which do I know enough about to provide 
information on, and which would I need to 
simply signpost for the client?
■■ Do I need to consider additional 
therapeutic support for the client?  
Where would this come from?
This guidance aims to empower and support 
conversations often already taking place 
between therapists and their clients. Therapists 
will need to decide for themselves whether, and 
to what extent, they wish to use this guidance 
in the context of their therapeutic work. These 
decisions will depend on their theoretical 
modality, practice setting and the individual 
needs of the client. The client’s agency, as 
always, should be supported and respected 
at all times. Clients should be encouraged to 
discuss withdrawal from prescribed psychiatric 
drugs with a knowledgeable prescriber who 
can give medical advice, oversee and manage 
any withdrawal process appropriately. While 
this guidance advocates the importance 
of informed client choice based on full 
information about potential benefits and risks, 
it does not advocate therapists telling their 
clients to take, not take, stay on or withdraw 
from psychiatric drugs. These matters should 
be left to the prescriber and client to decide.
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4. What psychiatric drugs do by class
 Professor Joanna Moncrieff & Dr Tom Stockmann 
4.1 Interpreting the evidence on psychiatric drugs
The most robust evidence for the use of psychiatric 
drugs is generally agreed to come from randomised 
controlled trials that compare a particular drug or 
intervention with a standard or ‘control’ condition, 
such as a placebo. Randomisation is important 
because it allows the effects of the intervention 
being tested to be distinguished from the effects 
of other things, such as the natural history of the 
condition and general factors that might produce 
improvement like seeing a specialist. To further 
reduce the risk of bias, the investigators and 
participants may be ‘blinded’, or made unaware 
of who receives the drug and who the control 
treatment or placebo. 
Combinations of the results of several different 
trials of the same treatment, called meta-
analyses, are also regarded as providing high 
quality evidence. However, a meta-analysis is 
only as good or as poor as the trials it combines. 
A meta-analysis of poorly conducted trials 
summates their deficiencies or biases and so  
the result may be more misleading than the 
original studies. 
Randomised controlled trials were developed to 
test the outcomes of interventions for physical 
medical conditions. Translating them into the 
area of mental health is not straightforward and 
there are various difficulties with interpreting  
the results. 
4.1.1 The validity of measurements
Emotional states and behaviours are properties 
of living human beings and cannot be described 
and quantified in the same way that we measure 
the properties of physical objects. Therefore, the 
meaning and validity of measurements of mental 
symptoms is not clear-cut.
4.1.2 Ignoring drug-induced 
alterations
Since most research is premised on the disease-
centred model of drug action, the general 
alterations that drugs produce on physical 
and mental functioning are often ignored and 
interpreted as changes in the underlying ‘disorder’. 
Yet these alterations may change people’s 
experience and behaviour without affecting the 
underlying problem.
4.1.3 ‘Publication bias’
Studies that find positive effects of drugs are 
more likely to be published than studies that find 
they have no benefits or cause harm.8 In addition, 
published reports of studies often emphasise the 
measures that show the drug in the best light.8 
Measures that show no benefit or that indicate 
harmful effects may not be published or may be 
concealed in the small print of the article. 
Some pharmaceutical companies have been 
shown to withhold data that do not show their 
drug in a favourable light.9 But doctors, researchers 
and editors have also played a part in focusing 
on research that highlights the positive and 
plays down the negative effects of drugs. There 
are extensive financial relationships between 
these groups, that have been shown to bias the 
undertaking, interpretation and reporting of 
research. 
4.1.4 Unblinding
The use of a placebo is meant to prevent 
participants and researchers from knowing 
whether they are getting the real drug or not. This 
is why studies using a placebo are referred to as 
‘double blind’. However, it is often quite easy for 
people in trials to tell whether they are taking the 
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drug or the placebo, due to the mental and physical 
alterations drugs produce independently of any 
effect they might have on the underlying disorder. 
The chance that people will detect whether they 
are taking a drug or a placebo is heightened 
because people who take part in trials are given 
detailed information about the ‘side’ effects of the 
drug being tested. 
What this suggests is that many trials that are 
supposed to be double blind are not. Many of the 
participants and some of the professionals involved 
are likely to be able to work out who is taking 
the real drug and who is on the placebo. Trials in 
which people are asked to guess what they are 
taking show that in most cases people can detect 
the nature of the pill they have been given.10 If 
people taking part in trials believe that drugs are 
likely to help them, they may have a heightened 
expectation of improvement if they suspect they 
are taking the real drug. Conversely, they may 
have lowered expectations if they believe they are 
on the placebo. Any differences in the outcome 
of treatment may be due to these different 
expectations, rather than the effects of the drug. 
4.1.5 Drug withdrawal effects in trials
Most trials of long-term treatment, and many trials 
of short-term treatment too, involve people who 
are already taking the drug that is being tested, or 
something similar. The people who are randomised 
to placebo are then taken off their existing treatment 
and may therefore be vulnerable to adverse effects 
related to the withdrawal of the prior treatment.11 
This is especially problematic because the 
withdrawal and transfer to placebo is usually done 
abruptly. Therefore, many studies, particularly those 
assessing long-term treatment, may assess the 
effects of withdrawing from prescribed drugs rather 
than the impact of starting on it in the first place. 
This array of potential problems suggests that 
care must be taken when interpreting research on 
psychiatric drugs, and the clinical guidelines based 
upon them. 
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During the 1950s, certain drugs were tried out 
on people who were depressed, which started 
to be called antidepressants. One group of these 
drugs, which are similar in structure to some of 
the early antipsychotics, is known as the tricyclic 
antidepressants. Another group is the monoamine 
oxidase inhibitors or MAOIs. These were the main 
types of antidepressant used until the late 1980s. 
Prozac was launched in 1988 and was the first 
of a series of new antidepressants introduced 
during the 1990s called the ‘selective serotonin 
re-uptake inhibitors’ (SSRIs). These were joined by 
a variety of other sorts of drugs also branded as 
antidepressants (including venlafaxine, duloxetine 
and mirtazapine). 
From the beginning of the 1990s, industry 
advertising campaigns and professional publicity 
increased the prescribing of these drugs 
substantially. Antidepressants are now by far the 
most commonly prescribed class of psychiatric 
drug, and their use continues to rise. In 2016 in 
England, over 65 million prescriptions were issued 
for antidepressants, a 6% increase on the previous 
year and over 500% increase since 1992.1
Antidepressants are regarded as useful treatments 
for depression and a range of other conditions and 
their use is recommended in various situations by 
official guidance.
4.2.2 Common short-term uses
Antidepressants are recommended for what is judged 
to be moderate or severe depression, and for less 
severe depression that is not helped by psychological 
interventions1. SSRIs are usually the first choice. 
People diagnosed with depression who recover 
after being prescribed an antidepressant for the 
first time, are generally advised to continue the 
drug for at least six months.2 Antidepressants are 
usually prescribed for a longer period if the patient 
has suffered several episodes, the symptoms have 
not disappeared entirely, the person has a long-
term physical health condition, or has ongoing 
life stressors. In such cases, antidepressants are 
recommended to be continued for a minimum of 
two years2, but increasingly people end up taking 
these drugs for multiple years and beyond. 
They are also prescribed for individuals who have 
received a diagnosis of a variety of other mental 
health difficulties, including anxiety, obsessive 
compulsive disorder, panic disorder, phobias, 
bulimia and post-traumatic stress disorder. Tricyclic 
antidepressants are sometimes also used to treat 
chronic pain, particularly pain of a neurological 
origin, or insomnia, usually at lower doses than 
those recommended for depression.
4.2.3 Theories of action 
The traditional view of antidepressant action, 
based on a disease-centred model (outlined in 
section 2), suggests that antidepressants help 
correct a chemical imbalance presumed to be 
present in depression. They are said to increase the 
availability of certain neurotransmitters that are 
thought to be deficient in depression. Older drugs, 
like the tricyclic antidepressants and the MAOIs 
are thought to act by increasing the availability of 
the neurotransmitter noradrenalin. The SSRIs are 
still generally believed to improve depression by 
correcting a deficiency of serotonin. 
Although the idea that depression is caused by 
a chemical imbalance has entered the public 
consciousness, the ‘monoamine’ theory of 
depression is not supported by evidence or expert 
opinion.3,4 Studies of serotonin receptors, for 
example, show contradictory findings, with some 
showing that receptor numbers are reduced in 
people with depression, compared to people 
without, some showing no difference, and some 
showing they are increased. Studies that aim to 
induce a lowering of serotonin levels through 
dietary means do not show any association 
with the onset of depression in people with no 
history of depression, although some studies 
show a deterioration of mood in people with a 
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previous history of depression who have been 
treated with SSRI antidepressants. Evidence on 
noradrenaline is also contradictory.5 In addition, 
numerous randomised trials have shown that 
drugs that are not thought of as antidepressants, 
and have actions on other neurotransmitter 
systems, including benzodiazepines, opiates, 
stimulants and antipsychotics, are as effective 
as recognised antidepressants in people with 
depression.5 Leading psychopharmacologists 
have concluded that direct evidence for the 
monoamine hypothesis is lacking.6,7 Indeed, the 
whole ‘chemical imbalance’ theory of depression 
is now dismissed as overly simplistic by academic 
psychiatry.8 Some official sources continue to 
suggest that antidepressants work by increasing 
‘levels of chemicals in the brain’ that are linked 
with depression8, but others, such as the Royal 
College of Psychiatrists public information leaflet, 
no longer mention reduced serotonin as a potential 
cause of depression.9 
The drug-centred model as outlined in section 
2, suggests that antidepressants produce 
mental and physical alterations, which interact 
with the symptoms of depression. These may 
potentially account for certain differences between 
antidepressants and placebo in randomised trials. 
For example, the sedation produced by older 
antidepressants may be experienced as helpful 
by some people with anxiety and insomnia, 
while the emotional numbness induced by some 
antidepressants may reduce the intensity of 
negative feelings for some. The mental and physical 
alterations may also reveal to people participating 
in randomised trials that they are taking an active 
drug, increasing the placebo effect. 
4.2.4 Drug effects
There has been little effort to characterise how 
antidepressants alter normal physical and mental 
functioning. 
Antidepressants come from many different 
chemical classes, and therefore can be expected 
to vary in the effects they produce. Tricyclic 
antidepressants, for example, appear to be 
pharmacologically similar to some of the older 
type of antipsychotics. They are strongly sedating 
drugs. They increase sleep and cause drowsiness 
during the day. Studies with healthy volunteers 
show that taking tricyclic antidepressants makes 
people slower in their reactions and impairs 
intellectual abilities such as attention and memory. 
Taking them is usually an unpleasant experience 
for volunteers (it is associated with ‘dysphoria’ in 
volunteer studies).14,15
SSRIs have more subtle effects in volunteer 
studies apart from their effects on the gut (most 
of the body’s serotonin is present in the gut). They 
commonly cause nausea and sometimes diarrhoea 
and vomiting. SSRIs also commonly produce 
mild drowsiness but can also cause insomnia. 
They can induce a state of emotional numbing or 
restriction.13 In addition, they can cause lethargy, 
reduced libido and sexual impairment. They 
also occasionally produce an unpleasant state 
of agitation and tension, especially in young 
people.14,16 These effects can be difficult  
to recognise.
4.2.5 Evidence of efficacy
4.2.5.1 Short-term use in depression
Antidepressants are one of the standard 
recommended treatments for depression and 
many people regard them as useful. Their use is 
based on evidence from hundreds of placebo-
controlled trials, which show that antidepressants 
are slightly better than a placebo in terms of scores 
on a depression rating scale, the principle outcome 
measure of these trials. Studies are inconsistent, 
however, and differences are small, especially 
when unpublished trials are included. 
The small difference between antidepressants 
and placebo raises questions about whether the 
effects are, indeed, worthwhile. For example, in 
an analysis, which combined the results of several 
American trials of SSRIs and other new drugs, the 
difference between the drugs and the placebo 
was less than two points on the commonly used 
Hamilton Rating Scale for Depression (HRSD).17 
Other meta-analyses, including the largest ever 
conducted, published in 2018, report similar small 
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differences between antidepressants and placebo.18 
The HRSD usually has 17 items and scores up to 54 
points. When a difference of around two points is 
compared to ratings on a commonly used global 
measure of people’s overall condition, the Clinical 
Global Impressions Scale19, it does not register as 
showing any difference at all. Indeed, a difference 
of eight points on the HRSD would be required to 
register as a ‘mild’ level of improvement on the 
Clinical Global Impressions Scale, a difference that 
is way above that found in any combined analysis 
of placebo controlled antidepressant trials.20 An 
analysis of trials conducted by the (then) National 
Institute of Clinical Excellence21 also found that 
the difference in depression scores between 
people randomised to antidepressants and people 
randomised to placebo was so small that it was, in 
the words of the Institute’s report, ‘unlikely to be of 
clinical significance’.21 
Although depression rating scales scores are the 
principle outcome measures of placebo-controlled 
trials, results are often presented in terms of the 
proportion of people who show a ‘response’ to the 
antidepressant compared with the proportion that 
respond to the placebo. The largest antidepressant 
meta-analysis reported, for example, that people 
randomised to take antidepressants were one and 
a half to two times more likely to show a ‘response’ 
than people allocated to placebo.18 There is no 
objective marker of ‘response’, however. It is 
simply defined, quite arbitrarily, as a certain level 
of reduction in depression measurement scale 
scores. When scores are categorised in this way, 
however, the difference between the groups can be 
inflated, so that small absolute differences in scores 
become quite large differences in response rates.22 
Therefore the depression scores are the most 
reliable measure of the outcome of these trials. 
The small difference between antidepressants 
and placebo that is indicated by depression scale 
scores may not even be a genuine difference 
in actual levels of depression, however, but 
may be an artefact of research designs or a 
consequence of the mental alterations produced by 
antidepressants. Publication bias, not accounting 
for withdrawal effects from previous treatment 
and various statistical issues may have artificially 
inflated differences between antidepressants and 
placebos in randomised trials and meta-analyses  
of these trials.23
Additionally, antidepressants may produce 
alterations that reduce depression-related 
symptoms without actually acting on depression 
itself. Depression often involves insomnia or 
sleeping difficulties and sometimes involves 
anxiety and agitation. Any drug with sedative 
properties will improve this aspect of the problem. 
The HRSD, for example, contains three items on 
sleep alone and these items can score up to six 
points. So, any difference between drugs and 
placebo may reflect the sedative qualities of 
some commonly used antidepressants (tricyclic 
antidepressants and mirtazapine, for example). 
Any drug that alters our consciousness may also 
obscure or suppress depressive feelings. SSRIs 
appear to dull or numb emotions, which could 
reduce the intensity of depressive feelings.16,24 
Tricyclic antidepressants may also promote a state 
of emotional indifference, given their affinity with 
antipsychotic drugs that are known to have this 
property. All these effects may reduce scores on 
depression rating scales. 
These and other alterations also mean that people 
involved in antidepressant trials are sometimes 
able to detect whether they are taking the active 
drug or the placebo. This may produce an unequal, 
amplified placebo response in people who are taking 
antidepressants in randomised trials. If people can 
improve by taking an inert placebo, what is known 
as the ordinary placebo effect, then people who 
take a drug that has noticeable effects may have 
an amplified placebo response. Conversely, people 
who take the placebo may realise this because they 
do not experience any of the ‘side’ effects they have 
been told to expect. Such people may do worse than 
they might do if they had not been enrolled in a trial 
in the first place. As such, the difference between 
antidepressants and placebo detected in clinical 
trials may be a result of ‘amplified’ placebo effects.25 
The idea that antidepressants may be working 
through inducing ‘amplified’ placebo effects 
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is supported by the finding that other drugs 
with noticeable effects, including stimulants, 
benzodiazepines, opiates, and antipsychotics 
have been found to have equal effects to standard 
antidepressants in randomised studies in people 
with depression.8 
In summary, antidepressants are only marginally 
better than placebo in randomised trials in people 
diagnosed with depression. Some evidence 
suggests the differences are unlikely to translate 
into meaningful clinical benefit. Moreover, there 
is no current evidence that strongly supports the 
idea that antidepressants produce their effects by 
acting on the underlying biological mechanism of 
depression.26 Although much research has been 
conducted to look for the underlying mechanisms 
of depression, no such mechanism has been 
confirmed, and there remains little evidence that 
serotonin or other neurochemical abnormalities 
are associated with depression, or account for 
antidepressant action. Moreover, there are other 
convincing explanations of how antidepressants 
affect people with depression.
4.2.5.2 Antidepressants in severe depression 
It is commonly stated that antidepressants are 
most effective in severe cases of depression. 
Overall, the evidence around this is contradictory. 
A NICE review claimed antidepressants have 
their most marked benefits in people with more 
severe depression, but the data actually found 
the greatest effects compared with placebo in 
people whose depression was in the middle range 
of severity, rather than in those with the most 
severe depression.21 A recent meta-analysis that 
specifically examined this issue found that the 
severity of depression was not correlated with 
drug-placebo differences.27
4.2.5.3 Long-term use for relapse prevention  
in depression
There are several studies that show that if you take 
people whose depression has improved while they 
are taking antidepressants, and you randomise 
some of them to have their antidepressant stopped 
and substituted with a placebo, then the people 
transferred to placebo will have more ‘relapses’ 
of depressive symptoms.28 Based on these 
studies, people who have had a single episode of 
depression are recommended to continue taking 
antidepressants for at least six months. People who 
have had recurrent episodes are recommended to 
take antidepressants on a longer-term basis. 
However, the interpretation of these studies 
has been challenged particularly because the 
people transferred onto placebo are liable to 
experience withdrawal effects provoked by 
stopping antidepressants (see section 4.1.5).29–31 
These effects include anxiety and mood changes 
and may be mistaken for a relapse of the original 
problem.32 
In addition, people who experience withdrawal 
effects may realise that they have been swapped 
onto the placebo and this may make them 
anxious and vulnerable. The next time they 
experience problems they may lapse into a 
state of depression because they have come to 
believe that they need the drug to remain well 
and because they realise that they have been 
taken off it. This situation is likely, because the 
participants of these maintenance treatment trials 
are a selected group who have made a good initial 
response to treatment.33 They may already be 
persuaded of the benefits of drug treatment, or, at 
least, they are likely to be nervous about having  
it withdrawn. 
However, non-randomised observational studies 
provide no evidence that antidepressants improve 
long-term outcomes of depression. In fact, some 
studies indicate that long-term antidepressant use 
is associated with increased relapse rates,34 and 
worse long-term outcomes,35,36 compared to people 
who do not use antidepressants. 
One such recent non-randomised study analysed 
the association of antidepressant use from the age 
of 20 and depressive symptoms over the course 
of the succeeding 30 years. Involving 159 people, 
it found that those who used antidepressants 
were more likely to have more severe symptoms 
during follow-up. However, it is likely that all 
these studies reflect the fact that people who 
take antidepressants generally have more severe 
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problems initially than those who decide not to 
take them, which may account for their worse 
outcomes. Some studies have taken indicators 
of initial severity into account in the statistical 
analysis to some degree, but it is difficult to exclude 
this problem altogether.37 
4.2.5.4 Use in anxiety disorders
A recent meta-analysis of studies of the treatment of 
anxiety showed that SSRI and SNRI antidepressants 
were superior to placebo in reducing scores on 
anxiety rating scales, but again the effect was 
modest. The difference in improvement between 
people taking the drug and those taking placebo 
was between two and three points on the Hamilton 
Anxiety Rating Scale, which has a maximum score of 
56 points.38 Another meta-analysis of 12 trials of the 
SSRI drug paroxetine found that, on average, people 
randomised to take paroxetine improved by 2.3 
points more than people randomised to placebo.39 
Studies comparing SSRI antidepressants with 
benzodiazepines for anxiety symptoms find that 
benzodiazepines have larger effects.40 
SSRIs and other antidepressants, particularly 
clomipramine, one of the old tricyclic 
antidepressants, are commonly prescribed 
to people who are diagnosed with obsessive 
compulsive disorder (OCD). They improve 
symptoms more than a placebo by around 3.2 
points on a 40-point OCD measurement scale.41 
Behaviour therapy has larger effects than 
medication, but most studies of therapy include 
people who are also on prescribed drugs.42
4.2.6 Common adverse effects 
Tricyclic antidepressants can slow down the 
conduction of electrical impulses in the heart and 
in high doses may cause dangerous irregularities of 
the heartbeat known as arrhythmias. Overdosing 
on these drugs is dangerous and often fatal. They 
also cause postural hypotension (a drop in blood 
pressure on standing up), which can lead to falls, 
and they increase the risk of seizures. They tend to 
have ‘anticholinergic effects’ including dry mouth, 
constipation, difficulty passing urine and blurred 
vision. At higher doses they may cause confusion. 
They also cause weight gain and sexual dysfunction 
including impotence, loss of libido and delayed 
orgasm. 
The effects of SSRIs and SNRIs are similar, 
although SNRIs may produce more noticeable 
effects. Both types of drug commonly affect gut 
activity and cause nausea, vomiting, diarrhoea, 
constipation, and abdominal pain. They are also 
associated with sexual dysfunction, especially 
delayed orgasm. There are mounting anecdotal 
reports that the sexual dysfunction associated with 
SSRIs can occasionally persist after the drugs are 
discontinued, sometimes for months or years.43
Both SSRIs and SNRIs can cause lethargy and SNRIs 
may cause drowsiness. The state of emotional 
numbing or detachment they produce can be 
experienced as unpleasant and debilitating44 and is 
associated with sexual dysfunction.45 They can also 
produce a state of anxiety and agitation, especially 
in younger people,46,47 which can also be extremely 
unpleasant and may be predictive of increased 
suicidal impulses (see below). 
4.2.7 Other adverse effects
Some SSRIs, particularly paroxetine, have been 
linked with birth defects,48 and as a class these 
drugs can thin the blood and produce bleeding 
disorders.49 
4.2.8 SSRIs and suicide
Several meta-analyses of antidepressant studies in 
children and adolescents show increased rates of 
suicidal behaviour associated with use of SSRIs.50–53 
Some meta-analyses of trials in adults indicate 
small increases in suicide attempts or self-harm in 
people on SSRIs compared with placebo.54,55 but 
others do not.56–58 A recent re-analysis of one of these 
negative studies revealed a significant increase in 
suicidal ideation and behaviour using a different 
statistical approach.59 However, where they have 
been compared with other types of antidepressants, 
SSRIs have not been found to be any worse in terms 
of increasing suicidal ideation and behaviour.60,54 A 
recent meta-analysis based on data from original 
trial reports (which can provide more transparent 
data than official publications) found increased rates 
of suicidal thoughts and behaviour in children and 
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young people taking antidepressants compared to 
those taking placebo, but there was no difference 
in adults. This analysis also found an increase in 
reports of aggressive behaviour among young 
people taking antidepressants compared to those 
on placebo.61 This confirms evidence from case 
reports of violent incidents, including legal reports 
and data from drug-monitoring agencies.62 It appears 
that these behaviours may be related to the state of 
agitation that SSRIs and related antidepressants can 
occasionally produce, which, for reasons that are 
not understood, seem to be more common among 
young people.47 
It is difficult to evaluate the conflicting evidence 
and claims about the relationship between 
antidepressants and suicide and violence because 
these situations are rare. On balance, the majority 
of evidence suggests that antidepressants can 
increase suicidal impulses and possibly also violent 
behaviour in children and young people. The 
evidence in adults is less conclusive.
4.2.9 Conclusion
Although antidepressants have been claimed 
to work by reversing underlying neurochemical 
abnormalities, no consistent abnormalities have 
been demonstrated in depression, and there is 
little evidence that antidepressants work in this 
way. Antidepressants show a minimal degree of 
superiority over placebo in short-term clinical 
trials (usually eight weeks) of depression. The 
small difference could be explained by drug-
induced effects of antidepressants, such as 
sedation and emotional blunting, boosting 
improvements on depression measurement 
scales, as well as methodological factors in 
trial design, analysis and publication, which 
can artificially inflate drug-placebo differences. 
Finally, the findings of the many short-term trials 
do not enlighten us about the effects of long-term 
treatment. Despite the fact that many people end 
up taking antidepressants for months and years, 
there is little robust research on the benefits and 
harms of long-term treatment. 
Some psychoactive effects of antidepressants may be 
experienced or perceived as useful for some people 
diagnosed with depression. Such effects vary in 
strength and character depending on chemical class 
and composition of the particular antidepressant. For 
example, tricyclic drugs are strongly sedating, which 
might be experienced as useful for insomnia, or to 
reduce anxiety and agitation. SSRIs, whilst exerting 
weaker and more subtle effects, can induce a state 
of emotional numbing or restriction, which may 
reduce the intensity of people’s feelings. However, 
the fact that drug-placebo differences are so small, 
and easily accounted for by non-pharmacological 
factors, suggests that antidepressant-induced 
alterations may not be clinically useful. Moreover, 
emotional restriction and other drug-induced mental 
alterations may complicate successful engagement in 
psychotherapy. 
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4.3 Benzodiazepines and related drugs
4.3.1 History 
Benzodiazepine is the chemical name for a group 
of drugs discovered in the 1960s, otherwise known 
as (minor) tranquilisers. The individual drugs are 
often more familiar by their trade names. One 
of the most commonly used benzodiazepines is 
diazepam, whose trade name is Valium. They also 
include chlordiazepoxide (librium), lorazepam and 
temazepam. 
From the 1960s onwards, benzodiazepines 
were widely prescribed to people with sleeping 
difficulties and people with anxiety and ‘neurotic’ 
disorders, especially women, often for long periods 
of time. In the 1980s it became apparent that many 
people who take benzodiazepines for more than a 
few weeks become physically dependent on them 
and experience significant withdrawal symptoms 
when they stop. Recommendations were then made 
that they should not be prescribed routinely other 
than for short periods. 
Starting in the late 1980s, the Z-drugs (zopiclone, 
zolpidem and zaleplon) were introduced. These 
are chemically different from benzodiazepines but 
have similar effects and are now widely prescribed 
for insomnia. The drugs pregabalin and gabapentin 
also bear some similarities to benzodiazepines 
in terms of their pharmacological actions. In 
psychiatry, they are prescribed for anxiety. They 
are also used for epilepsy and nerve pain. In 2013, a 
UK study reported that pregabalin and gabapentin 
prescribing had increased by 350% and 150% 
respectively in just five years1. Withdrawal reactions 
have been described following discontinuation, 
which are similar to benzodiazepine withdrawal 
reactions.2,3 
4.3.2 Theories of action
Benzodiazepines act by enhancing the activity of 
the brain chemical known as gamma aminobutyric 
acid (GABA). GABA has an inhibitory effect and 
benzodiazepines increase this. Therefore, they 
lower the activity of the brain, causing sedation and 
relaxation at lower doses, progressing to sleep and 
then coma and death at very high doses. Z-drugs 
also work by stimulating the GABA system. 
In most situations benzodiazepines are regarded as 
non-specific treatments. In other words, they are 
thought to work according to a drug-centred model 
by producing an artificial drug-induced sedative 
state, rather than reversing an underlying disease. 
Since it is well known that they induce similar 
effects in everyone, regardless of whether or not 
they suffer from a psychiatric problem, it is difficult 
to deny the impact of their drug-induced effects. An 
exception to this is the case of anxiety. It has been 
suggested that anxiety is caused by abnormalities of 
GABA activity, which can be specifically reversed by 
the action of benzodiazepines on the GABA system. 
However, there is limited evidence of this.4 
4.3.3 Drug effects
Benzodiazepines and similar drugs have sedative 
properties, similar in nature to alcohol. They cause 
a sensation of relaxation, which is both mental 
and physical, and they are recognised muscle 
relaxants. Like alcohol they may occasionally lead 
to disinhibited or aggressive behaviour, although 
there is little robust evidence in clinical or help-
seeking populations.4a The alterations they produce 
are usually experienced as pleasurable, and they are 
used for recreational purposes, especially by those 
who prefer sedative drugs or ‘downers’. 
4.3.4 Evidence of efficacy 
Short-term studies of benzodiazepines show that they 
reduce anxiety more than a placebo and are slightly 
more effective than other common drugs treatments 
for anxiety such as SSRIs.5 However, studies generally 
only last a few weeks, so it is not certain whether this 
effect persists, since the body adapts to counteract 
their effects. This is the mechanism of dependence. 
The body’s arousal mechanisms are stepped up to 
counteract the effects of the drugs, leading to the 
need for greater doses to produce the same effects 
and causing unpleasant withdrawal symptoms when 
they are stopped. 
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Randomised controlled trials of benzodiazepines 
for insomnia show that they increase duration of 
sleep by around an hour on average, but do not 
improve the time it takes to get to sleep (sleep 
latency).6 In contrast, a recent meta-analysis of 
Z-drugs found that sleep latency was reduced by 
an average of 22 minutes compared to placebo, a 
difference which the authors concluded may not be 
clinically meaningful, and there was no evidence of 
improvement of sleep duration, although there was 
insufficient evidence on this particular outcome.7 
4.3.5 Common uses
Benzodiazepines are recommended for the short-
term treatment of anxiety and Z-drugs for the short-
term treatment of insomnia. Benzodiazepines 
are also prescribed for the treatment of alcohol 
withdrawal and are frequently prescribed to people 
with severe psychiatric problems because of their 
sedative properties. As such, they are prescribed 
extensively to psychiatric inpatients with various 
diagnoses. 
Within psychiatric hospitals, benzodiazepines 
are commonly used in emergency situations to 
sedate people who are behaving in a disturbed or 
aggressive way. Studies show that benzodiazepines 
are effective and comparable to other sedative 
agents (such as antipsychotics) in this situation.8 
However, evidence about whether they can reduce 
disturbed behaviour over a long period is lacking. 
Benzodiazepines and Z-drugs have modest effects in 
insomnia and so they might be useful, temporarily, 
in someone who is having trouble sleeping. 
However, this effect will wear off, and if they are 
taken for more than a few weeks, withdrawing from 
them will itself produce sleeping difficulties. It is a 
similar situation with anxiety. Benzodiazepines can 
have remarkable effects in reducing anxiety initially, 
but these effects are likely to decline with time. 
When the drugs are stopped, anxiety will be induced 
by the process of withdrawal. For this reason, it is 
recommended that benzodiazepines be reserved for 
short-term use only.9 
Despite benzodiazepines being generally 
recommended for short-term use only, many 
people appear to be prescribed benzodiazepines 
over long periods. Recent research estimates 
that the current number of people taking 
benzodiazepines long-term (beyond one year) in 
England is over 266,000.10 
4.3.6 Common adverse effects 
Like all sedative drugs, benzodiazepines impair 
people’s ability to perform simple physical and 
mental tasks like driving and mental arithmetic. 
As with alcohol, people are often unaware of their 
impairment and rate themselves as functioning 
better than they are. It may only be after they 
withdraw from the drugs that they realise how 
impaired they were.11 Other effects that derive from 
the ability of benzodiazepines to suppress nervous 
activity include confusion, slurring of speech and 
loss of balance and usually only occur at higher 
doses, or if some other factor (like a physical illness 
of some sort) is present. These effects are more 
likely to occur in elderly people, and when they 
do, elderly people can have falls and suffer other 
accidents because of being over-sedated. 
At very high doses, such as when they are taken 
in an overdose, benzodiazepines can, like other 
sedative drugs, suppress the respiratory system 
and cause death. 
There has been some concern that benzodiazepines 
may occasionally lead to disinhibited behaviour 
and aggression. This mainly seems to occur when 
high doses are used in people with a prior history of 
behavioural problems and in people who are more 
vulnerable to this, like children, the elderly and 
people with learning disability.12 
Pregabalin and gabapentin also suppress the 
activity of the central nervous system, and their use 
can result in drowsiness, sedation, and reduced 
breathing. These risks are raised by higher doses, 
such as might be taken in an overdose, or when 
they are used in combination with other drugs that 
depress the nervous system. Like benzodiazepines, 
this can lead to respiratory failure and death in 
extreme cases. They are also associated with 
weight gain, which is not generally thought to occur 
with benzodiazepines. 
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Benzodiazepines are well-recognised recreational 
drugs, often used alongside other illicit substances 
like opiates. The agents with the shortest half-life 
are the most susceptible to abuse, and some, like 
temazepam, have been added to the schedule 
for controlled drugs. There have also been calls 
to make pregabalin and gabapentin-controlled 
substances, due to their propensity to become 
drugs of recreational or illicit use.13 Both are 
reported to produce a ‘high’ in those taking them. 
The abuse potential may be higher with pregabalin, 
which is absorbed faster and is more potent than 
gabapentin.14,15 However, gabapentin can also 
produce euphoria.16
4.3.7 Long-term harm
A few studies have looked at whether long-term 
use of benzodiazepines affects the structure of 
the brain. Two of these studies found a reduction 
in the amount of brain matter after long-term 
use of benzodiazepines, similar to findings with 
antipsychotics.17,18 However, two other studies 
found no effects.19,20 
Some studies have reported an increased incidence 
of dementia in people taking benzodiazepines 
compared to those who are not taking them.21,22 
However, since people with dementia can 
often present initially with increased anxiety or 
depression, for which they may be prescribed 
benzodiazepines, these studies do not necessarily 
indicate a causal relationship. However, a meta-
analysis found that the risk of dementia was raised 
in people who had taken benzodiazepines in the 
past as well as those taking them currently or 
recently.23 It also found that the risk of dementia 
was higher in people who took higher doses 
of benzodiazepines compared to those who 
took lower doses, and a correlation between 
increased risk and dose is generally regarded 
as a likely indicator of causation. A more recent 
study, however, suggested that the association 
might be accounted for by other drugs being 
taken alongside the benzodiazepines.24 Despite 
remaining uncertainties, the evidence reinforces 
current recommendations that the drugs should be 
reserved for short-term use where possible.9
Benzodiazepines are definitely to be avoided 
during the last part of pregnancy, as they can cause 
neurological toxicity in the newborn infant.25
Together with drowsiness and confusion 
caused by their sedative properties, the most 
pressing concern regarding benzodiazepine use 
is dependence. The occurrence of withdrawal 
syndromes after stopping benzodiazepines and 
Z-drugs is well established and also reported in 
relation to gabapentin and pregabalin (see section 
5 for further information). 
4.3.8 Conclusion
Benzodiazepines are effective in reducing feelings 
of anxiety and have a modest effect in insomnia in 
the short-term. The main concern with their use is 
the significant risk of tolerance and dependence, 
and the associated difficulties that people can 
experience when trying to withdraw from the 
drugs. 
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The types of drugs that are now commonly called 
antipsychotics were previously referred to as 
neuroleptics or as major tranquillisers. 
The first drugs of this sort were introduced in 
the 1950s and 1960s. At that time, psychiatrists 
viewed them following a drug-centred model as 
substances that happened to have the ability to 
suppress thoughts and emotions without simply 
putting people to sleep in the way the older 
sedatives did. The mental restriction the drugs 
produced was noted to be part of a general state 
of physical and mental inhibition that at extremes 
resembled Parkinson’s disease. Early psychiatrists 
regarded this state of neurological suppression as 
useful but as potentially damaging to the brain. 
Over time, these drugs have come to be regarded 
as treatments that target an underlying brain 
abnormality, particularly through their effects on 
the neurotransmitter, dopamine. Parallel to this 
view, they have come to be called ‘antipsychotics’.1 
The first of these drugs are now sometimes referred 
to as ‘first generation’ or ‘typical’ antipsychotics. 
From the 1990s a new range of these drugs 
was introduced, known as ‘atypical’ or ‘second 
generation’ antipsychotics. The second-generation 
antipsychotics were claimed to be more effective 
and less prone to side effects than the older 
drugs, but this is now known not to be the case. 
In fact, the distinction between the two classes is 
regarded now as unhelpful. Both classes contain a 
diverse range of individual substances with varying 
pharmacological profiles and range of effects. 
4.4.2 Common uses of 
antipsychotics
Antipsychotic medication is a mainstay of 
treatment for people diagnosed with psychosis 
and schizophrenia. They are used to treat acute 
episodes of psychotic disturbance. People who 
experience a first episode of psychosis in the UK 
are often cared for by specialist early intervention 
in psychosis teams. After taking antipsychotic 
drugs for a further one to two years after recovery 
from the acute episode, they may be supported to 
stop. People who have more than one episode are 
recommended to stay on these drugs long-term for 
relapse prevention.
As well as being used for treating those with 
a diagnosis of psychosis or schizophrenia, 
antipsychotic drugs are also used in a range 
of other situations, particularly to calm and 
subdue people who are agitated or aggressive. 
Therefore, they are also prescribed to people who 
are diagnosed with mania, personality disorder, 
dementia, learning difficulties, autism and anxiety. 
They are also prescribed for depression and 
insomnia. Some antipsychotics are considered to 
be ‘mood stabilisers’ and prescribed for long-term 
treatment of people with bipolar disorder (see 
section 4.7 on ‘mood stabilisers’).
4.4.3 Theories of action
Antipsychotic drugs had been in use for at least a 
decade before it was discovered that some of them 
strongly counteract the effects of the brain chemical 
called dopamine. This finding led to the ‘dopamine 
hypothesis’ that suggested that ‘schizophrenia’ was 
a result of abnormally increased dopamine activity. 
In this view, antipsychotics are thought to reverse 
the chemical imbalance causing the symptoms of 
‘schizophrenia’ or psychosis. 
The dopamine hypothesis has developed over time, 
and now incorporates ideas about other causal 
factors including genetics, environmental stress 
and other neurotransmitter abnormalities, but 
amongst this complexity, the general assumption 
remains that dopamine dysfunction is part of 
the causal pathway to psychosis. The disease-
centred view of antipsychotics is that they work by 
correcting, or partially correcting, this underlying 
abnormality by lowering dopamine activity.
Although some experts still adhere to the 
dopamine hypothesis2, the majority of evidence 
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that has been collected over the last 50 years has 
not confirmed any differences in indicators of 
dopamine activity between people with a diagnosis 
of psychosis or schizophrenia and people without.3 
The few studies that show differences include very 
few people who have not already been treated with 
antipsychotics (which modify dopamine activity 
in themselves) and have not controlled for the 
other factors that are associated with increased 
dopamine activity, such as stress and arousal.3,4 
4.4.4 Drug effects
Antipsychotic drugs vary in their pharmacology 
and profile of effects, but they all produce a state of 
global physical and mental inhibition or restriction. 
Many older antipsychotics act predominantly by 
blocking dopamine receptors, which produces a 
global neurological state resembling Parkinson’s 
disease, a condition caused by degeneration of the 
dopamine producing cells. Its symptoms reflect a 
reduction of the activity of the dopamine system, 
which consist of reduced movement and slowed 
mental processes. However, all antipsychotics 
affect other neurotransmitter systems to some 
degree, and some, such as clozapine, have 
relatively weak actions on the dopamine system 
and a wide array of actions on other systems 
that are likely to be relevant to the mental and 
behavioural alterations they produce.
All antipsychotics appear to dampen down 
emotional responses. Associated with this, people 
find it difficult to motivate themselves to do 
things, or to take the initiative to act. Two Israeli 
doctors who took an injection of haloperidol for 
experimental purposes described how they were 
unable to read, use the telephone or perform 
household tasks of their own will, but could do so if 
instructed to by somebody else.5
Animal and volunteer studies show that individuals 
taking antipsychotics perform less well on tests 
of learning, memory, attention, reaction times 
and other tests of cognitive abilities.6–9 Psychotic 
symptoms can also impair cognitive function, so 
antipsychotics may actually improve functioning 
in people who are symptomatic. However, there is 
some evidence that long-term use of antipsychotics 
may impair some aspects of cognitive performance 
in people who have recovered from their 
psychosis.10 
In contrast to the disease-centred view that 
antipsychotics work by correcting an underlying 
dopamine abnormality, the drug-centred model 
suggests that the ‘antipsychotic’ effect is achieved 
by this state of neurological restriction that 
antipsychotics induce. This artificial state of 
suppression may reduce the intensity of ‘abnormal’ 
thoughts and experiences such as delusions and 
hallucinations and render them less distressing 
and intrusive. In this way, antipsychotics can be 
useful for the symptoms of acute psychosis or 
what are known as the ‘positive symptoms’ of 
‘schizophrenia’. However, there is no evidence 
that antipsychotics are selective for ‘abnormal’ 
thoughts or psychotic symptoms, and evidence 
from volunteer studies8,9 and accounts by people 
who have taken these drugs for a variety of 
problems4 suggest that they affect a wide range of 
mental processes.
4.4.5 Evidence of efficacy
4.4.5.1 Short-term use in psychosis
Although there is no evidence that antipsychotics 
treat or target the condition known as 
schizophrenia or psychosis, placebo-controlled 
randomised trials show that antipsychotics reduce 
the general disturbance in people who have an 
acute psychotic episode or exacerbation, improve 
their global condition and reduce abnormal 
experiences like delusions and hallucinations more 
than placebo.11,12 However, a significant proportion 
of people does not improve substantially with 
antipsychotic treatment and have persistent 
symptoms despite treatment. 
Evidence about whether antipsychotics are superior 
to other sorts of sedative drugs is more equivocal. 
Two trials suggested they were superior to 
barbiturates, but studies comparing antipsychotics 
to opium and benzodiazepines have not clearly 
differentiated the different types of drugs.13–15 
The question as to whether people with psychosis 
can recover without the use of antipsychotics 
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received interest several decades ago but has 
been neglected more recently. A study in the 
1970s compared people who entered the Soteria 
project, a small homely unit in California designed 
to care for people with psychotic disturbance or 
a diagnosis of schizophrenia, whilst avoiding the 
use of antipsychotics if possible, to similar people 
treated with antipsychotics at a conventional 
hospital. Thirty percent of people randomised to 
Soteria avoided the use of antipsychotics, but both 
groups did equally well.16 A more recent study in 
Finland of people with a first psychotic episode 
also found that 43% of people could be successfully 
managed without antipsychotics.17 So a reasonable 
proportion of people with an episode of psychosis 
may recover without the need for antipsychotics, 
but more research is needed in this area. 
4.4.5.2 Long-term use for relapse prevention 
The evidence base for the long-term prescription 
of antipsychotics to people diagnosed with 
schizophrenia or other psychotic conditions 
consists of many randomised and non-randomised 
studies showing that people on placebo or no 
treatment relapse more commonly than those who 
take continuous antipsychotic treatment. These 
studies have important limitations, however.18–20 
First, the studies are too short to provide useful 
information about the benefits and risks of long-
term antipsychotic treatment, with most lasting 
less than six months. Second, the randomised 
controlled trials all involve people who are already 
taking antipsychotics, often for many years before 
the study begins. The people who are randomised 
to placebo, therefore, have their previous drug 
treatment discontinued, usually abruptly over 
a few days, and replaced by placebo. They are 
therefore liable to the adverse effects associated 
with discontinuing antipsychotics. Withdrawal 
effects include agitation and insomnia, which may 
be mistaken for relapse, especially in trials that 
use broad definitions of relapse. There is some 
evidence, moreover, that antipsychotic withdrawal 
may precipitate a relapse of the underlying 
disorder that would not otherwise have occurred 
at that point, or that withdrawal itself can produce 
a psychotic state.21 Therefore, the outcome of 
people in the placebo group in randomised trials 
of long-term treatment likely reflects the effects 
of antipsychotic discontinuation rather than the 
benefits of initiating preventive treatment. 
Finally, most studies of long-term antipsychotic 
treatment have not investigated outcomes other 
than relapse, such as people’s overall ability to 
function, their ability to work, to have relationships 
and to enjoy their lives. 
4.4.5.3 Recent evidence on long-term 
antipsychotic use
Recent naturalistic, non-randomised follow-up 
studies suggest that long-term antipsychotic use 
may be associated with poorer outcomes. For 
example, studies in the USA, Finland and Denmark 
found that people who took antipsychotics 
on a continuous basis did less well in terms 
of ‘symptom’ levels and general functioning, 
than people who did not take antipsychotics or 
took them only occasionally after 10–20 years 
of follow-up.22–24 However, these studies were 
not randomised and those patients able to stop 
their antipsychotic drugs may have had a milder 
condition than those who continued. The results 
are consistent, though, with the findings of a 
long-term follow-up of participants from a Dutch 
randomised trial.25
This study randomised people who had recovered 
from a first episode of psychosis to routine 
‘maintenance’ treatment with antipsychotics, or 
to have their antipsychotics reduced in a flexible 
manner and stopped if possible. After the first 
follow-up at 18 months, twice as many people had 
experienced a relapse in the discontinuation group 
as in the maintenance group, although relapse 
was defined broadly as an increase in a single 
‘symptom’ of psychosis, and rates of hospitalisation 
were not different. Only 20% of the discontinuation 
group had stopped antipsychotics at this point. 
Seven years later, 42% of the discontinuation 
group and 24% of the maintenance treatment had 
stopped antipsychotics or were taking only very 
low doses. By this point, there was no longer a 
difference in relapse rates, and levels of psychotic 
symptoms were similar in both groups. However, 
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people in the discontinuation group were more 
than twice as likely to have recovered from a 
functional point of view (40% vs 18%). 
Since this was a randomised trial, differences 
between groups cannot be attributed to differences 
in the severity of their underlying condition. 
Therefore, the results provide some evidence that 
long-term antipsychotic use impairs some people’s 
ability to function, which may be expected given 
their known inhibitory effects. It also suggests that 
attempting a gradual and supported reduction of 
antipsychotics may lead to people doing better in 
the long-term. 
The results of a 10-year follow-up of people 
who took part in a placebo-controlled trial of 
quetiapine have also been reported recently.26 
This trial was reported as showing that people 
who were originally randomised to placebo 
had poorer outcomes than those who were 
randomised to quetiapine at 10 years. However, 
people who were defined as showing a ‘poor’ 
outcome included people with a mild increase 
in symptoms, and also included people whose 
symptoms were measured only after the original 
trial, and not at the 10-year follow-up. In fact, the 
‘symptom’ scales and measures of functioning 
indicated no difference between people who 
were originally randomised to quetiapine and 
those originally randomised to placebo at the 10-
year follow-up, which is not surprising, since the 
original trial was only a few months’ long for the 
majority of participants.27 
Long-term antipsychotic treatment may be helpful 
to reduce the intensity of ongoing psychotic 
symptoms or to prevent recurrence in some people. 
The balance of benefits and harms still needs to be 
elucidated, however, especially given the serious 
physical complications that antipsychotics can 
produce. A randomised controlled trial to evaluate 
a strategy of gradual reduction and discontinuation 
of antipsychotics compared with maintenance 
treatment in people with recurrent psychosis or a 
diagnosis of schizophrenia is currently under-way 
in the United Kingdom to provide more evidence in 
this area.28 
4.4.6 Evidence for use in other 
disorders
There are studies that show that some 
antipsychotics are more effective than placebo 
for people diagnosed with depression, but as 
described in the section on antidepressants, almost 
any drug with noticeable effects has been found 
to have ‘antidepressant’ effects in one study or 
another, strongly suggesting that the effect is in fact 
an amplified placebo effect. 
By reducing physical movement and arousal, 
antipsychotics may theoretically be useful 
in people who are hyperactive, agitated or 
aggressive. Trials have been conducted of the 
use of antipsychotics for the treatment of short-
term aggressive behaviour, which show their 
effects are comparable with those of other types 
of sedative.29–31 Trials of longer-term treatment 
for challenging behaviour in people with learning 
disability and dementia have found little or 
no benefit.32,33 With regards to the diagnosis 
of personality disorder, only the category of 
‘borderline’ or ‘emotionally unstable’ personality 
disorder has been frequently studied.34 No 
evidence has been found for a positive effect of 
antipsychotics on the core features of the diagnosis 
itself, but NICE guidelines suggest short-term 
use of antipsychotics can be considered for crisis 
symptoms, such as impulsivity and aggression.35
Antipsychotics have been found to provide no net 
benefit for the core symptoms of autism in both 
children and adults.36 NICE found ‘moderate to 
low’ quality short-term evidence for a range of 
behaviours including irritability and parent-defined 
challenging behaviours, but strong evidence of 
adverse effects.37 Problems with the evidence 
included inconsistent results and risks of bias, such 
as unclear blinding procedures. The NICE guidance 
suggests considering antipsychotics for managing 
severely challenging behaviour in autism if other 
interventions are not possible or effective. Another 
meta-analysis judged the evidence for the use of 
antipsychotics for irritability and aggression in 
autism to be of better quality, but also noted the 
risk of adverse effects.38
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There is a lack of evidence for the use of 
antipsychotics in insomnia39, and limited evidence 
for anxiety. According to a recent meta-analysis 
one antipsychotic (quetiapine) may have modest 
benefits compared to placebo in reducing anxiety 
symptoms, but it also has significant adverse 
effects and it is not clear that the benefits can 
compensate for these.40 The results were also 
inconsistent, and all the individual trials were 
funded by the manufacturer. Other antipsychotics 
have been trialled for anxiety, with negative 
results.41
Overall, since antipsychotics are associated with 
serious adverse effects (see below), the balance of 
benefit to harm is not likely to be positive in less 
serious mental health difficulties, especially with 
long-term use.
4.4.7 Adverse effects 
Antipsychotics frequently produce a variety of 
bodily alterations that can be harmful, including 
metabolic disturbance and neurological effects. 
Less commonly, they are associated with 
dangerous and sometimes life-threatening 
complications. 
Extra-pyramidal effects: This is the term used 
to describe symptoms produced by the effects 
of antipsychotics on a part of the brain involved 
in bodily movement called the extra-pyramidal 
system. They include Parkinson’s disease-type 
symptoms of muscle stiffness, tremor and slowness 
of both movement and thought. Sometimes a 
‘dystonic’ reaction can occur, when the muscles 
uncontrollably spasm. Most often this occurs 
shortly after starting the drug, but it can occur 
after longer periods of treatment too. Acute 
dystonia, which most often affects the head and 
neck muscles can be frightening and painful, and 
potentially fatal, if it is severe and not treated 
quickly. Another ‘extra-pyramidal side effect is 
akathisia, which is a state of intense restlessness, 
causing people to feel compelled to move about, 
together with a feeling of psychic tension or 
anxiety. Although this is classified as an extra-
pyramidal side effect, the exact mechanism behind 
it is unknown. 
Metabolic abnormalities: Antipsychotics 
frequently cause people to gain weight.42 They 
cause a noticeable increase in appetite and 
craving for carbohydrate-rich foods and decrease 
movement and energy use. Antipsychotics are 
also linked to disruptions of the body’s normal 
metabolic processes that can lead to diabetes 
and raised cholesterol. These may, in turn, lead to 
increased rates of cardiovascular disease (including 
heart attacks and strokes).43 
Structural brain changes: Recent studies in both 
animals and people have revealed that long-term 
antipsychotic treatment is associated with reduced 
brain weight and volume.44, 45
Tardive dyskinesia: This is a neurological 
condition involving involuntary movements, 
usually of the face. Several studies suggest that 
intellectual or cognitive deterioration also forms 
part of the syndrome46,47. Recent studies find that 
tardive dyskinesia affects approximately 4%–5% 
of people per year who take antipsychotics48,90 
(although this may be lower in ordinary psychiatric 
practice in the UK, possibly due to use of lower 
doses). It occurs more frequently in the elderly. It 
can be permanent, persisting after the drugs are 
stopped. 
Neuroleptic malignant syndrome: This is an 
uncommon and dangerous reaction that occurs 
in around 0.5% of people newly started on 
antipsychotics. The exact mechanism is not known. 
It consists of a sudden reaction in which people 
have a high temperature, muscular rigidity and 
there is a risk of death. 
Effects on the heart: All antipsychotics can cause a 
defect in the ability of the heart muscle to conduct 
electrical impulses. In particular, the drugs can 
cause prolongation of part of the heart’s cycle of 
activity and they can cause irregular heartbeats 
or arrhythmias. Rarely, these effects can lead to 
sudden death, which is more common with higher 
doses.50 
Hormonal abnormalities: Dopamine inhibits the 
production of the hormone prolactin. Therefore, 
reducing dopamine activity leads to an increase in 
prolactin levels. This is the hormone that stimulates 
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production of breast milk, and high levels can 
result in breast growth in men, lactation, infertility, 
impotence, reduced sex drive, and the bone-
wasting condition, osteoporosis. This effect is more 
common with some individual antipsychotics, but 
sexual dysfunction is a common side effect of all, or 
most, antipsychotics. 
Increased mortality: Evidence on whether long-
term use of antipsychotics increases the risk of 
premature death is inconsistent. It is well known that 
people with a diagnosis of schizophrenia or another 
severe mental illness die earlier than the general 
population, partly due to lifestyle factors such as 
high rates of smoking and lack of exercise. Some 
studies suggest that antipsychotic drugs play a role, 
after taking account of these lifestyle factors.51,52 
However, other studies have reported reduced 
mortality among people who use antipsychotics 
compared to those who do not.53,54 Being on more 
than one sort of antipsychotics is associated with a 
particularly high risk of early death.52 
Other adverse effects: Many antipsychotics block 
the activity of the transmitter acetylcholine and 
produce what are called ‘anticholinergic effects’. 
These include symptoms such as dry mouth, 
blurred vision and constipation. Many of the 
drugs cause postural hypotension, a drop in blood 
pressure on standing, due to effects on a type of 
noradrenalin receptor. Many antipsychotics can 
cause epileptic fits, particularly at higher doses, 
especially clozapine.
Clozapine can also cause a dangerous drop in the 
white blood cells that provide the body’s immunity 
from infection. This can be dangerous and can lead to 
death from common infections. Everyone who takes 
clozapine requires regular monitoring of his or her 
blood cells to detect this effect early when it occurs.
4.4.8 Conclusion
Antipsychotics are powerful drugs. Most of them 
produce a state in which people’s physical actions 
and mental processes are slowed up and restricted. 
These effects may be useful in suppressing certain 
mental experiences like delusions and hallucinations 
and in controlling disruptive behaviour, especially 
in the short term. The evidence on the benefits and 
harms of long-term drug treatment for people with 
a diagnosis of psychosis or schizophrenia is more 
difficult to interpret. Over the long term, the drugs 
are probably beneficial for some, but not necessarily 
for everyone with these conditions, and they are 
undoubtedly associated with severe adverse effects. 
For an individual, the decision about whether 
to take antipsychotic drugs, or whether to stop 
taking them once they are started, depends on a 
fine balance between many considerations. For 
someone suffering unpleasant symptoms such 
as abusive hallucinations, they may have useful 
effects. People testify that antipsychotics help 
suppress distressing psychotic symptoms, but they 
also highlight how these benefits come at a price. 
Many of those taking these drugs experience the 
mental slowing and emotional restriction produced 
by antipsychotics as unpleasant, and their use 
can lead to a variety of physical complications. 
The harms related to antipsychotic drugs are 
particularly likely to outweigh any benefits they 
might produce in people with less severe mental 
health difficulties. 
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4.5 Lithium and other drugs referred to as mood stabilisers
4.5.1 History 
Drugs labelled as ‘mood stabilisers’ are most 
commonly used by people diagnosed with bipolar 
disorder. Bipolar disorder replaced the term manic 
depression to describe a pattern of behaviour that 
had been recognised for a long time, consisting 
of episodes of extreme arousal, hyperactivity 
and elation, known as mania, often followed by 
episodes of severe depression. Although the idea 
of a ‘mood stabiliser’ implies specific effects on the 
underlying biological basis of mood variability, in 
fact nothing like this has ever been demonstrated 
for any of the drugs referred to as mood stabilisers. 
The term ‘mood stabiliser’ merely refers to drugs 
that have been licensed for, or are commonly 
used in, the treatment of people diagnosed with 
bipolar disorder or manic depression. The first 
drug that was regarded as a specific treatment for 
manic depression was lithium. Lithium is an alkali 
metal, with sedating effects that are closely linked 
to neurological toxicity. The concept of a ‘mood 
stabiliser’ appeared in the 1990s at about the 
time that an old epilepsy drug, sodium valproate, 
started being marketed for the treatment of 
manic depression in a new preparation known 
as Depakote.1 Other epilepsy drugs, such as 
carbamazepine and lamotrigine have also been 
marketed for this use. The implication that they 
stabilise mood has allowed these drugs to be 
prescribed to a wide proportion of ‘psychiatric 
patients’ who exhibit emotional turmoil from 
time to time. Since the invention of the concept 
of the mood stabiliser, such signs of emotion can 
be interpreted psychiatrically as a pathological 
or abnormal instability of mood and used as the 
justification for prescription of ‘mood-stabilising’ 
drugs. Hence, a large proportion of people who 
attend psychiatric services are now prescribed one 
of these drugs. However, there is little evidence 
that any of these drugs normalise emotional 
responses or stabilise mood. 
Currently the group of drugs recommended for 
long-term treatment of manic depression or bipolar 
disorder includes lithium, sodium valproate other 
anti-epileptics such as carbamazepine and the 
newer drug lamotrigine and several antipsychotics 
(e.g. olanzapine, quetiapine and ariprazole). 
The antipsychotics that are officially referred 
to as ‘mood stabilisers’ are the ones that have 
been tested and marketed for this indication, 
but most antipsychotics are commonly used for 
the treatment of people diagnosed with bipolar 
disorder or acute mania. 
4.5.2 Common uses
The commonest use of lithium and other ‘mood 
stabilisers’ is for the long-term treatment of people 
diagnosed with bipolar disorder. Guidelines 
suggest that they should be prescribed on a 
long-term basis to reduce the risk of relapse into 
a further episode of either mania or depression. 
An episode of acute mania is usually treated with 
various sedative agents including drugs referred to 
as mood stabilisers, like sodium valproate, but also 
benzodiazepines and all sorts of antipsychotics. 
Over the last few decades, the idea that there are 
less severe forms of bipolar disorder has been 
popularised and the concept of the disorder has 
become malleable. Concepts such as ‘bipolar 
2 disorder’, which is said to consist of recurrent 
depression with mild periods of mania, and 
‘bipolar personality’ have been created, but are not 
universally accepted. It has been claimed that up to 
20% of the population may suffer from some sort 
of ‘bipolar spectrum’ disorder.2 Alongside these 
changing notions of the condition, there have been 
increasing rates of prescription of drugs referred to 
as ‘mood stabilisers’, particularly newer or atypical 
antipsychotics3, some of which have been heavily 
marketed for this indication.4 
4.5.3 Theories of action
Lithium is chemically similar to sodium, which is 
involved in many biological processes. Researchers 
have proposed various theories of the mechanisms 
for lithium’s supposed anti-bipolar action. These 
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include correcting ‘abnormal’ sodium and calcium 
levels within cells, correcting ‘abnormal’ sodium 
dependent processes, effects on dopamine and 
serotonin pathways, and neuroprotective effects.5 
However, it remains widely acknowledged that 
there is no clear evidence as to the mechanism of 
action of lithium. This is also the case for the other 
drugs referred to as mood stabilisers.6
Although there is no clear biochemical theory, such 
as the dopamine hypothesis of ‘schizophrenia’, 
that helps to rationalise a disease-centred view of 
the action of these drugs, they appear not to be 
regarded simply as sedatives. If this were the case, 
the risk of toxic effects, especially with lithium, 
would be difficult to justify. Instead lithium and 
the other drugs are regarded as having specific, 
although yet unidentified, actions on a presumed 
biological basis of abnormal mood or manic 
depression.
From a drug-centred perspective, all drugs 
currently designated as ‘mood stabilisers’ have 
sedative effects and hence they are likely to 
reduce arousal and the emotions associated with 
heightened arousal like elation and irritability. The 
main research that has been conducted into their 
effects on people with relevant diagnoses, and 
that is used to justify the term ‘mood stabiliser’, 
concerns whether they suppress signs of mania 
and prevent relapse in people diagnosed with 
classical manic depression, now known as ‘bipolar 
1 disorder’. The only tests that have been done to 
look at how these drugs affect the variability of 
mood in healthy volunteers were done with lithium 
and found that lithium did not reduce normal 
fluctuations of mood.7,8
4.5.4 Drug effects
Lithium is a metal that can have dangerous effects 
on the nervous system, the gut and the kidneys 
at relatively low doses. Mild symptoms of toxicity 
include neurological symptoms such as tremor 
and lethargy. Progressive toxicity results in 
diarrhoea and vomiting, incontinence, drowsiness, 
disorientation, abnormal jerking movements, loss 
of balance (ataxia) and slurred speech (dysarthria), 
finally giving rise to convulsions, coma and death. 
The effects deemed therapeutic are on a continuum 
with the manifestations of the toxic state. Thus, 
before the signs of full-blown toxicity start, lithium 
causes suppression of nervous conduction leading 
to sedation and impairment of cognitive functions.9 
These effects are clearly demonstrated in volunteer 
studies.8,10 After two to three weeks on lithium 
volunteers show decreased ability to learn new 
information, prolonged reaction times, poor 
memory, loss of interest and reduced spontaneous 
activity. Therefore, it is not surprising that people 
with mania and other forms of over-arousal are 
subdued when given lithium. The trouble is, the 
doses required to achieve a potentially useful 
sedative effect are close to those that cause a 
dangerous toxic state. Hence patients on lithium 
must have their blood lithium levels monitored on 
a regular basis. 
Other drugs now referred to as ‘mood stabilisers’ 
all suppress nervous activity in different ways. They 
can all cause drowsiness at normal therapeutic 
doses and, like lithium, the anticonvulsant drugs 
cause signs of nervous toxicity such as slurred 
speech (dysarthria) and loss of balance (ataxia), 
usually at higher doses. 
4.5.5 Evidence for their efficacy
4.5.5.1 Treatment of acute mania
Lithium reduces the symptoms of acute mania 
better than a placebo, but there is little evidence 
that it is better than other sorts of drugs with 
sedative effects. In fact, two studies of drug 
treatment for people with acute mania found that 
lithium was inferior to antipsychotics, probably 
due to the limitations caused by its toxicity.11,12 
In contrast, a Japanese study found lithium to be 
superior. However, doses of lithium were four times 
those of the antipsychotic used and patients were 
less severely ill, and therefore probably did not 
require the same level of sedation as patients in the 
other studies.13 
Two studies have examined whether people 
with a diagnosis of mania do better with 
lithium compared to people with a diagnosis of 
another sort of acute psychosis, such as acute 
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schizophrenia. Both studies compared lithium with 
an antipsychotic and found that diagnosis did not 
predict which drug treatment people responded 
to. In other words, people with mania responded 
just as well to the antipsychotic drug as they 
did to lithium and people diagnosed with acute 
schizophrenia responded just as well to lithium.14,15 
There has been little research into the effects 
of benzodiazepines in mania, even though they 
are widely used in this condition. Since they 
are sedative drugs, and mania is a condition of 
increased arousal, benzodiazepines would be a 
logical intervention and target for research. Some 
small studies that compared a benzodiazepine 
called clonazepam with lithium reported that the 
clonazepam was superior, but these were never 
followed up.16,17 Whether this means that the results 
did not fulfil their early promise or whether the 
drug company that conducted them decided to aim 
the drug at a different market is uncertain. 
Symptoms of acute mania are also improved 
by sodium valproate and the antipsychotic 
olanzapine, both of which have strongly sedating 
actions.18 
4.5.5.2 Long-term use 
Recommendations for long-term treatment of 
people diagnosed with ‘manic depression’ or 
‘bipolar disorder’ are based on placebo-controlled 
trials, some of which show that people taking 
a mood stabiliser relapse less frequently than 
people taking placebo. However, these trials are 
mostly discontinuation studies. In other words, 
people who are already taking drug treatment are 
randomised either to continue to take it or to have 
it substituted with a placebo. Therefore, people 
who take placebo are, in most cases, people who 
have just had their previous prescribed drugs 
withdrawn. 
There is good evidence that discontinuing lithium 
can induce a relapse in someone diagnosed with 
‘manic depression’ or ‘bipolar disorder’, especially 
a relapse of mania. Several studies indicate that 
the likelihood of having a relapse after stopping 
long-term lithium is higher than it is before lithium 
is started.19,20 The early studies of lithium of lithium 
maintenance, which were conducted in the 1970s, 
mostly involved people who were taking lithium 
prior to the study. 
A few further studies have been carried out since 
1990. Although not reported in all studies, where 
it was, a proportion of patients were reported to 
have been on lithium prior to entering the study. 
One of these studies found no difference between 
lithium, sodium valproate and placebo.21 One 
found a difference between lithium and placebo, 
but it was clinically small.22 Another reported a 
more substantial difference, but it appears that a 
large proportion of patients may have been taking 
lithium prior to the study (up to 69%, although 
the published paper does not make this clear) and 
the pattern of early relapses in the lithium group 
strongly suggests a discontinuation-related effect.23 
The most recent study is a large trial comparing 
quetiapine, lithium and placebo.24 Patients were 
stabilised on quetiapine prior to randomisation 
and may have been on long-term drug treatment 
prior to this. Again, the pattern of relapses suggests 
a discontinuation effect. Almost half the patients 
randomised to placebo (48%) experienced a 
relapse of ‘any mood event’ during an average of 
four months follow-up, versus 26.4% of the lithium-
treated patients and 23.6% of those on quetiapine 
(during an average of six months). Relapse rates 
in both groups are much higher than the natural 
history of manic depression recorded for patients 
treated before the introduction of modern drug 
treatment in the early 20th century. Historical 
studies show relapse rates of around 50% over a 
period of two and a half to three years in the late 
19th and first half of the 20th century.25 Another 
problem with this study is that 54 patients who 
did not show adequate lithium blood levels were 
excluded from the population that were included 
in the final analysis. We know that non-compliance 
is associated with poorer outcomes regardless of 
the effects of the treatment26, so this is also likely to 
have inflated the outcomes of the lithium group. 
Another recent study found no significant 
difference in terms of rates of relapse between 
lithium, fluoxetine and placebo for the long-term 
treatment of people diagnosed with ‘bipolar 2 
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disorder’. Time to first relapse was significantly 
longer with fluoxetine compared to the two other 
treatments, but there was no difference between 
lithium and placebo.27 
Despite the mixed results and methodological 
issues, reviews and meta-analyses continue to 
recommend that lithium should be considered as 
the ‘first line’ treatment for ‘bipolar disorder’.28 
The evidence is just as poor for other ‘mood 
stabilisers’, if not worse. Despite the widespread 
use of sodium valproate and similar preparations, 
the only long-term study that compared it with 
placebo and lithium found no difference between 
any of the treatments on any of the major 
outcome measures.21 Lamotrigine, a relatively 
new ‘mood stabiliser’, was found to be better 
than placebo for preventing depressive but not 
manic episodes in two trials sponsored by the 
manufacturer.22,23 However, since lamotrigine is a 
drug with noticeable sedative drugs, there is likely 
to be a substantial ‘amplified placebo effect’ in 
people with a diagnosis of depression. The one 
placebo-controlled trial of olanzapine for the 
prevention of future episodes of manic depression 
found a lower rate of relapse (mostly of mania) 
in people treated with olanzapine compared to 
those randomised to placebo.29 Results indicate 
a probable discontinuation effect, however, since 
the majority of the relapses in the placebo group 
occurred in the first three weeks of the study and 
all had occurred by three months. Quetiapine 
performed slightly better than lithium and was 
statistically significantly superior to placebo in the 
large, industry-sponsored study described above, 
but again a discontinuation effect is likely.24 
4.5.6 Common adverse effects 
Lithium is highly toxic to the nervous system, the 
digestive system and the kidneys. This means 
that blood levels that are only slightly higher than 
the levels usually associated with current doses 
can cause an acute toxic state. This can be fatal 
if lithium is not stopped immediately. This toxic 
state can occur if an overdose of lithium is taken, 
but it also occurs if blood levels increase because 
of dehydration or interactions with other drugs. 
The toxic state can also sometimes occur at what 
would normally be regarded as safe blood levels of 
lithium.30 Before the full-blown toxic state develops, 
lithium’s effects on the kidneys result in extreme 
thirst and excessive urination. Its effects on the 
nervous system commonly result in a hand tremor 
as well as reduced reaction times, slow thinking and 
reduced creativity.31 Lithium also frequently causes 
weight gain. In a small proportion of patients, long-
term lithium treatment may result in irreversible 
kidney damage.32 Lithium also frequently results 
in under-activity of the thyroid gland. Up to 20% 
of women on long-term treatment develop this 
complication and require treatment with thyroid 
hormones.33 It is usually reversible on stopping 
lithium. Lithium can also affect the parathyroid 
gland, which affects calcium levels and bone health.
As explained above, withdrawal of lithium in 
someone with a diagnosis of bipolar 1 or manic 
depression increases the risk of a relapse, especially 
a relapse of mania. The mechanism for this is 
unclear, but it is as if removing the neurological 
suppression produced by lithium causes the nervous 
system of a susceptible person to go into over-drive, 
precipitating a rebound manic episode.
Sodium valproate can cause nausea, lethargy and 
sedation, hair loss, weight gain and polycystic 
ovaries, a condition associated with reduced 
fertility. It is also known to produce a high rate of 
foetal abnormalities if it is taken early in pregnancy 
and should not be prescribed to women of 
childbearing age. Valproate has dangerous but rare 
complications including liver failure, pancreatitis, 
and blood disorders.
Carbamazepine can cause a rash, nausea, sedation 
and signs of neurotoxicity such as loss of balance 
(ataxia) and double vision (diplopia). Rarely it can 
also cause serious blood disorders, such as aplastic 
anaemia and agranulocytosis, by suppressing the 
production of blood cells in the bone marrow. Very 
rarely it causes a drug-induced reaction known as 
‘hypersensitivity syndrome’, a dangerous condition 
that can lead to failure of internal organs, especially 
the liver, and has a death rate of 8%. It can also 
cause a serious skin reaction (toxic epidermal 
necrolysis).
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Lamotrigine also causes neurological symptoms 
such as loss of balance (ataxia) and double vision 
(diplopia). It can cause a serious hypersensitivity 
reaction and may impair liver function. It has also 
been associated with blood disorders.
4.5.7 Conclusion
Sedative drugs of various sorts help to reduce the 
manifestations of ‘acute mania’. Despite mania being 
self-limiting and eventually subsiding naturally, 
while it lasts it can be overwhelming and difficult to 
control. Therefore, the short-term use of sedative 
drugs, including antipsychotics, benzodiazepines, 
some drugs that are referred to as ‘mood stabilisers’, 
may be helpful while the disturbance runs its course. 
Although lithium is recommended for this purpose, 
its toxicity means that other options are safer. 
Based on current evidence, it is unclear whether 
any drug reduces the risk of having a further 
episode of ‘bipolar disorder’ because of the strong 
possibility that trials of preventive treatment 
reflect the effects of withdrawing from previous 
treatment. From a drug-centred perspective, it is 
plausible that sedative drugs might suppress the 
occurrence of mania, since it is a state of increased 
arousal. However, it is also possible that the 
body’s adaptations to the long-term use of a drug 
will counteract any suppressant effect the drug 
might initially exert. It is less clear how the use of 
sedative, neurological suppressants like lithium, 
antipsychotic and anti-epileptic drugs would 
prevent the occurrence of ‘depression’. 
For people diagnosed with bipolar disorder, the 
potentially disabling and sometimes dangerous 
effects of the various drugs commonly on offer 
need to be weighed with a possible reduction 
in the risk of relapse. Mania can have harmful 
consequences and some people may feel that even 
the hope of protection may compensate for all 
the adverse effects of long-term drug treatment. 
Some may prefer to find other ways to try and exert 
some control over their experiences. For example, 
some people manage to identify the early warning 
signs of mania and use sedative drugs and lifestyle 
measures such as avoiding stress and taking time 
off work, to try and avert an impending relapse. 
Other people may simply prefer to live with the risk 
of recurrence and seek intervention for an ‘episode’ 
if and when they need it. 
With regards to people who do not have symptoms 
of ‘classical’ ‘bipolar disorder’, there is no clear 
evidence to support the use of a so-called mood 
stabiliser. No drugs have been shown to ‘normalise’ 
or smooth out moods. All drugs described as mood 
stabilisers are sedative drugs, which suppress 
mental and physical activity and may reduce 
people’s emotional responses to their environment, 
in a similar way to antipsychotics, many of which 
are now regarded as mood stabilisers. For most 
people the adverse effects of these drugs would 
be likely to outweigh any benefits in terms of 
managing emotions that they may obtain from the 
alterations the drugs produce. 
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Stimulants are a group of drugs that are still 
referred to by the type of effect they induce, rather 
than the condition for which they are prescribed. 
They are controlled drugs and some, such as 
amphetamines and cocaine, are commonly used 
recreationally. Stimulants are today mainly 
prescribed for what is referred to as attention 
deficit hyperactivity disorder (or ADHD) – namely, 
a set of behavioural problems deemed to occur in 
children and increasingly in adults. The stimulant 
methylphenidate (Ritalin) is most commonly 
prescribed, but various forms of amphetamine, 
including dexamfetamine and lisdexamfetamine, 
are also used, and a drug called atomoxetine is also 
used, which was originally claimed to be different 
from stimulants, but shows a stimulant-like profile 
of effects.
4.6.2 Common uses
In current guidelines stimulants are recommended 
as the first intervention for a diagnosis of severe 
ADHD in children, or if psychological therapy is 
judged to have been ineffective in less severe cases. 
In adults, they are the first line recommended 
intervention.1
4.6.3 Theories of action
Stimulants increase the availability and activity of 
excitatory neurotransmitters, such as dopamine 
and noradrenaline, within the brain, but they have 
effects on a wide range of neurotransmitters and 
biochemical systems. 
Traditionally, stimulants are said to work by correcting 
a shortage or malfunction of these neurotransmitters, 
with most research attention focusing on dopamine. 
However, there is no consistent evidence of a 
specific chemical abnormality in the brains of 
people diagnosed with ADHD, and no evidence that 
stimulants work by reversing it. 
There is a simple alternative explanation for how 
stimulants work in ADHD. The main physiological 
effect of stimulant drugs is to increase arousal. At 
high doses this results in increased activity and it 
can cause obsessive-compulsive behaviours and 
abnormal movements such as tics and grimaces. 
At lower doses the main manifestation of increased 
arousal is an increased ability to concentrate, and 
a feeling of calm. This is familiar to people who 
smoke cigarettes, since nicotine is a mild stimulant 
drug. Therefore, stimulants would be expected to 
improve attention and reduce hyperactivity in the 
relatively low doses at which they are prescribed. 
This drug-centred model of how stimulants work 
suggests that the effects of stimulants in people 
diagnosed with ADHD are the same as those that 
are observed in people with no such diagnosis. 
This is confirmed by research that showed that 
giving methylphenidate (Ritalin) to both healthy 
volunteers and people diagnosed with ADHD 
led to similar increases of brain dopamine in 
the two groups and the same improvements in 
concentration and attention.2 These results are 
consistent with the effects that are observed 
in animals.3 This demonstrates that there is no 
need to construct a disease-centred account for 
the action of stimulants. A drug-centred model, 
in which low-level stimulant-induced alterations 
improve concentration and attention on a single 
task, can account for their effects in people 
diagnosed with ADHD. 
Animal studies also show that stimulants inhibit 
spontaneous exploratory behaviour, reduce an 
animal’s interest in its environment and reduce its 
social interactions with other animals. Instead, the 
animal shows repetitive, over-focused, pointless 
behaviours such as pacing, scratching, excessive 
grooming, gnawing and staring at small objects. They 
also develop tics and other involuntary abnormal 
movements.4 In children too, it is recognised that 
stimulants can suppress interest, spontaneity and 
emotional responsiveness.5 Therefore it seems 
stimulants increase the ability of a person or an 
animal to focus on a single task by reducing their 
interaction with the rest of the environment. 
64 Guidance for Psychological Therapists
Adults typically enjoy the effects of stimulant drugs, 
hence their use as recreational drugs. Children, 
however, generally dislike the experience of being 
on stimulants.6,7 However, children may also see 
the benefits of taking stimulants from the point of 
view of their behaviour or school performance.8 
When stimulants are used recreationally, people 
often need to increase the dose to keep getting the 
same desired effect. This shows that stimulants, 
like other psychoactive drugs, induce ‘tolerance’. 
In other words, the body adapts to counteract 
their effects, so if you use them continuously, you 
must increase the dose to get the same effects. 
Tolerance to stimulants prescribed for ADHD has 
been demonstrated in animals9 and documented 
in children10, although the fact that children are 
naturally maturing during treatment may obscure 
tolerance effects. If tolerance occurs, it suggests 
that any beneficial effects that are experienced 
in the early days of stimulant treatment would 
gradually be lost. 
4.6.4 Evidence of efficacy
Studies in children and adults find that stimulants 
reduce the symptoms of ADHD more than a 
placebo, as measured by various rating scales. 
This is not surprising, given the alterations they 
are known to cause in humans and animals 
regardless of whether or not they have a diagnosis 
of ADHD. The effects are not large, however. One 
study of methylphenidate (Ritalin) in adults found 
differences of between four and five points on a 
56-point rating scale, for example11, and another 
found a difference of between three and six points 
on a 54-point rating scale score.12 A meta-analysis 
of trials of methylphenidate in children found that 
the drug was more effective than placebo at a level 
that was just above that judged to be a minimally 
relevant difference.13 
In addition, few studies provide data on long-
term outcomes and controlled trials do not 
show evidence of beneficial effects on school 
achievement in children, or employment or other 
aspects of general functioning in adults. One of the 
few trials that looked at these sorts of outcomes, 
a placebo-controlled trial of atomoxetine in adults 
diagnosed with ADHD, found no difference in work 
productivity between people randomised to take 
the active drug and people randomised to placebo 
(the main outcome of the study), and no difference 
in driving behaviour either.14 
Moreover, many of the studies in children and 
adults have been conducted by a group of 
researchers at Harvard University who were 
revealed to have received millions of dollars from 
the pharmaceutical industry in consulting fees 
and other payments.15 Studies conducted by this 
group show consistently larger effects than other 
studies.16 
Two large randomised studies have been 
conducted that explored the long-term outcomes 
of stimulant treatment and psychotherapy for 
ADHD – one in children and one in adults.
In the first study, children were randomly allocated 
to four different types of treatment: intensive 
behavioural therapy, an intensive ‘medication 
management’ regime with frequent medical 
reviews, a combination of behavioural therapy and 
‘medication management,’ and routine community 
care, in which children often received prescribed 
stimulants.17 
The first set of results, based on data from the first 
14 months of the study, showed that all groups 
displayed a substantial decline in the severity of 
their symptoms. The ‘medication management’ 
group fared better than the group that had 
behaviour therapy on the core symptoms of 
inattention, as rated by parents and teachers, and 
hyperactivity as rated by parents only. The study 
showed no differences between the groups for 
the other factors that were evaluated, including 
social skills, parent–child relations, academic 
achievement and aggression. 
However, ratings by the only blinded rater, 
a classroom observer, showed no difference 
between the treatment groups for attention or 
hyperactivity.18 In addition, around 60% of the 
routine community treatment group were also 
prescribed stimulants and this group fared the 
same as the behavioural therapy group. Hence it 
may have been something about the intensity of 
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the contact involved in the intensive ‘medication 
management’ group that improved symptoms 
apart from, or as well as, their prescribed drug 
treatment. 
At the three-year follow-up, there was no 
difference between the original groups in 
terms of any outcome measures.19 This study 
is important because it is the only randomised 
study that has followed-up children with ADHD 
for more than a year. Its results are difficult to 
interpret and not decisive, but they suggest that 
stimulants, coupled with assertive monitoring, 
may improve teacher or parent ratings of 
children’s attention and activity levels in the 
short to medium term, but long-term benefits are 
not established. 
The study in adults was conducted in Germany 
and participants were randomised to one of four 
treatment conditions: to take methylphenidate 
with routine care, to take methylphenidate 
in combination with a cognitive-behavioural 
group psychotherapy programme or to take 
placebo in combination with routine care or 
the group psychotherapy programme. The first 
follow-up was conducted at three months, and 
subsequently at six months, a year, and two 
and a half years after the trial commenced. 
Methylphenidate performed better than 
placebo at all follow-up points in this study, 
but differences were small. At three months 
the difference in symptom scores was 1.7 
points on a 36 point scale, at one year it was 2.2 
points20 and at two and a half years’ follow-up 
the difference was 1.4 points.21 Although these 
differences were statistically significant, there 
is no research that has established what sort of 
differences in symptom scales might translate 
into meaningful or observable improvement in 
ADHD, as there is for the diagnosis of depression. 
In other words, we cannot be sure of the clinical 
significance of the findings, but the differences 
detected appear to be modest. There was no 
difference in symptom scores between those who 
were randomised to the group psychotherapy 
programme and those who received routine care 
at any follow-up point in this study.
4.6.5 Common adverse effects 
Stimulant drugs increase the activity of the 
heart, raising the heart rate and increasing 
blood pressure.20 There is considerable debate 
as to whether these effects translate into serious 
consequences such as an increased risk of heart 
attacks, cardiac arrhythmias (irregularities of heart 
rhythm which can lead to death) or stroke. The 
sorts of changes to heart rate and blood pressure 
that are observed with stimulant treatment have 
been shown to lead to more serious cardiac 
effects in other contexts.22 Some studies of adults 
who are prescribed stimulants for ADHD show 
an increased incidence of arrhythmias, transient 
ischaemic attacks and sudden death23,24, but 
others have shown no detrimental cardiovascular 
effects.25 A recent meta-analysis found increased 
rates of sudden death due to a cardiac arrhythmia 
with all drugs prescribed for ADHD and with 
methylphenidate specifically, but no increased risk 
of myocardial infarction, stroke or all-cause death.26 
Overall, the data suggest that prescribed stimulants 
cause a slight increased risk of serious cardiac 
events, particularly arrhythmias and sudden death. 
Recreational use of stimulants is well known to lead 
to cardiac complications in some cases, but doses 
taken are usually considerably larger than those 
that are prescribed.27 
In some cases, stimulants induce a depressive 
picture, with lethargy, withdrawal, and loss of 
emotional responsiveness, sometimes referred 
to as a ‘zombie’ effect.28 In others they may cause 
agitation and anxiety. Insomnia is very common. 
Rarely, stimulants can induce a psychotic episode. 
A recent study found that being prescribed 
stimulants for an ADHD diagnosis increased the risk 
of developing Parkinson’s disease or a similar brain 
condition by more than eight times.29 The association 
between taking stimulants and Parkinson’s disease 
is well established among people who take them 
recreationally30, so it is plausible that prescribed use 
will have some effect too. 
An important adverse effect of stimulants in 
children is growth suppression. The three-year 
follow-up of the MTA study showed that children 
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who had taken stimulants on a continuous basis 
were 2.3cm smaller than a non-ADHD comparison 
group and 4.2cm shorter than those children in the 
study who had not used stimulants.31 
Although not all studies show negative effects on 
growth, another recent study looking at growth 
rates over five years confirmed the MTA findings 
and showed that higher doses of stimulants had 
a stronger retarding effect on growth than lower 
doses.32 The exact mechanism whereby stimulants 
suppress growth is not yet known. It may be related 
to the fact that they reduce appetite, but they are 
also known to have an impact on several hormones 
that may be involved in growth including growth 
hormone, prolactin and thyroid hormones.
4.6.6 Conclusion
Stimulant drugs have generalised effects that may 
help to reduce symptoms such as inattention and 
hyperactivity in children and adults diagnosed 
with ADHD. Trials reveal consistent, but relatively 
modest, benefits on symptom levels compared to 
placebo, but no trials have established beneficial 
effects on other outcomes such as school or work 
performance or achievement. 
Stimulants are associated with psychiatric problems 
– commonly anxiety and insomnia. They may be 
associated with an increased risk of serious conditions 
such as heart attacks and Parkinson’s disease. The 
desire for short-term symptom reduction must be 
balanced against these potential adverse effects, as 
well as the evidence suggesting that the beneficial 
effects on attention are achieved by suppressing 
the person’s ability to interact with their wider 
environment in a playful or creative manner. 
References
1.  National Institute for Health and Clinical Excellence (2008). 
Attention Deficit Hyperactivity Disorder. Diagnosis and 
management of ADHD in children, young people and adults. 
National Clinical Practice Guideline Number 72. London: 
National Institute for Health and Clinical Excellence.
2.  Rapoport, J.L., Buchsbaum, M.S., Weingartner, H., Zahn, T.P., 
Ludlow, C. & Mikkelsen, E.J. (1980). Dextroamphetamine. Its 
cognitive and behavioral effects in normal and hyperactive boys 
and normal men. Archives of General Psychiatry, 37(8), 933–43.
3.  Arnsten, A.F. & Dudley, A.G. (2005). Methylphenidate improves 
prefrontal cortical cognitive function through α2 adrenoceptor 
and dopamine D1 receptor actions: Relevance to therapeutic 
effects in Attention Deficit Hyperactivity Disorder. Behavioral 
and Brain Functions, 1(1), 2.
4.  Breggin, P. (2001). Talking back to Ritalin. What doctors aren’t 
telling you about stimulants and ADHD. Cambridge, MA: 
Perseus Publishing.
5.  Rie, H.E., Rie, E.D., Stewart, S. & Ambuel, J.P. (1976). Effects 
of methylphenidate on underachieving children. Journal of 
Consulting and Clinical Psychology, 44(2), 250–60 [cited in 
Breggin (2001), ibid, p.84].
6.  Eichlseder, W. (1985). Ten years of experience with 1,000 
hyperactive children in a private practice. Pediatrics 76(2), 176–84.
7.  Sleator, E.K., Ullmann, R.K. & von Neumann, A. (1982). How do 
hyperactive children feel about taking stimulants and will they 
tell the doctor? Clinical Pediatrics (Phila) 21(8), 474–9.
8.  Brinkman, W.B., Sherman, S.N., Zmitrovich, A.R., Visscher, 
M.O., Crosby, L.E., Phelan, K.J. & Donovan, E.F. (2012). In their 
own words: Adolescent views on ADHD and their evolving role 
managing medication. Academic Pediatrics, 12(1), 53–61.
9.  Askenasy, E.P., Taber, K.H., Yang, P.B. & Dafny, N. (2007). 
Methylphenidate (Ritalin): Behavioral studies in the rat. 
International Journal of Neuroscience, 117(6), 757–94.
10.  Ross, D.C., Fischhoff, J. & Davenport, B. (2002). Treatment 
of ADHD when tolerance to methylphenidate develops. 
Psychiatric Services, 53(1), 102.
11.  Rosler, M., Fischer, R., Ammer, R., Ose, C. & Retz, W. (2009).  
A randomised, placebo-controlled, 24-week, study of low-dose 
extended-release methylphenidate in adults with attention-
deficit/hyperactivity disorder. European Archives of Psychiatry 
and Clinical Neurosciences, 259(2), 120–129.
12.  Medori, R., Ramos-Quiroga, J.A., Casas, M., Kooij, J.J., Niemela, 
A., Trott, G.E., Lee, E. & Buitelaar, J.K. (2008). A randomized, 
placebo-controlled trial of three fixed dosages of prolonged-
release OROS methylphenidate in adults with attention-
deficit/hyperactivity disorder. Biological Psychiatry, 63(10), 
981–989.
13.  Storebo, O.J., Krogh, H.B., Ramstad, E., Moreira-Maia, C.R., 
Holmskov, M., Skoog, M., Nilausen, T.D., Magnusson, F.L., 
Zwi, M., Gillies, D., Rosendal, S., Groth, C., Rasmussen, K.B., 
Gauci, D., Kirubakaran, R., Forsbol, B., Simonsen, E. & Gluud, 
C. (2015). Methylphenidate for attention-deficit/hyperactivity 
disorder in children and adolescents: Cochrane systematic 
review with meta-analyses and trial sequential analyses of 
randomised clinical trials. BMJ 351, h5203.
14.  Adler, L.A., Spencer, T.J., Levine, L.R., Ramsey, J.L., Tamura, 
R., Kelsey, D., Ball, S.G., Allen, A.J. & Biederman, J. (2008). 
Functional outcomes in the treatment of adults with ADHD. 
Journal of Attention Disorders, 11(6), 720–727.
15.  Harris, G. & Carey, B. (2008). Researchers Fail to Reveal Full 
Drug Pay. New York Times. New York. 8 June 2008.
16.  Koesters, M., Becker, T., Kilian, R., Fegert, J.M. & Weinmann, 
S. (2009). Limits of meta-analysis: Methylphenidate in the 
treatment of adult attention-deficit hyperactivity disorder. 
Journal of Psychopharmacology, 23, 733–744.
17.  Schachter, H.M., Pham, B., King, J., Langford, S.& Moher, D. 
(2001). How efficacious and safe is short-acting methylphenidate 
for the treatment of attention-deficit disorder in children and 
adolescents? A meta-analysis. CMAJ. 165(11), 1475–88.
18.  The MTA Cooperative Group (1999). A 14-month randomized 
clinical trial of treatment strategies for attention-deficit/
December 2019 67
hyperactivity disorder. Multimodal Treatment Study of 
Children with ADHD. Archives of General Psychiatry 56(12), 
1073–86.
19.  Jensen, P.S., Arnold, L.E., Swanson, J.M., Vitiello, B., Abikoff, 
H.B., Greenhill, L.L. et al. (2007). Three-year follow-up of the 
NIMH MTA study. Journal of the American Academy of Child and 
Adolescent Psychiatry, 46(8), 989–1002.
20.  Philipsen, A., Jans, T., Graf, E., Matthies, S., Borel, P., Colla, 
M., Gentschow, L., Langner, D., Jacob, C., Gross-Lesch, S., 
Sobanski, E., Alm, B., Schumacher-Stien, M., Roesler, M., Retz, 
W., Retz-Junginger, P., Kis, B., Abdel-Hamid, M., Heinrich, 
V., Huss, M., Kornmann, C., Burger, A., Perlov, E., Ihorst, 
G., Schlander, M., Berger, M. & Tebartz van Elst, L. (2015). 
Comparison of and A.S.C. Psychotherapy in adult: Effects of 
group psychotherapy, individual counseling, methylphenidate, 
and placebo in the treatment of adult attention-deficit/
hyperactivity disorder: A randomized clinical trial. JAMA 
Psychiatry 72(12), 1199–1210.
21.  Lam, A.P., Matthies, S., Graf, E., Colla, M., Jacob, C., Sobanski, 
E., Alm, B., Rosler, M., Retz, W., Retz-Junginger, P., Kis, B., 
Abdel-Hamid, M., Muller, H.H.O., Lucke, C., Huss, M., Jans, T., 
Berger, M., Tebartz van Elst, L., Philipsen, A., M. Comparison of 
& A.S.C. Psychotherapy in Adult (2019). Long-term effects of 
multimodal treatment on adult attention-deficit/hyperactivity 
disorder symptoms: Follow-up analysis of the COMPAS Trial. 
JAMA Network Open 2(5), e194980.
22.  Sinha, A., Lewis, O., Kumar, R., Yeruva, S.L. & Curry, B.H. 
(2016). Adult ADHD Medications and Their Cardiovascular 
Implications. Case Rep Cardiol 2016: 2343691.
23.  Holick, C.N., Turnbull, B.R., Jones, M.E., Chaudhry, S., Bangs, 
M.E. & Seeger, J.D. (2009). Atomoxetine and cerebrovascular 
outcomes in adults. Journal of Clinical Psychopharmacology, 
29(5), 453-460.
24.  Schellman, H., Bilker, W.B., Kimmel, S.E., Daniel, G.W., 
Newcomb, C., Guevara, J.P., Cziraky, M.J., Strom, B.L. & 
Hennessy, S. (2012). Methylphenidate and risk of serious 
cardiovascular events in adults. American Journal of Psychiatry, 
169(2), 178–185.
25.  Habel, L.A., Cooper, W.O., Sox, C.M., Chan, K.A., Fireman, B.H., 
Arbogast, P.G., Cheetham, T.C., Quinn, V.P., Dublin S., Boudreau 
D.M., Andrade, S.E., Pawloski, P.A., Raebel, M.A., Smith, D.H., 
Achacoso, N., Uratsu C., Go, A.S., Sidney, S., Nguyen-Huynh, 
M.N., Ray, W.A. & Selby, J.V. (2011). ADHD medications and risk 
of serious cardiovascular events in young and middle-aged 
adults. JAMA 306(24), 2673–2683.
26.  Liu, H., Feng, W. & Zhang, D. (2018). Association of ADHD 
medications with the risk of cardiovascular diseases: a 
meta-analysis. European Child & Adolescent Psychiatry. doi: 
10.1007/s00787-018-1217-x. [Epub ahead of print] https://doi.
org/10.1007/s00787-018-1217-x.
27.  Ghuran, A. & Nolan, J. (2000). The cardiac complications of 
recreational drug use. Western Journal of Medicine, 173(6), 
412–415.
28.  Breggin, P. (1999). Psychostimulants in the treatment of 
children diagnosed with ADHD: Risks and mechanism of 
action. International Journal of Risk and Safety in Medicine, 
12(1), 3–35.
29. Curtin, K., Fleckenstein, A.E., Keeshin, B.R., Yurgelun-Todd, 
D.A., Renshaw, P.F., Smith, K.R. & Hanson, G.R. (2018). 
Increased risk of diseases of the basal ganglia and cerebellum 
in patients with a history of attention-deficit/hyperactivity 
disorder. Neuropsychopharmacology 43(13), 2548–2555.
30.  Curtin, K., Fleckenstein, A.E., Robison, R.J., Crookston, M.J., 
Smith, K.R. & Hanson, G.R. (2015). Methamphetamine/
amphetamine abuse and risk of Parkinson’s disease in Utah: A 
population-based assessment. Drug and Alcohol Dependence, 
146,  30–38.
31.  Swanson, J.M., Elliott, G.R., Greenhill, L.L., Wigal, T., Arnold, 
L.E., Vitiello, B. et al. (2007). Effects of stimulant medication 
on growth rates across 3 years in the MTA follow-up. Journal 
of the American Academy of Child and Adolescent Psychiatry, 
46(8), 1015–27.
32.  Charach, A., Figueroa, M., Chen, S., Ickowicz, A. Schachar, R. 
(2006) Stimulant treatment over 5 years: Effects on growth. 
Journal of the American Academy of Child and Adolescent 
Psychiatry, 45(4), 415–21.
68 Guidance for Psychological Therapists
4.7 Combined psychotherapeutic and 
psychopharmacological intervention in depression 
A combination of prescribed drugs and 
psychotherapy is often regarded as a superior 
intervention to the use of these drugs or therapy 
alone, particularly with depression. The current NICE 
guidance1 for depression includes recommendations 
for combined treatment, especially for more severe 
symptoms and for when previous treatments or 
various types have been ineffective. 
On the other hand, it has long been recognised that 
the effects produced by taking psychoactive drugs, 
whether prescribed or illicit, may interfere with 
the learning and personal development that is an 
integral part of therapy. For example, if someone is 
taking benzodiazepines that dampen anxiety, then 
they may not be able to learn other techniques 
to manage the anxiety. Any drug that dampens 
emotions or sensitivity may interfere with efforts 
to control and manage emotional reactions in non-
pharmacological ways. 
The idea that combined intervention is more 
effective is based on several assumptions. 
Antidepressant drugs are assumed to target 
the biological causes of depression, whilst 
psychotherapy separately targets perpetuating 
psychological factors, with the two interventions 
leading to a cumulative therapeutic effect.2 
However, this is problematic for several reasons. 
As outlined in 4.2, there is no convincing evidence for 
any biological abnormalities underlying depression, 
which are effectively targeted by antidepressant 
drugs. In other words, current evidence does not 
support the idea that antidepressants improve 
or correct a specific biological component to 
depression (a disease-centred model), which could 
act in parallel with psychotherapy. 
In addition, the evidence for the actual 
effectiveness of antidepressants in depression is 
beset by multiple flaws (see section 4.2.5). Meta-
analyses have reported that antidepressants 
may have slightly more effect than placebo in 
the short-term reduction of depression symptom 
scale scores, but it is not clear that such an effect is 
clinically relevant and could provide an additional 
benefit to psychotherapy, or that it is a specifically 
pharmacological effect as opposed to an amplified 
placebo effect. 
NICE suggest that antidepressants can enable 
more effective therapy through effects such as 
improved sleep, motivation and cognitive ability.2 
Antidepressants do produce psychological and 
behavioural changes, as described in Section 
1.2. Some antidepressants have sedative 
effects that may improve sleep, but there is no 
evidence that any antidepressant increases 
motivation or cognitive ability more than a 
placebo. From what we know of the alterations 
antidepressants produce, it is not clear that they 
would aid psychotherapy, and they may even be 
counterproductive. 
The sedation produced by some antidepressants, 
for example, may be useful in terms of increasing 
sleep and reducing anxiety, but may hamper 
therapy by impairing clarity of thinking and 
cognitive function during the day. The emotional 
restriction associated with SSRIs may, in theory, 
numb intense hopelessness and feelings of 
depression, which may help people to engage in 
therapy, but may also prevent people from learning 
how to manage their emotions in other ways. 
Questions remain about the psychological effects 
of taking antidepressants and how they may 
impact on therapy. Many people understand 
antidepressants to work by reversing the 
underlying biological causes of depression, 
because, despite the lack of evidence for this 
position, this is what they have been told. 
Therefore, taking antidepressants can signal the 
idea that depression is a biological condition, 
over which the individual has little control. This 
position is logically inconsistent with the aims of 
therapy to enable people to gain more control over 
their feelings and behaviour and this is explored in 
section 3.
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Multiple individual studies have looked at whether 
combined antidepressants and psychological 
intervention is superior to antidepressants 
or therapy alone. Overall, the results are 
contradictory. For example, when comparing a 
psychological intervention alone to a combined 
intervention, some studies found the combined 
intervention to be more effective,3,4 others found 
no difference,5–7 and others found the psychological 
intervention alone more effective.8,9 Similarly, when 
comparing a combined intervention to the drugs 
alone, some studies found a combination to be 
more effective,10–12 whilst others did not.13–15
As a result of this confusing overall picture, several 
meta-analyses of randomised studies have been 
performed, with many reporting an advantage, of 
varying degrees, for the use of a combination of 
antidepressants and psychotherapy over either 
drugs or psychotherapy alone.16–19 However, 
judging by two recent meta-analyses, the quality 
of the individual studies included in these studies 
varies greatly, leading to questions about the 
reliability of their results.
For example, one 2009 meta-analysis combined 
studies that compared antidepressants alone to a 
combination of antidepressants and psychotherapy 
for depression.18 It included 25 randomised trials 
and found that combination was better than 
antidepressants alone in the short term, in term of 
changes in depression symptom scores. However, 
the effect size was small, and whilst statistically 
significant, possibly not clinically relevant. There 
was insufficient data to look at longer-term 
outcomes. The number of studies included was 
limited, and the individual trials were also fairly 
small. The average number of patients per study 
was 81, and 15 studies contained fewer than 50 
patients. The trials varied in their target population, 
with 16 looking at adults in general with 
depression, and others focusing on more specific 
groups, such as bereaved older people, and people 
with other physical or psychiatric conditions in 
addition to depression. 
Many of the studies contained crucial flaws. 
Understandably, no study could blind participants 
to their treatment allocation, but only 18 reported 
blinding of assessors. In addition, only 16 studies 
conducted intention to treat analysis, in other words 
including the outcomes of all people who entered 
the trial. As the dropout rates varied significantly 
between combined and individual treatment groups, 
this may have impacted on results. 
Another 2009 meta-analysis combined 19 
studies comparing combination treatment to 
psychological treatment alone.19 This also found a 
small difference in favour of combined treatment 
between the two groups in the short term, similar 
in magnitude to the other meta-analyses, which the 
authors admitted may be too small to be clinically 
relevant. Some limited follow up data were 
available, with no difference found between the 
two groups after three to six and 12 months. 
The study populations also varied in this study. All 
looked at people with depression, with 14 studies 
looking at adults in general, and five at specific 
populations (adults with HIV, multiple sclerosis, 
chronic depression; older adults). The authors found 
that the difference between combined treatment and 
psychological treatment was much smaller when only 
data from the general adult samples were looked at. 
Only a minority of studies (11) reported blinding of 
assessors and a limited number of studies employed 
an intention to treat method. As the dropout rates 
were highly variable, and as high as 55% in one paper, 
this may have distorted results too. 
Overall, evidence that a combination of 
antidepressants and psychotherapy is superior to 
either intervention given alone is not conclusive. 
The assumptions behind this research, for 
example, that antidepressants are effective, 
and that antidepressants and psychotherapy 
provide distinctive, additive mechanisms against 
depression have not been proven. 
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4.8 Conclusion: Understanding psychiatric medication 
In general, the orthodox ‘disease-centred’ view is 
that psychiatric medications reverse or partially 
reverse an underlying biological ‘abnormality’. The 
existing evidence for this has been questioned. It 
is suggested that, in the absence of clear evidence 
for targeted actions by psychiatric medications on 
specific pathologies, an alternative, ‘drug-centred’ 
model is more valid and useful.
A drug-centred model views drugs as producing 
characteristic altered states, which vary according 
to the pharmacological properties of the drug 
concerned. These effects can alter, suppress or 
obscure the manifestations of mental health 
difficulties, and may be experienced as useful for 
some people with these problems. Within this 
model, there still remains a role for the careful and 
judicious prescribing of certain psychiatric drugs 
in some situations involving mental distress and 
disturbance.
However, the drug-centred model does entail 
a different relationship between person and 
prescriber. Rather than centring the discussion 
on what intervention is deemed appropriate for a 
specific diagnosis, people using services and their 
networks can ask and debate with their doctor 
about what sort of drug-induced effects might or 
might not be useful in their specific situation. They 
can explore by themselves and with others what 
the benefits of a drug-induced state would be and 
what negative consequences are likely to flow from 
that state. 
People who are already taking psychiatric drugs 
might want to reflect on what drug-induced effects 
they are experiencing, and how these effects 
might be affecting their lives. They will want to 
balance any positive effects they feel they obtain 
against the negative or unpleasant effects and the 
evidence for long-term harm. People who want 
to stop their medication, either because they are 
stable, or because they feel it has not helped, will 
need information about the nature of the drug they 
are on before they can decide the best method for 
coming off it. 
The drug-centred model makes the service user 
the expert in their own drug management. It is up 
to them to decide whether they find certain effects 
useful or not (unless drugs are being prescribed 
against the patient’s wishes for purposes of 
social control). The model highlights how taking 
psychiatric drugs is always a delicate balancing act 
between benefits and harm. The useful effects that 
drugs have are part and parcel of a drug-induced 
state, a state of intoxication that is not the same 
as the ordinary state of the body and mind. Taking 
psychoactive drugs is likely to impair and suppress 
aspects of our mental and emotional functioning 
to a greater or lesser degree. If so, the question 
is whether that impairment is preferable to the 
distress that is being experienced. 
Although many people are advised to take 
psychiatric drugs for long periods after their 
problems have subsided, the evidence for the 
benefits of long-term treatment is limited and 
harmful effects accumulate with long-term use. 
Therefore, deciding to stop taking prescribed 
drugs long-term can be a logical decision in many 
situations, and it is important that professionals 
provide support to people to do this as safely as 
possible.
Much of the material in this section is a condensed 
and updated version of material contained in A 
Straight Talking Introduction to Psychiatric Drugs by 
Joanna Moncrieff, published by PCCS Books, and 
used with the publisher’s kind permission.
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5. What do we know about withdrawal?
  Professor John Read & Dr James Davies, with Luke Montagu  
& Professor Marcantonio Spada 
5.1 A general introduction to dependence and withdrawal 
Drugs are foreign substances from the point of view of 
the body, and therefore the body tries to counteract 
their effects. This is sometimes referred to as the body 
‘adapting’ to the presence of a drug. The adaptation 
can occur in a variety of ways. In the presence of a 
drug that reduces the activity of a neurotransmitter, 
like dopamine, noradrenalin or serotonin, the 
body may increase the number of receptors for the 
particular neurotransmitter, or existing receptors may 
become more sensitive. Such adaptations can mean 
that, over time, higher and higher doses are required 
to achieve the same drug effect, as is seen for example 
with benzodiazepines and alcohol. When this occurs, 
the individual is said to have developed ‘tolerance’ to 
the effects of the drug. 
If the drug is stopped then the body’s adaptations 
are suddenly unopposed by the presence of the 
drug, and they give rise to withdrawal symptoms. 
For example, people taking dopamine receptor-
blocking drugs such as antipsychotics will 
manufacture more dopamine receptors in their 
brains, and those receptors that already exist will 
change and become more sensitive to dopamine. 
This is the body’s way of trying to increase the 
activity of dopamine despite the presence of a 
chemical that tends to reduce its activity. When the 
drug is stopped, these extra dopamine receptors 
will still be present, and may increase the activity 
of dopamine above normal levels until they reduce 
back down to normal numbers. 
Usually the body’s adaptations disappear gradually 
when the drug is no longer present, and the 
withdrawal reactions subside. However, we know 
very little about the body’s response to long-term 
drug consumption and how the body reacts to the 
withdrawal of such consumption. It is possible that 
the adaptations sometimes persist or that it can take a 
long time for them to revert to normal. Even relatively 
shorter-term treatment can result in adaptations and 
resulting symptoms persisting a long time.
For example, we know that the abnormal 
movements of tardive dyskinesia, a potential effect 
of long-term antipsychotic use, often get worse 
when antipsychotics are reduced or stopped. This 
is likely to be mediated by the increased numbers 
and activity of dopamine receptors. Sometimes 
the movements improve with time as the body 
readjusts to the fact the drug has been stopped. 
However, sometimes they are permanent, implying 
that the adaptation of the body’s dopamine 
system to the presence of antipsychotics can be 
irreversible. Something similar may be occurring 
after discontinuation of benzodiazepines or 
antidepressants, when, in some cases, withdrawal 
reactions last for long periods. 
Most psychiatric drugs affect a range of different 
brain chemicals or neurotransmitters, and 
withdrawal effects can reflect the drug’s impact 
on any of these chemical systems. Withdrawal 
reactions themselves may be mild and annoying, 
they may be unpleasant and sometimes they are 
unbearable. In addition, withdrawal from sedative 
drugs often causes agitation and insomnia, which 
can easily be mistaken for early signs of relapse. 
When drugs have been taken for a long time, 
such as several years, it is possible that the body 
will take a considerable time to readjust and 
withdrawal reactions may go on for some time. 
Often the worst withdrawal effects are experienced 
at the end of the withdrawal process, when dosage 
has been reduced to almost zero. Repeated 
attempts at withdrawal may result in what is 
known as the ‘kindling’ effect where neuronal 
hypersensitivity results in the progressive 
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worsening of withdrawal symptoms at each 
subsequent withdrawal episode. It is reported that 
this can also happen when drugs are reinstated. 
Therapists should also be aware that withdrawal 
reactions are not limited solely to during or 
immediately after the withdrawal process but may 
last over a period from six to 18 months, and in 
some cases, several years.
Withdrawing from psychiatric drugs has some 
similarities to giving up recreational drugs. For 
example, people may become dependent on 
psychiatric drugs in both physical and psychological 
senses as they do with drugs of misuse. One clear 
difference is that recreational drugs have effects that 
are pleasurable, and so people crave the drug when 
they stop taking it. In contrast, people do not usually 
crave the effects of drugs such as antipsychotics or 
antidepressants, since these do not cause euphoria. 
People can, however, have strong beliefs about what 
such drugs do for them and may become anxious if 
they withdraw from them. As anxiety can occur as 
a withdrawal reaction it may not be possible to tell 
such feelings apart until withdrawal is complete. 
The danger is that any anxiety may be mistaken for 
a relapse of the original condition – see 5.4.2 for 
further discussion of this.
In general, if a drug is stopped suddenly, the 
withdrawal reactions will be more intense, but 
they may last for a shorter period (especially if 
the drug has only been taken for a short period; 
with longer-term use the body’s response is more 
unpredictable). If a drug is gradually reduced, the 
withdrawal reactions will usually be less intense, 
and may not even be noticed by some people. The 
way the body reacts is not entirely predictable, 
however, and therefore withdrawal reactions can 
still be severe in cases where the drug is gradually 
reduced and when taken short-term.
Different drugs differ in their ability to cause 
withdrawal reactions. ‘Short-acting’ drugs that 
act quickly and are rapidly eliminated from the 
body cause more intense withdrawal reactions 
than ‘long-acting’ drugs that stay around in the 
body for longer. The rate of elimination of a drug is 
measured in what is called its ‘half-life’. A half-life 
means the time it takes for the concentration in the 
body to decline by half. Drugs with a short half-life 
are eliminated rapidly, while drugs with a long half-
life remain in the body for longer. 
Heroin, for example, has a short half-life and causes 
more reactions after stopping than methadone, 
which has a long half-life. This is the principle 
behind the practice of prescribing methadone 
to people who are dependent on heroin to help 
them withdraw. The antidepressant fluoxetine is 
another example of a drug with a long half-life. It 
is eliminated from the body slowly over a period 
of weeks. Therefore, its effects generally wear off 
more gradually following cessation than those of 
drugs with a shorter half-life. In contrast, drugs such 
as the benzodiazepine lorazepam, antidepressant 
paroxetine and antipsychotic clozapine are 
eliminated rapidly from the body – they have short 
half-lives. That is why you must take repeated doses 
of them every day to get an even amount of the drug 
in the body over a daily period. These drugs cause 
more intense withdrawal reactions when stopped. 
When embarking upon any account of how 
therapists may best support clients either 
withdrawing or considering withdrawing from 
psychiatric drugs, we encounter a number of 
immediate obstacles: 
■■ In the first place, beyond the considerable work 
undertaken on benzodiazepine withdrawal, 
it is widely acknowledged that research into 
antipsychotic and antidepressant withdrawal 
is comparatively limited. One of the major 
outcomes of the recent antidepressant 
withdrawal debates1 was that numerous 
admissions made by mainstream psychiatry 
showed serious gaps in our understanding of 
withdrawal. It also showed that established 
thinking on withdrawal (captured by NICE 
guidelines) is in significant need of revision 
(a revision which, as we mentioned in the 
introduction to this guidance, has now taken 
place). 
■■ While the prescribing professions still 
have much work to do in deepening our 
understanding of withdrawal, research into how 
therapists may best support clients either in or 
considering withdrawal is even more sparse. 
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What is therefore offered in this section is largely 
derived from the combined experience of those who 
have worked directly with people withdrawing from 
psychiatric drugs. Although more research on such 
practices is still needed, experiential knowledge of 
successful withdrawal management has become 
sufficiently comprehensive to merit providing a 
picture of what we know, to date, works best.
This section will first summarise broadly what 
is known about withdrawal from each class of 
psychiatric drug, paying especial attention to the 
incidence, severity and duration of withdrawal. 
Finally, some background information regarding 
the medical management of the withdrawal 
process is provided alongside the definition of key 
terms.
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5.2 Evidence on the likelihood, range of possible experiences, 
duration and severity of withdrawal per drug class
* Two excluded studies, which reported low incidence rates (12%), were simply ‘chart reviews’ of medical notes (Coupland et al., 1996; 
Himei & Okamura, 2006) which are notoriously weak owing to their reliance on practitioners being aware of, and recording, withdrawal 
reactions. A further excluded study, which reported very high incidence rates (97%), comprised 693 people who were all involved in a 
withdrawal programme using tapering strips (and were answering a question about their previous attempts to come off) (Groot & Van 
Os, 2018). This sample was unrepresentative because people who have not experienced withdrawal reactions are unlikely to enter a 
tapered withdrawal programme. (See 5.4.1 for information about tapering).
5.2.1 Antidepressants
Although further and better research is 
clearly needed in this area, it is safe to say, 
from the best available studies to date, that 
at least half of people who try to stop, or 
reduce, their antidepressants will experience 
withdrawal effects, while about half of those 
people describe the effects as ‘severe’, and the 
duration varies enormously.1
5.2.1.1 Withdrawal reactions








Vivid dreams Heart palpitations
Muscle stiffness Sensory 
Hallucinations hypersensitivity
Imbalance Confusion
Agitation Inability to cry
Shorter half-life antidepressants (such as 
venlafaxine, paroxetine, duloxetine and 
imipramine) are expelled from the body more 
rapidly (also see section 5.1). Antidepressants 
that are eliminated more slowly (e.g. fluoxetine) 
allow the body time to re-adapt to being without 
the drug and hence the withdrawal reactions are 
usually (but not always) less severe.
5.2.1.2 Incidence – How many people experience 
withdrawal reactions?
A recent systematic review of the literature on 
withdrawal from all types of antidepressants, 
but predominantly covering selective serotonin 
reuptake inhibitors (SSRIs), revealed 17 studies that 
contained data on withdrawal incidence – namely, 
on how many people taking antidepressants will 
experience withdrawal1. 
Seventeen different studies were reviewed (these 
ranged from small, industry funded drug trials to 
large independent online surveys of people who 
take antidepressants). These produced incidence 
rates from five percent to 97%. Of these 17 studies, 
three were excluded on methodological grounds.* 
The remaining 14 studies were methodologically 
diverse (comprising six RCTs, five naturalistic 
studies and three surveys) and produced incidence 
rates ranging from 27% to 86%. When grouping the 
three types of study together, the weighted average 
for each group was: 
■■ The three surveys – 57.1% (1790/3137),
■■ The five naturalistic studies – 52.5% (127/242)
■■ The six RCTs – 50.7% (341/673)
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As getting similar findings from different 
methodologies is typically seen to strengthen 
confidence in an overall, combined estimate, the 
most recent evidence suggests that at least half of 
people suffer withdrawal reactions when trying to 
come off antidepressants (median 55%).
5.2.1.3 Treatment duration – does the length 
of time spent on an antidepressant affect 
withdrawal?
When comparing the studies, there was no obvious 
relationship between incidence of withdrawal 
reactions and duration of treatment, but, as noted 
above, the information on treatment duration 
was incomplete. There were some useful data, 
however, within some of the studies. Two studies 
found no significant difference in the treatment 
duration of those who did and did not experience 
withdrawal reactions,2,3 demonstrating that 
withdrawal reactions do not only occur in people 
who had been on the drugs for long periods of 
time. Both an international online survey4 and 
an even larger NZ survey5,6 found that those who 
had been on the drugs for more than three years 
were significantly more likely to report withdrawal 
effects, but these findings could partly be explained 
by a larger number of withdrawal attempts. Most 
participants in all four of these studies had been on 
antidepressants for months or years, so the studies 
were not able to assess whether there is a plateau, 
within the first few weeks of treatment, beyond 
which the probability of withdrawal reactions does 
not increase for most people. 
5.2.1.4 Self-reported addiction
Another approach to the question of the incidence 
of withdrawal reactions is to ask how many people 
report becoming ‘addicted’ to or dependent on 
antidepressants. Traditional studies ignore this 
somewhat taboo topic. We do have important 
data, however, on how many recipients experience 
antidepressants as ‘addictive’. 
Three studies have provided percentages, which 
range from 27% to 37%. Of 192 people taking 
antidepressants in the Netherlands, 30% described 
their drugs as addictive. The two large online 
surveys found that 27% of 1,5215 and 37% of 9434 
also described their antidepressants as addictive. 
The weighted average of these three studies is 
30.8%. While it is difficult to extrapolate these 
findings to the wider population of those taking 
antidepressants, it is nevertheless important to 
note in these studies that nearly a third of those 
taking antidepressants, when asked, report being 
addicted to the drugs, according to their definition 
of the term.
5.2.1.5 Severity of withdrawal based on surveys
Unfortunately, questions as to the severity of 
withdrawal have not been sufficiently addressed in 
randomised trials. Therefore, the preponderance 
of data we have on withdrawal severity is derived 
from direct-to-consumer surveys.1 As it is difficult 
to extrapolate from surveys to the general 
antidepressant population (e.g. people who 
experience withdrawal may be more likely to respond 
to surveys) population level estimates are hard to 
make. Nonetheless, the survey data are important 
as they indicate that for a proportion of those taking 
antidepressants withdrawal can be severe.
For example, in a recent New Zealand survey, 46% 
of the 750 who experienced withdrawal effects 
reported those effects to be ‘severe’ rather than ‘mild’ 
or ‘moderate’,5,6 which was very similar to the 43% 
finding in the international sample.4 Furthermore, a 
recent Dutch study found that of 671 people who had 
experienced some degree of withdrawal effects, 51% 
reported the most extreme of six levels of withdrawal. 
Additionally, a recent international survey of 605 
people, all self-identifying on antidepressant 
withdrawal websites as experiencing withdrawal, 
asked participants to rate on a scale of 0–10 how 
severely withdrawal had impacted upon their life. The 
average rating was 8.4 with 41% indicating the highest 
level of severity on the scale.7 
The percentages selecting the most extreme level 
of severity on offer in each of these four studies 
ranged from 41% to 51%, with a weighted average 
of 45.3%. So regardless of the scale used, nearly 
half of all people surveyed in these studies who 
experienced withdrawal effects ticked the most 
extreme level of severity on the scale they were 
presented with. 
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5.2.1.6 Difficulty, and duration, of withdrawal
In a recent UK survey, 245 responded to the 
question ‘How easy did you find it to come off your 
medication?’ 
■■ 20% ticked ‘very easy’; 
■■ 51% ticked ‘fairly easy’; and 
■■ 29% ticked ‘not easy at all’.8
Of the 247 who responded to ‘How long did it take 
you to come off your medication?’ 
■■ the majority (68%) did so within three months; 
■■ but 21% took between three to six months; 
■■ 6% took between six and 12 months; and 
■■ 5% took more than a year.8
5.2.1.7 Duration of withdrawal reactions
A recent systematic review of antidepressant 
withdrawal identified 10 relevant studies that 
had gathered data on the duration of withdrawal 
reactions.1 While this review could not provide 
firm conclusions about the average duration of 
withdrawal reactions (because of the variety of 
methodologies and ways duration was reported), 
it did conclude that there is far more variability in 
duration than previously believed.E Nine of the 10 
studies found that a significant number of people 
experience withdrawal reactions beyond a week, 
while seven of the 10 studies showed that it is not 
uncommon for people to experience withdrawal for 
several months. 
This review’s findings were consistent with other 
reviews. For instance, a 2015 review of quantitative 
studies and case reports noted that in only four out 
of 18 case reports (22%) did withdrawal reactions 
spontaneously remit within two weeks, and in 
two cases withdrawal effects were ongoing a year 
after discontinuation. It concluded that withdrawal 
reactions ‘typically last a few weeks’ but noted that 
‘many variations are possible, including…longer 
persistence of disturbances’.9 A more recent review, 
of research just on withdrawal from serotonin-
norepinephrine reuptake inhibitors (SNRIs), 
concluded that ‘Symptoms typically ensued within 
a few days from discontinuation and lasted a few 
weeks, also with gradual tapering. Late onset and/
or a longer persistence of disturbances occurred 
as well’ and recommended that ‘Clinicians need to 
add SNRIs to the list of drugs potentially inducing 
withdrawal symptoms upon discontinuation’.9
Even longer durations have been reported by 
two real life samples of people experiencing 
difficulties with withdrawal. For instance, a recent 
international survey of people self-identifying as 
experiencing withdrawal found that when 605 
people who had experienced withdrawal were 
asked ‘How long have you experienced withdrawal 
symptoms?’ 87% responded at least two months, 
59% at least one year, and 16% more than three 
years.7 Additionally, a recent content analysis of a 
population likely to have experienced withdrawal 
difficulties assessed the content of 137 online posts 
about AD withdrawal in the real world. The mean 
duration of withdrawal reactions was 90.5 weeks 
for the 97 taking SSRIs and 50.8 weeks for the 40 
taking SNRIs. Although neither of the above two 
study samples are representative of all those taking 
antidepressants, they nevertheless indicate that it 
is not as rare as sometimes thought for withdrawal 
reactions to last more than a year.1 
5.2.1.8 Qualitative studies on antidepressant 
withdrawal
Qualitative studies are consistent with and serve 
to bring to life the findings of the recent review 
of quantitative research.1 Illustrative examples 
of personal testimony regarding the severity and 
duration of withdrawal effects follow:
“I am currently trying to wean myself off of 
Venlafaxine, which honestly is the most awful thing 
I have ever done. I have horrible dizzy spells and 
nausea whenever I lower my dose. 
“It took me almost two years to get off Paroxetine 
and the side effects were horrendous. I even had 
to quit my job because I felt sick all the time. Even 
now that I am off of it, I still feel electric shocks in 
my brain.”10 
“It took me two months of hell to come off the 
antidepressants. Was massively harder than I 
expected.
“I forgot to take my Citalopram for two days and 
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woke up one morning with severe dizziness. It was 
so extreme that I fell over when I tried to get out of 
bed, and I threw up.”6 
“The withdrawal effects if I forget to take my pill 
are severe shakes, suicidal thoughts, a feeling of 
too much caffeine in my brain, electric shocks, 
hallucinations, insane mood swings. … kinda stuck 
on them now coz I’m too scared to come off it.”11 
“While there is no doubt I am better on this 
medication, the adverse effects have been 
devastating – when I have tried to withdraw – 
with ‘head zaps’, agitation, insomnia and mood 
changes. This means that I do not have the 
option of managing the depression any other 
way because I have a problem coming off this 
medication. 
The difficulty of getting off has been a tough road 
and taken me years of trying and is something 
that doctors could be more knowledgeable of and 
supportive with.”12 
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Withdrawal symptoms after selective serotonin reuptake 
inhibitors discontinuation: A systematic review. Psychotherapy 
and Psychosomatics, 84, 72–81.
10.  Pestello, F. & Davis-Berman, J. (2008). Taking anti-depressant 
medication: A qualitative examination of internet postings. 
Journal of Mental Health, 17, 349–360.
11.  Gibson, K., Cartwright, C. & Read, J. (2016). ‘In my life 
antidepressants have been….’: A qualitative analysis of users’ 
diverse experiences of antidepressants. BMC Psychiatry, 16, 
135. 
12.  Cartwright, C., Gibson, K., Read, J., Cowan, O. & Dehar, T. 
(2016). Long-term antidepressant use: Patient perspectives 
of benefits and adverse effects. Patient preference and 
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5.2.2 Benzodiazepines and Z-drugs
The incidence of withdrawal range in different 
studies from 20% to 100%. Rather than report all 
the studies that draw these estimates, it can safely 
be concluded that these drugs are highly addictive 
and that dependence and withdrawal reactions 
are common. For this reason, the British National 
Formulary (2012)1 recommends that uninterrupted 
usage, for both benzodiazepines and Z-drugs, does 
not exceed four weeks, because the drugs so quickly 
lead to tolerance and to physical and potentially 
psychological dependence. However, it is now clear 
that there are substantial numbers of people taking 
them for longer than two years (see 4.3.5).
Benzodiazepines are a drug-class that includes 
sedatives and anxiolytics: 
■■ Sedatives (otherwise known as hypnotics or 
sleeping pills), such as flurazepam, temazepam, 
nitrazepam and loprazolam, tend to be short 
acting.
■■ Anxiolytics (also known as tranquillisers or anti-
anxiety drugs), such as diazepam, alprazolam, 
chlordiazepoxide, oxazepam and lorazepam, are 
longer-acting. 
‘Z-drugs’ are non-benzodiazepine sedatives/
hypnotics. The Z-drugs available in the UK are 
zaleplon, zolpidem, and zopiclone. 
Both benzodiazepines and Z-drugs boost the effect 
of a substance in the brain called Gabba Amino 
Butyric Acid (GABA), which is thought to have a 
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calming effect. Because the Z-drugs are short-
acting, it was hoped they may avoid or minimise 
dependence and withdrawal. However, there seems 
to be no robust evidence that they are significantly 
less addictive, or less often lead to withdrawal 
reactions, than short-acting benzodiazepines. 
5.2.3.1 Withdrawal reactions
Someone who uses benzodiazepines for more than 
a few (two to four) weeks is likely to experience 
withdrawal reactions when they stop them. The 
reactions include anxiety, agitation, insomnia 
and muscle stiffness. Since benzodiazepines 
suppress nervous activity, stopping them increases 
the activity of the nervous system. Withdrawal 
can therefore induce unusual and usually 
unpleasant sensory experiences such as tingling 
and numbness, electric shock-like feelings and 
occasionally delusions and hallucinations.
Withdrawal reactions usually start between six and 
48 hours of stopping, or after reducing the dose of 
a benzodiazepine, but can start later for longer-
acting drugs, such as anxiolytics. 
The most common withdrawal effects of these 
drugs include: 
Table 2: Most common withdrawal effects of 







But many other reactions may be experienced, 
including: 
Table 2.1: Other withdrawal effects of 
benzodiazepines and Z-drugs
Panic attacks Restlessness
Weight loss Abdominal cramps
Depression Poor memory and concentration
Agoraphobia Burning sensations in the skin
Table 2.1: Other withdrawal effects of 
benzodiazepines and Z-drugs
Flu-like symptoms Sore tongue and metallic taste
Blurred vision Tinnitus (ringing in the ears)
Nightmares Tingling in the hands and feet
Lethargy Hallucinations and delusions
Sudden cessation of benzodiazepines and Z-drugs 
increases the probability of these withdrawal 
reactions and may also cause grand mal seizures, 
hallucinations, and suicidality.1-7 
5.2.3.2 Severity of withdrawal 
The severity of these reactions increases with:
■■ longer usage
■■ higher dosage
■■ the use of multiple benzodiazepines
■■ oral rather than injected use
■■ shorter half-life benzodiazepines (such as 
lorazepam or temazepam) because these are 
expelled from the body more rapidly. Drugs that 
are eliminated more slowly allow the body time 
to re-adapt to being without the drug and hence 
the withdrawal reactions are usually (but not 
always) less severe
■■ an abrupt cessation, and so it is recommended 
that benzodiazepines are withdrawn slowly. 
5.2.3.3 Incidence – How many people experience 
withdrawal reactions?
Although initially marketed as a non-addictive 
alternative to barbiturates, benzodiazepines have 
long been recognised as highly addictive. Estimates 
of how many people experience withdrawal effects 
are determined by how long they have been on 
the drugs, how quickly they withdrew from them, 
and the definition or measure used to assess 
the withdrawal effects. Approximately 40% of 
people will become addicted within six weeks of 
taking them.8 Some research finds that everyone 
who has been on benzodiazepines for at least six 
months and then tries to stop the drugs quickly will 
experience some withdrawal reactions, and for 40% 
the reactions will be moderate or severe.3 
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5.2.3.4 Duration
Estimates of how long withdrawal reactions last 
vary greatly, and are largely determined by duration 
of treatment, dosage and drug type. Almost all 
people stopping or reducing benzodiazepines will 
experience an ‘acute’ phase of withdrawal, which 
typically lasts for two weeks to two months. A 
minority will experience protracted (or ‘post-acute’) 
withdrawal phases, for a year or more,9,1,10,11 with 
anecdotal reports of five to 10 years. 
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5.2.4 Antipsychotics
The most recent survey found that of 105 
people who tried to come off antipsychotics, 
65 (62%) experienced unwanted withdrawal 
effects ‘across the full-range of physical, 
emotional, cognitive, and functional domains’1
Drugs that were developed in the 1950s to treat 
people diagnosed with schizophrenia were 
initially described as ‘major tranquillisers’, 
acknowledging their powerful sedating effects. 
They have since become known as ‘antipsychotics’ 
or ‘neuroleptics’. They are now often used on 
other groups besides those diagnosed with 
schizophrenia, including prisoners; children with 
learning and other difficulties, and people in care 
homes for the elderly. The first antipsychotics 
included chlorpromazine, haloperidol, pimozide 
and trifluoperazine. These ‘first generation’ 
antipsychotics had a disturbing adverse effects’ 
profile (including tardive dyskinesia – a usually 
irreversible movement disorder). A second 
generation of antipsychotics, sometimes referred 
to as ‘atypical’ were developed, in the 1990s.2 
These include: amisulpride, aripiprazole, clozapine, 
olanzapine, quetiapine and risperidone.
We were introduced to the concept of withdrawal 
effects after stopping antipsychotics in section 4.4.5, 
in relation to understanding efficacy studies. As is the 
case for other central nervous system drugs, such as 
benzodiazepines and alcohol, the brain can develop 
a tolerance to antipsychotics.3 Antipsychotics, 
however, are clearly not addictive, if one’s definition 
of addiction involves a craving for the drugs. In fact, 
because of the unpleasant adverse effects many 
people try hard to stop taking antipsychotics soon 
after commencing them,4,5 or have to be forced to take 
them against their will via the Mental Health Act, often 
with involuntary, long-acting injections.6 About half of 
people prescribed antipsychotics for ‘schizophrenia’ 
are ‘noncompliant’.5 In one large sample, 74% tried at 
least once to discontinue the antipsychotics within 18 
months of starting treatment.7 
The adverse effects that lead to people trying to 
come off these drugs include8-11: 
Table 3: The adverse effects that lead to people 
trying to come off these drugs
Sedation Cardiovascular effects (arrhythmia & 
sudden cardiac death)
Dizziness Akathisia (extreme restlessness)
Sexual 
dysfunction
Metabolic effects (obesity, glucose 
intolerance, high cholesterol and diabetes)
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In an international survey of 832 people taking 
antipsychotics, twice as many (395) cited 
‘unpleasant side effects’ than ‘felt better and didn’t 
need it’ (195) as their main reason for wanting to 
stop their antipsychotics.12
Despite not being addictive in the strict sense of that 
word, there are two types of withdrawal syndrome 
that can make it very difficult to reduce, or come off, 
these drugs. The first type has much in common with 
the withdrawal effects of the other central nervous 
system drugs discussed in this guidance, such as 
benzodiazepines. The second type is somewhat 
more specific to psychosis and/or antipsychotics.
5.2.4.1 Classic withdrawal reactions
A recent review3 found that antipsychotics share a 
range of ‘classic symptoms of withdrawal’ with all 
central nervous system drugs. These reactions, which 
usually emerge within four days of stopping, include:







The reviewers suggest that these reactions usually 
last ‘up to six weeks’ and ‘may last more than six 
weeks and become a post-withdrawal disorder’ 
but the review provides no data to support these 
suggestions. 
There are, in fact, relatively few studies of the 
frequency or duration of classic withdrawal 
reactions following discontinuation of 
antipsychotics. The largest direct-to-user, 
international survey, of 832 people prescribed/
taking antipsychotic medication, found that 65% 
reported withdrawal effects when trying to stop 
or reduce, and that half of those people (51%) 
described those withdrawal effects as ‘severe’.12 
Reported withdrawal was strongly correlated with 
duration of treatment (p < .001). 
5.2.4.2 Antipsychotic induced psychosis and 
tardive dyskinesia
As described in section 4.4.3, antipsychotics 
blockade, to a varying degree, the dopamine 
system and other neurotransmitter systems 
(along with many other effects on the brain and 
body).13 This led to the notion that ‘schizophrenia’ 
is ‘caused’ by an overactive dopamine system, a 
hypothesis that was never proved and that is now 
largely abandoned. The brain tries to compensate 
for the blockade. 
As early as 1974 Dr Solomon Snyder, Professor of 
Psychiatry and Pharmacology at John Hopkins 
University warned that:
Something within the neurons recognises this 
sudden absence of neurotransmitter molecules 
at their appropriate receptor site and one way 
or another transmits a message back to the 
dopamine neurons saying something like the 
following: ‘We don’t have enough dopamine. 
Please send us some more!’ Whereupon the 
dopamine neuron in question proceeds to fire 
at a more rapid rate.14
It has since been established that the brain’s 
attempted compensation also includes an increase 
in the number, and sensitivity, of dopamine 
receptor cells,3 a process that is not unique to 
antipsychotics. When an antipsychotic, and the 
dopamine blockade, are removed, or reduced, the 
brain is effectively overwhelmed with dopamine, 
partly because of the abnormal drug-induced 
sensitivity and number of dopamine receptor 
cells. This process is likely to apply to the other 
neurochemical systems that antipsychotics 
influence. These effects may result in a withdrawal 
psychosis, which is often mistaken for a return of 
the ‘schizophrenia’ that the drugs were intended 
to treat. This in turn often leads to a reinstatement 
of the drugs that have, paradoxically, caused the 
neurotransmitter abnormalities.15,2,14 
The first cases of dopamine ‘Supersensitivity 
Psychosis’ [SP] were reported 40 years ago.16 A 2006 
reviewer of the available evidence concluded:
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There is evidence to suggest that the process 
of discontinuation of some antipsychotic 
drugs may precipitate the new onset or 
relapse of psychotic symptoms. Whereas 
psychotic deterioration following withdrawal 
of antipsychotic drugs has traditionally been 
taken as evidence of the chronicity of the 
underlying condition, this evidence suggests 
that some recurrent episodes of psychosis may 
be iatrogenic [caused by medical treatment]. 
Clinicians may therefore want to re-evaluate 
the benefits of long-term treatment in some 
patients.15 [Definition added]
There have been two recent, comprehensive 
reviews of the research literature on what 
now tends to be called ‘antipsychotic-induced 
Dopamine Supersensitivity Psychosis’ or 
‘Supersensitivity Psychosis’ [SP] for short.3,17 One 
of the reviewers has designed criteria for two 
SP-based withdrawal syndromes, differentiated 
primarily by duration.
5.2.4.3 Rebound psychosis
One set of criteria for ‘Rebound Psychosis’, or 
‘Withdrawal Psychosis’, are new psychosis reactions 
occurring, or old psychotic reactions recurring at 
above pre-treatment levels, after antipsychotic 
discontinuation, reduction, switching or in between 
dose intervals, usually (but not always) after 
about three months continuous exposure to the 
drug (the time necessary for increased dopamine 
receptor density to occur), and causing distress or 
impairment in functioning.3 These reactions usually 
appear within roughly four days of stopping oral 
antipsychotics but can take several weeks to emerge 
after cessation of long-acting injections. Rebound 
psychosis seems to be rather rare and the evidence 
most clearly supports it in relation to withdrawal 
from clozapine. British psychiatrist Joanna Moncrieff 
prefers the term ‘Rapid Onset Psychosis’ because it 
is neutral about the underlying mechanisms that, 
she suggests, are unclear.15 
5.2.4.4 Persistent Postwithdrawal 
Supersensitivity Psychosis (PPSP)
Some researchers think that if Rebound 
Psychosis lasts longer than six weeks it should 
be reclassified as ‘Persistent Postwithdrawal 
Supersensitivity Psychosis’,3 but this area is hard 
to research and there are a range of opinions 
on the topic. If PPSP does exist it is one of two 
long-lasting Postwithdrawal Disorders caused by 
antipsychotics. The other is the movement disorder 
Tardive Dyskinesia that is discussed later. 
5.2.4.5 How many people experience Rebound 
Psychosis and PPSP and for how long?
Few studies have addressed the incidence or 
duration of withdrawal induced psychosis. The 
2006 review mentioned earlier had reported 
mostly only case studies, including nine people 
with no previous history of psychosis, whose new 
psychosis (typically hallucinations or delusions) 
usually responded to reintroduction of the 
antipsychotic.15 It was possible, however, to 
estimate that 20–25% of people withdrawing from 
a specific antipsychotic, clozapine, experienced 
Supersensitivity Psychosis (SP) or, as the reviewer 
prefers to call it ‘Rapid Onset Psychosis’. 
An early study estimated that between 22% and 43% 
of 224 outpatients diagnosed with schizophrenia 
had SP. Two recent studies of atypical antipsychotics 
have reported SP incidence rates of 65%18 and 
72%.19 All three studies, however, included cases 
that occurred due to tolerance (see section 1.8) 
while the person was still taking the antipsychotics. 
In the latter study, 42% of the cases were identified 
as ‘Rebound Psychosis’, which means that overall 
30% of the sample, not all of whom had tried to stop 
their antipsychotics, had experienced withdrawal-
induced psychosis. Another study found SP in 26% 
of people while changing from one antipsychotic 
to another.20 This is, however, a very difficult issue 
to research because of the fluctuating nature of the 
underlying psychosis.
In a recent international survey of people taking 
antipsychotics, ‘new or increased psychosis’ was the 
second most frequently reported ‘other side effect’ 
(after ‘akathisia/restlessness’). Thirteen reported 
new reactions and six reported the exacerbation 
of previous reactions. It was not known, however, 
how many of the instances of new or exacerbated 
psychosis reactions followed withdrawal.12 
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There is some evidence that antipsychotics with 
shorter half-lives (e.g. clozapine, metroclopromide, 
sulpiride and amisulpiride) are more likely to 
provoke SP.15,3 
5.2.4.6 Tardive Dyskinesia
Tardive Dyskinesia (TD), also mentioned briefly 
in section 4.4.7, is a disabling, often irreversible, 
antipsychotic-induced neurological disorder involving 
uncontrollable movements of the face, tongue, 
arms and legs. It is also associated with cognitive 
impairment.21 It is likely, but not proven, to be the result 
of the over activity of the dopamine system caused 
by changes such as increased receptor numbers and 
sensitivity caused by antipsychotics. Some researchers 
consider TD to be either a component or predictor 
of SP.3,18,19 The average prevalence of TD in people 
taking antipsychotics is about 30%,22,23,2 rising to 
57% after 15 years of treatment with first generation 
antipsychotics.22 The prevalence was thought to be 
lower for second generation, ‘atypical’, antipsychotics, 
but the difference has found to be slight or non-
existent,22,2 or the consequence of second generation 
antipsychotics being prescribed at lower dosages. 
It is listed here as a withdrawal effect because the 
reactions of TD are often masked by the withdrawal 
of antipsychotics. When the drugs are stopped, it is 
thought that dopamine activity increases due to the 
increased sensitivity of the dopamine system produced 
by long-term antipsychotic treatment. Increased 
dopamine activity can produce abnormal movements. 
Thus, the overt physical reactions (but not necessarily 
the cognitive reactions) of TD are often either seen for 
the first time, or are exacerbated, after discontinuation, 
reduction or switching of antipsychotics.22,2 People 
over 50 are three to five times more likely than younger 
people to develop TD.22
5.2.4.7 Withdrawing slowly, with support
A recent study exploring the personal accounts 
of individuals discontinuing antipsychotic drugs 
identified that ‘weaving a safety net to safeguard 
well-being’ was a pivotal process in drug reduction. 
This involved taking precautionary steps prior to 
reducing drugs taken to establish interpersonal 
alliances with family, friends, support groups and 
mental health professionals that can be activated 
should problems arise.23
In another study, 55% of 105 people who attempted 
discontinuation of APs described successfully 
stopping all APs for varying lengths of time, half 
reported no current use, and half described having 
some form of professional, family, friend, and/
or service user or peer support for their attempt. 
Having support was associated with less relapse.1 
Furthermore, withdrawing gradually across more 
than one month was positively associated with 
successful withdrawal.24 There will, of course, be 
large variability in how long people need to take to 
withdraw.
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5.2.5 Lithium and other ‘mood 
stabilisers’
The relatively small amount of research 
conducted suggests that reducing, or 
withdrawing from, Lithium does not seem to 
cause the physical reactions caused by coming 
off other psychiatric drugs. Several studies, 
however, show that stopping Lithium can cause 
a relapse of mania, and that the probability of 
having such a relapse when withdrawing after 
long-term use is higher than before Lithium was 
started.1–4
Lithium is a toxic alkali metal, similar to sodium 
and potassium. It is prescribed primarily for people 
who experience relatively extreme emotional highs 
and lows, who often receive the diagnostic label 
‘Manic Depression’ or, more recently, ‘Bipolar 
Disorder’. The dose considered to be therapeutic 
is so close to the dose that causes a hazardous 
toxic state (which can be fatal if the Lithium is not 
stopped immediately) that levels of lithium in the 
blood have to be carefully monitored.2
The mental health charity Mind advises that:
There do not appear to be physical 
withdrawal symptoms with lithium. 
However, if you come off lithium too quickly 
you are very likely to have a rebound manic 
or psychotic episode and become quite ill, so 
you need to be cautious, reduce gradually – 
over at least one month, and much longer if 
you have been taking it for years. If relapse 
occurs, it happens in the first few months 
after withdrawal and then tails off.5  
(Mind, 2018).
Some studies have reported increased suicidality 
following withdrawal from Lithium, especially if 
abrupt.6,7 
Other drugs, sometimes described as ‘mood 
stabilisers’, include the three anticonvulsants 
carbamazepine (Tegretol), lamotrigine (Lamictal) 
and valproate (Depakote, Epilim). Little research 
has been conducted into the withdrawal 
reactions for people taking these drugs who do 
not have seizure disorders. A case series of six 
people coming off lamotrigine found distressing 
psychiatric reactions, especially anxiety and 
irritability.8 A study of 90 people who withdrew 
from carbamazepine found that 26 (29%) 
reported withdrawal reactions within four days 
of withdrawal. Reactions, which alleviated 
within one week, included insomnia, dysphoria, 
hallucination, hand fremitus (vibratory sensation), 
and headaches.9
For the withdrawal effects of asenapine (Sycrest), 
an antipsychotic which is sometimes used as a 
mood stabiliser, see the section on antipsychotics.
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lithium-and-other-mood-stabilisers/coming-off-mood-
stabilisers/#.W0R0UYcVCpo. (Accessed July 2018.)
6.  Baldessarini, R., Tondo, L. & Hennen, J. (1999). Effects of 
lithium treatment and its discontinuation on suicidal behavior 
in bipolar manic-depressive disorders. Journal of Clinical 
Psychiatry, 60 (Supplement 2), 77–84. 
7.  Tondo, L., Baldessarini, R. J., Hennen, J., Floris, G., Silvetti, 
F. & Tohen, M. (1998). Lithium treatment and risk of suicidal 
behavior in bipolar disorder patients. The Journal of Clinical 
Psychiatry, 59(8), 405–414.
8.  Frey, L., Strom, L., Shrestha, A. & Spitz, M. (2009). End-of-dose 
emergent psychopathology in ambulatory patients with 
epilepsy on stable-dose lamotrigine monotherapy: A case 
series of six patients. Epilepsy & Behavior, 15, 521–523. 
9.  Chen, M., Zhang, W., Guo, Z., Zhang, W., Chai, Y. & Li, Y. (2014). 
Withdrawal reaction of carbamazepine after neurovascular 
decompression for trigeminal neuralgia: A preliminary study. 
Journal of Neurological Science, 338, 43–45. 
5.2.6 Stimulants prescribed for ADHD
The effects of withdrawing from stimulant drugs 
like cocaine and amphetamines that are taken 
for recreational purposes are well-documented. 
Even after taking stimulants for a day or two, 
people taking them typically experience a period 
characterised by reduced energy, depression, 
irritability, hunger and excessive sleeping, which 
can last for a couple of days. When someone has 
taken stimulants continuously for a long period, 
they may initially have insomnia, and feel anxious, 
sad and agitated, and they can experience chills 
and intense cravings for the drug. 
After this, the person withdrawing will likely begin 
feeling both mental and physical exhaustion, start to 
sleep excessively, although they may still experience 
periods of insomnia, and become more depressed. 
They may continue to feel anxious and irritable 
and stop feeling pleasure, they may become less 
sensitive to stimuli such as touch and sound, be 
socially withdrawn and have vivid dreams. 
The depression can be intense, and it may be 
accompanied by suicidal thoughts. The symptoms 
can persist for between a few days and several 
weeks or even months.1 
Withdrawal from prescribed stimulants is less 
commonly described. Studies that have explored 
the consequences of withdrawal have focused only 
on whether or not it is associated with a relapse of 
the symptoms of ADHD, without considering the 
possible physiological and psychological effects 
of the withdrawal itself.2,3 However, it has long 
been recognised that use of prescribed stimulants 
by people with ADHD is associated with the 
phenomenon known as ‘rebound’. 
This occurs when the effects of a dose of a 
stimulant wear off, usually towards the evening, 
and consists of a worsening of the symptoms of 
ADHD beyond their original level before treatment 
was started. Children, in which ‘rebound’ has 
mainly been noted, become highly excitable and 
distractible. Since low- dose stimulants reduce 
activity and increase focused attention, these 
rebound effects are a predictable response to the 
wearing off of the direct effects of the drug. 
Rebound is also characterised by the onset of some 
new symptoms including tearfulness, irritability 
and emotional lability, which are not usually part 
of ADHD.4–6 These rebound effects suggest that 
stimulants restrict or dampen emotional responses 
at the doses used in clinical practice. It has also 
been shown to manifest in the worsening of driving 
performance in adults who had taken a dose of a 
stimulant several hours earlier compared to those 
who took a placebo.7 
The existence of rebound suggests the presence 
of the drug has modified the brain in some way, 
which in itself consists of a form of withdrawal 
syndrome. The rebound phenomenon also 
illustrates how quickly the body adapts to the 
presence of a drug and how rapidly withdrawal 
symptoms can occur after the effects of a drug 
have worn off. 
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A few case reports document a withdrawal 
syndrome following the complete discontinuation of 
prescribed stimulants in children which, as in adults, 
includes depression and malaise. New episodes of 
migraine and psychosis have also been reported.8-10 
However, there is no research that could confirm 
how common or severe this withdrawal syndrome is, 
and how long it might last when it occurs. 
As with research on the long-term effects of other 
psychiatric drugs, the probable existence of a 
withdrawal syndrome following discontinuation of 
stimulant treatment is likely to confound attempts 
to assess relapse or recurrence of ADHD symptoms 
after medication is stopped. 
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5.2.7 Polypharmacy
Polypharmacy, the prescribing of more than one 
drug at the same time, has increasingly become the 
norm in psychiatry.1 By the 1990s 80% of people 
receiving psychiatric intervention were on more than 
one drug.2 A particularly common combination is 
antidepressants and benzodiazepines.3 A 2009 study 
found that up to one third of psychiatric outpatients 
were on three or more psychiatric drugs.4 
Despite its commonality, little research has 
explored the role that this multiple prescribing 
has on the frequency, severity or duration 
of withdrawal effects, or has studied how 
polypharmacy affects the process of coming off the 
various combinations of drugs.
In the large New Zealand online survey5 people 
who were taking, or had taken, more than one 
antidepressant reported a higher incidence of 
withdrawal effects (68.3%) than those who had 
taken just one antidepressant (e.g. Fluoxetine – 
35.5%), with the exception of Paroxetine (75.9%) 
and Venlafaxine (70.4%).
In the large international online survey6 55.4% 
of those who had taken only antidepressants 
reported withdrawal effects, compared to 65.9% 
of those who had taken both antidepressants and 
antipsychotics. The figures for reported addiction 
were 36.8% and 47.7% respectively.
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5.3 Overall impacts of withdrawal on individuals
In addition to understanding the objective effects 
of withdrawal, it is also necessary to understand 
the subjective impact that withdrawal can 
have on the lives of individuals. It is important 
to be particularly mindful of how debilitating 
– physically, psychologically and relationally – 
withdrawal, in some cases, can be. 
A recent survey of 319 people using services in 
England, all self-identifying as experiencing varying 
degrees of antidepressant withdrawal, showed that 
half reported being incapacitated in some way by 
the experience, with their capacity to perform basic 
daily tasks being impaired.1 A full (27), reporting 
more extreme withdrawal reactions, indicated 
that the experience had ‘ruined their lives’ or had 
led them to ‘lose everything’. Many individuals 
also reported that their reactions had a significant 
impact on their ability to work. Decision-making, 
memory, concentration and communication skills 
were also affected, to varying degrees, leading 
some participants to take time off or struggle 
through in a ‘brain-fog’ or a ‘zombie-like’ state.1 
As a result, many participants experienced some 
level of financial loss, while many experienced a 
significant lowering of their confidence and self-
esteem. 
Withdrawal can have far-reaching consequences, 
extending beyond those personally impacted to 
affect families, friends and associates. In the same 
survey, some individuals reported that withdrawal 
undermined their ability to support and take 
sufficient care of others, including their children. 
They also reported that their ability to engage 
socially was significantly impaired, leading to 
increased isolation. 
A lack of understanding by family members about 
withdrawal reactions can also place further strain 
on relationships. When withdrawal is perceived as 
an ‘over-reaction’ this can lead to a breakdown of 
mutual trust and understanding. Alternatively, a 
decrease in self-care can also lead to heightened 
dependency on others, again compounding 
relational strain. 
At its most extreme, then, withdrawal can lead to 
family break-ups, job losses and unemployment, 
reliance on state benefits, bankruptcy and even 
suicide.2 While this study cannot be said to 
represent all those taking antidepressants, or 
even all those who experience withdrawal, it 
nevertheless indicates that for some, withdrawal 
can be a highly destructive experience, adversely 
impacting families and beyond.
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5.4 The withdrawal process and terminology
Before outlining some key strategies therapists 
can use to support clients through withdrawal in 
section 6, it will be useful to first provide some 
background information regarding the medical 
management of the withdrawal process.
5.4.1 Some background on tapering
Tapering is defined here as the slow reduction over 
time of a prescribed drug. It should be managed 
by a knowledgeable prescriber. There are various 
successful recommended protocols for tapering. 
All agree that people should never stop taking 
psychiatric drugs abruptly or use a rushed tapering 
schedule.
Schedules should be flexible and the reduction rate 
based on the individual’s withdrawal reactions, 
intensity of reactions, their ability to cope and 
whether there is sufficient support available.1 A 
knowledgeable prescriber will be mindful of such 
factors when supporting a person through tapering. 
People’s experience can vary significantly, with some 
experiencing no withdrawal reactions whilst others 
can experience severe and protracted withdrawal.
Whilst it is beyond the remit of the psychological 
therapist to give specific tapering advice, there 
are some helpful rules of thumb and practical 
considerations with which it is useful to become 
familiar, especially with respect to those who do 
experience severe and protracted withdrawal:
■■ Schedules: there are multiple online resources 
that anyone can consult for information 
on tapering. One such resource distils 
wide experiential knowledge shared by 
individuals with lived experience of tapering 
and withdrawal into clear information about 
tapering schedules. For example, it states that: 
‘...most people most of the time have the 
least-disruptive, least-disabling, and most 
successful outcomes by reducing their 
psychiatric drugs at a rate between 5–10% 
per month, recalculated each month based on 
the most recent, previous month’s dose.’2
Recent research in the Lancet Psychiatry also 
supports the vital need for long tapering for some 
people.3 
■■ Given the need to taper slowly, two years to 
complete withdrawal is not exceptional.4
■■ Tapering strips can help facilitate a successful 
withdrawal. These strips comprise a roll of 
small pouches that each contain a daily dose of 
antidepressant. Each strip contains 28 pouches, 
with the dose in each pouch getting successively 
lower over a 28-day period. In a recent study 
of 895 individuals wishing to discontinue their 
antidepressants, 71% were able to withdraw 
successfully with the use of one to three strips.5 
These are not currently available on the NHS 
but can be ordered by a prescriber from the 
Netherlands. See the resources section for links 
for further information.
■■ Some prescribed psychiatric drugs are available 
in liquid form, which can make reducing dosage 
easier.
■■ It is helpful to also be aware that some 
psychiatric drugs, such as antidepressants, 
may interact with other prescribed medical 
drugs. It would clearly be part of the role of 
the prescriber to decide if any readjustment is 
needed if a client decides to withdraw.6
5.4.2 Clarifying the language of 
withdrawal
In order to support clients who have decided to 
withdraw from psychiatric drugs, it is important to 
become familiar with the language used to describe 
withdrawal. Some of the key terms are:
‘Withdrawal’, ‘withdrawal reaction’ or ‘symptom’ or 
‘discontinuation syndrome’ 
All these terms refer to the various adverse 
reactions that result from reducing or discontinuing 
a drug. While the first three terms are non-
contentious, ‘discontinuation syndrome’ is 
controversial. Its current meaning was first defined 
at the ‘Discontinuation Consensus Panel’ funded 
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by Eli Lilly in 19967 and has been criticised for 
obscuring and minimising withdrawal (perhaps 
for commercial reasons). 8 It is advised that it be 
replaced with one of the less problematic terms 
such as ‘withdrawal reaction’ or ‘withdrawal 
symptom’ or just simply ‘withdrawal’.
‘Relapse’ 
This term refers to the gradual return of the original 
issue, at the same intensity, for which the drug was 
initially taken.9,6
‘Rebound’ 
This refers to one’s pre-drug problems returning 
with greater intensity after the drug is withdrawn 
and is directly linked to withdrawal from the drug.10
‘Recurrence’ 
This term is used to denote a new episode of distress 
(as opposed to the return of the original ‘episode’). 
This new ‘episode’, following withdrawal, may be 
induced by the withdrawal itself.10
‘Persistent postwithdrawal disorder’ 
This refers to the return of the original symptoms 
at greater intensity and/or additional symptoms 
related to a supposed new emerging ‘disorder’, 
which have persisted for at least six weeks after 
drug withdrawal.6,10 This term is controversial, 
however, given that it can be used to ascribe 
wrongly the responsibility for an adverse 
withdrawal reaction to an unspecified, unidentified 
‘disorder’ within the individual – thus medicalising 
a drug-induced reaction.
‘Tolerance withdrawal’ 
Withdrawal reactions can be experienced at any 
stage during the prescription course and not 
just during tapering or after discontinuation. For 
instance, withdrawal reactions can be experienced 
when there is a marked decrease in the drug’s 
effect (which may lead to higher drug doses 
being prescribed to maintain a said effect). This 
experience is termed ‘tolerance withdrawal’ – an 
experience that, if not properly acknowledged, is 
susceptible to being either denied or misdiagnosed 
(e.g. as failure to respond to treatment). 
‘Inter-dose withdrawal’ 
Clients who take their antidepressants or other drugs 
only sporadically, can experience what is known as 
‘inter-dose withdrawal’. This refers to withdrawal 
reactions that are caused by the drug’s effects wearing 
off before the next scheduled dose is taken. Inter-dose 
withdrawal is more likely to be encountered with 
benzodiazepines or drugs with a short half-life (see 5.1). 
In some cases, withdrawal reactions resulting 
from tolerance or inter-dose withdrawal can be 
as disabling as those experienced during and 
after tapering, and so should not be overlooked 
as reasons why a client may start displaying 
debilitating reactions.1 
5.4.3 How withdrawal can be 
misinterpreted or misdiagnosed
When these different types of experience are 
either overlooked or confused, withdrawal can be 
misunderstood or misdiagnosed, with detrimental 
effects for the client.
In 2007, and with respect to antidepressants, 
Haddad and Anderson11 provided an instructive 
list of the various ways in which withdrawal can be 
misdiagnosed:
i. as relapse (i.e. the original problem returning) 
with drugs being reinstated as a consequence. 
For example, as antidepressants are now widely 
prescribed for anxiety-related problems, and 
as increased anxiety is a common withdrawal 
reaction, ignorance of withdrawal reactions 
could have led, in the past, to relapse being 
overestimated when antidepressants were 
withdrawn.12 This could still be leading, in the 
present, to genuine withdrawal being misread 
as relapse with drugs being reinstated.13
ii. as failure to respond to treatment (e.g. 
patients not taking prescribed drugs as directed, 
leading to withdrawal reactions which are then 
mistaken for the condition worsening, leading 
to dose increase or drug switching). 
iii. as a new mental health ‘condition’ such as 
‘bipolar I or II’ (e.g. with ‘manic’ of ‘hypomanic’ 
withdrawal reactions being misdiagnosed as the 
early onset of ‘bipolar’).
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iv. as side effects of a new drug e.g. withdrawal 
reactions can also be experienced when 
‘switching’ between antidepressants. If this is not 
correctly recognised, such reactions are liable to 
being misdiagnosed as side effects of the new 
drug to which the person has now switched.11 
v. as new physiological conditions such as 
‘functional/somatic system disorders’ or 
‘medically unexplained symptoms’.14
While we do not currently possess any clear 
evidence as to how common the misdiagnosis of 
withdrawal by doctors may be, we do know from 
anecdotal reports and qualitative survey data that it 
may be more common than traditionally supposed. 
For this reason, some general rules of thumb have 
been devised to help safeguard against, or identify, 
such misdiagnosis: 
■■ When did the experience arise? One prevailing 
view has been that it is possible to distinguish 
antidepressant withdrawal from relapse as the 
former usually commences within a few days 
of stopping the drugs and resolves quickly 
if the drug is reinstated, whereas relapse is 
uncommon in the first weeks after stopping 
treatment.12,15 While this view on timing makes 
intuitive sense, it has limitations as many 
withdrawal variations are possible, including 
late onset of withdrawal and/or longer 
persistence of disturbances.16 Also, the evidence 
is unclear as to whether relapse is uncommon in 
the first weeks after stopping treatment.
■■ Are emotional and physical reactions occurring 
at the same time? e.g. if unattributed feelings 
of anxiety or depression are present alongside 
physical reactions this increases the likelihood 
of their being related to withdrawal.17,15 
■■ Is there any evidence of other medical 
problems? If physical reactions cannot be 
attributed to other identifiable medical 
problems they may well indicate withdrawal.18 
■■ How does the experience ‘feel’? many people 
say that withdrawal related reactions feel 
qualitatively different to the client’s original 
presenting issue, with some describing 
withdrawal reactions as having a ‘chemical’ feel.18
■■ Fuller lists of commonly experienced withdrawal 
reactions can be found online, a good example 
being that given by the Withdrawal Project2 (see 
resources section).
Guidance on how a psychological therapist 
might ethically consider using this information 
to assist both prescriber and client can be 
found in section 3. As mentioned previously, 
tapering should ideally be performed under 
the supervision of a knowledgeable medical 
professional although the current reality is 
sometimes the right support is not offered 
leaving people to withdraw on their own or 
with the support of online information and 
communities.19
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6.  The role of the therapist in assisting 
withdrawal from psychiatric drugs – 
what do we know about what is helpful?
  Dr Anne Guy, with Dr James Davies, Daniel C. Kolubinski,  
Luke Montagu & Baylissa Frederick
Currently in the UK there are no national dedicated 
services working with dependency and withdrawal 
issues. The services that do exist cover less than 
three percent of the national population (see 3.2 
for further information about these). However, 
psychological therapists are already working with a 
proportion of those who are likely to be dependent 
on such drugs and who have no access to other 
services. For example, a 2018 survey of BPS, BACP 
and UKCP members asked what percentage of their 
clients were taking prescribed psychiatric drugs – it 
showed that: 
■■ 27% said between 25-50% 
■■ 23% said between 50-75% 
■■ 31% said more than 75%.1
Given that all therapists are likely to have already 
found themselves in the position of working with 
a client in withdrawal, therapists may provide 
vital support by acquiring some basic additional 
knowledge. They do not need to be ‘specialists’ in 
order to be helpful. Education and awareness of the 
issues raised in this guidance will allow therapists 
to consider whether, and how, to begin integrating 
issues of prescribed drug dependence within their 
practice.
This guidance aims to empower and support 
conversations often already taking place 
between therapists and their clients. Therapists 
will need to decide for themselves whether, and 
to what extent, they wish to use this guidance 
in the context of their therapeutic work. These 
decisions will depend on their theoretical 
modality, practice setting and the individual 
needs of the client. The client’s agency, as 
always, should be supported and respected 
at all times. Clients should be encouraged to 
discuss withdrawal from prescribed psychiatric 
drugs with a knowledgeable prescriber who 
can give medical advice, oversee and manage 
any withdrawal process appropriately. While 
this guidance advocates the importance 
of informed client choice based on full 
information about potential benefits and risks, 
it does not advocate therapists telling their 
clients to take, not take, stay on or withdraw 
from psychiatric drugs. These matters should 
be left to the prescriber and client to decide.
Therapists are often in the advantageous position 
of having a pre-existing therapeutic relationship 
with an individual. Based on this relationship it is 
possible that therapists can respond to prescribed 
drug issues, including withdrawal, in an integrated 
process.2 There are two distinct aspects to the role 
that psychological therapists can play:
The first is that of helping the client understand 
and manage any causes and effects of emotional 
distress that led them to be prescribed psychiatric 
drugs in the first place.* The second is to support 
the client during drug withdrawal if this becomes 
necessary, when, dependent upon the clients’ 
experience, the first role might need to be largely 
placed on hold. 
*  It is important to note, however, that some people are prescribed such drugs for physical conditions.
December 2019 93
6.1 The combined wisdom approach
Although there is a lack of formal research into the 
effectiveness of therapeutic strategies aimed at 
supporting withdrawal, the theoretical, experiential 
and anecdotal evidence from those working in 
this field nonetheless offers useful suggestions. 
What follows in this section is a summary of the 
combined wisdom from these sources.2–8 
There are five relevant factors that have been found 
to be helpful in supporting people to successfully 
withdraw:
■■ access to accurate information about 
withdrawal and an opportunity to discuss 
it and find answers to any questions before 
withdrawal starts
■■ the involvement of a knowledgeable 
prescriber to devise, help monitor and manage, 
a tapering programme that is tolerable and 
agreeable to the client
■■ access to client-centred, non-authoritarian 
support that empowers client choice and 
enables understanding of withdrawal 
experiences
■■ access to information about and help in 
engaging with useful coping strategies and/or 
supportive lifestyle changes 
■■ awareness of the need to suspend customary 
assumptions about the source of distress 
and associated interventions (i.e. emotional 
processing or analysis) for the duration of 
withdrawal. This obliges both client and 
therapist to judge carefully when to resume 
conventional therapeutic work, ideally after any 
adverse withdrawal effects have abated.
Stages of support
The combined wisdom approach comprises three 
stages. First, the therapist helps the client prepare 
for the onset of withdrawal. Second, the therapist 
offers support during withdrawal. And finally, 
the therapist helps the client to adjust to a new 
‘normal’ once withdrawal has ended. Each of these 
stages will now be considered in turn.
6.1.1 Stage 1: Before withdrawal is 
started – preparation
Preparation is essential to any successful withdrawal, 
and therapists may need to consider with the client 
whether they are ready to take their first reduction. 
Understanding the withdrawal process, alongside 
adopting a stance of non-judgmental acceptance, 
may assist the therapist in engaging the client in a 
discussion about the advantages and disadvantages 
of withdrawal. It also opens up a space where the 
client’s motivations and goals can be discussed.
Before withdrawal begins, 10 areas to consider 
reviewing with the client are:
1. exploring whether a client feels physically and 
emotionally ready to begin the withdrawal process; 
2. exploring who is going to provide medical 
support, and their relationship with their GP or 
other prescriber;
3. signposting and discussing relevant information 
on withdrawal (e.g. the desirability of slow 
tapering: see 5.4.1 and online resources at the 
end of this section);
4. discussing the possibility and general nature of 
withdrawal effects so clients know what to look for; 
5. clarifying the high-level definitions of relapse, 
rebound, recurrence and withdrawal and 
how they might be mistaken (see 5.4.2 for the 
difference between these terms);
6. addressing any potential fears about the 
withdrawal process, including understanding 
what happened during previous attempts or 
concerns about living without psychiatric drugs; 
7. identifying possible ways the attempt might be 
inadvertently sabotaged, either by the client or 
others;
8. identifying potential support networks. Are 
friends, family or others prepared to assist if 
withdrawal becomes either severe or protracted? 
9. discussing the idea of the client using a diary 
or log to keep track of drug reductions and 
experiences (see the resources in Appendix A for 
examples of these);
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10. discussing the availability of extra sessions or 
other contact if needed in between scheduled 
meetings, being clear about the limits of what 
can be provided.2 
It may be useful here again to clearly distinguish 
between medical advice and medical information. 
Whilst it is clear that psychological therapists are 
neither trained to issue medical diagnoses nor to 
prescribe medical or pharmacological treatment, 
they may frequently be asked by clients for medical 
information. Discussing facts, scientific evidence or 
information where appropriate with clients differs 
substantially from offering a diagnosis, prescribing 
drugs or advising withdrawal. It is important to be 
clear about this distinction with clients (see 3.2.5 
for further discussion on this).
6.1.2 Stage 2: During withdrawal – 
support
Therapists are likely to have more regular contact 
with a client than a prescriber – they are therefore 
in a strong position to offer the client ongoing 
support for the withdrawal process.3,8 During 
withdrawal itself, practitioners have identified a 
number of useful ways of supporting clients: 
■■ Helping clients to identify withdrawal reaction 
and offering reassurance that they will pass.6,7 
It is important to assume that any reactions 
that emerge during the transition are due to 
withdrawal unless proven otherwise.3,7 
■■ Encouraging the client to proceed at whatever 
pace is right for them, while continuing to draw 
on relevant information to support the client’s 
decision making.
■■ Suspending any attempt to understand deeper 
psychological material during periods when 
withdrawal reactions are strong, shifting instead 
to providing support.
■■ Helping clients to identify supportive practices, 
which enable them to manage and tolerate 
withdrawal experiences while they last. These 
may include coping strategies – see the list of 
‘coping mechanisms’ below.
■■ Continuing to provide a warm and attentive 
therapeutic relationship, and, if consistent 
with your way of working, facilitate open 
communication between the individual, family 
members, the prescriber and other health 
professionals. 
Frederick7 states that as clients may experience 
intense anxiety and fluctuating levels of physical 
and mental pain during withdrawal, they should 
be encouraged to make sense of their experiences, 
as well as to accept them as normal to the 
process. Reactions can also come and go, and this 
is sometimes referred to as ‘waves’ and ‘windows’, 
where the ‘waves’ of reaction slowly decrease in 
intensity and are interspersed with ‘windows’ of 
no or reduced reactions. Some clients may only 
experience ‘waves’ within ‘waves’. 
It is also important to help manage expectations 
while advocating the use of self-care tools and 
techniques (see below). It is helpful for therapists 
to also be aware that ‘emotional anaesthesia’ – the 
inability to feel pleasure or pain – is a common 
withdrawal effect. If the client therefore feels 
distant from their emotions, any therapeutic work 
may need to take account of this, focusing on 
helping with withdrawal experiences rather than 
attempting to process deeper emotional material. 
Equally, as clients reduce their drugs, feelings can 
come back in sudden and very powerful ways; 
feelings that the client may be learning to cope 
with for the first time without drugs.2 
6.1.2.1 Coping tools for use during withdrawal
The experience of those working with withdrawal 
supports the use of a range of coping tools. As 
withdrawal can sometimes be severe, it might 
be challenging for a client to learn new coping 
strategies during the withdrawal itself. For this reason, 
therapists might consider supporting their clients in 
selecting coping strategies that are both realistic and 
appropriate to clients’ needs and current capacities.7,8 
Such client strategies may include: 
a. Acceptance/non-resistance: maintaining a non-
resisting attitude is one of the most important 
requirements for managing withdrawal. It 
involves clients staying with painful experiences 
as they become aware of them without 
struggling or attempting to stop them.
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b. Mindfulness*: this encompasses a variety of 
practices that help clients get in closer touch 
with the present moment including their 
thoughts, feelings and physical sensations, 
importantly without judgment or resistance.
c. Positive self-support and self-talk*: this 
is a technique often used in CBT to help the 
client influence their mood by developing self-
awareness of how they think about themselves, 
their present and future and where thought 
patterns start to become unhelpfully negative.
d. Breathing exercises*: such as diaphragmatic 
breathing can be generally helpful to clients 
when anxious or panicked.
e. Emotional freedom technique (EFT)*: this 
is an acupressure technique often described 
as ‘psychological acupuncture’ and involves 
tapping particular meridian points on the face, 
body and hands. 
f.  Exercise: (if tolerated and appropriate to the 
client’s level of fitness and capacity – it can 
trigger a ‘wave’ of reactions in some).
g.  Faith: where there is an existing faith or practice 
this can prove helpful for some people – for 
example, some report using prayer as a way of 
achieving a more tranquil and hopeful state.
h. Grounding†: this is a term used to describe a 
strong feeling of connection between mind and 
body, including a sense of being fully present. 
There are various exercises that can promote that 
sense including some mindfulness exercises.
i.  Healthy distractions
j. Hobbies: coping with an intense withdrawal can 
leave some clients with a sense that all normal 
life has been lost, in some cases, irrevocably. 
For many clients it is helpful, when possible, 
to resume elements of a more balanced life, 
appropriate to their capacity and circumstances.
k.  Meditation*: for those with less intense 
withdrawal reactions formal methods of 
meditation can be helpful to experience 
periods of respite.
l.  Self-compassion work*: sometimes linked 
*  Some introductory sources of information for these can be found in the resources section in appendix A. Interested clients or therapists 
will be able to find further information on any of the above tools for themselves and the list is by no means exhaustive – it is intended 
to give an idea of the range of activities that might be of use.
with mindfulness, this includes the idea of 
moving past self-criticism into self-kindness.
m. Sleep: it is important that clients take 
reasonable steps to maximise the probability of 
achieving satisfactory levels of sleep and rest. 
n. Keeping a diary*: this can be used to track 
changes in experiences such as sleep and mood 
as reductions in dosages are made. It could also 
include goal setting for the next day if found to 
be helpful.
o.  Visualisation*: this involves clients focusing on 
an image of what they want and visualising it as 
if it were already there.
p. De-catastrophising*: clients learning to 
recognise when they are thinking about worst 
case scenarios, while also working to bring 
attention back to what is actually happening. 
Once a client has made a number of small reductions 
successfully and has learned what works for them 
in coping with any reactions that arise, some clients 
might choose to withdraw from counselling until 
they are completely off the drugs and can resume or 
review therapeutic work again if needed.2
6.1.3 Stage 3: After withdrawal is 
complete
At the end of withdrawal, therapists may find it useful 
to review the client’s experience and to determine 
with them what further therapeutic needs they have. 
It may be helpful to remember the following points:
■■ If the client has experienced any cognitive problems 
as a part of their withdrawal experience it may take 
a while for confidence in decision making to rebuild 
(including the ability to say ‘no’ to others).
■■ Ensure the clients’ aims and assessment of progress 
are realistic given their experience of withdrawal.
■■ If the clients’ withdrawal was experienced as 
traumatic this might need to be considered in 
any further therapeutic work.9
■■ Post-withdrawal reactions can occur for some 
time after stopping prescribed psychiatric drugs. 
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6.2 Psychiatrist led multidisciplinary models
There are examples in the theoretical and research 
literature of psychiatrist/ prescriber-led models 
to support withdrawal that may be of interest for 
further reading if a therapist has an opportunity 
to suggest this in a multidisciplinary team setting. 
They are most notably:
6.2.1 Breggin’s ‘person-centred 
collaborative approach’ to 
psychiatric care
This model was developed by the US psychiatrist 
Peter Breggin. It is a model for prescribers working 
with patients in psychiatric outpatient settings 
in the US, and is based on the core principles 
of working within an empathic relationship, 
communicating information openly and honestly 
and fostering empowerment and respect for the 
client’s viewpoint, wishes and needs.3
Whilst it can be used in any circumstance in which 
a person might need more support than can be 
provided in a one-to-one relationship (with a 
prescriber or therapist), it is suggested that this 
approach might be of particular use when working 
with ‘vulnerable’ clients, such as:
■■ Adults who are dependent on others such as 
their parents or state authorities
■■ Adults who are seriously disabled, emotionally 
or cognitively
■■ Adults receiving routine psychiatric drugs 
including the elderly
■■ Any individual whose judgment or ability to take 
care of themselves is seriously impaired.3
6.2.2 Fava and Belaise’s (2018) 
three-module approach6 
This model for psychotherapeutic management of 
antidepressant withdrawal was developed in Italy 
by the psychiatrists, Gatti Fava and Guidi Belaise. 
It also advocates collaborative team working (e.g. 
comprising a psychiatrist trained in psychotherapy, 
a physician and clinical psychologists) to support 
the client’s withdrawal from, in this case, 
antidepressants. They used CBT as their core 
therapeutic modality and, as with the common 
wisdom model already described, focused on 
different tasks in preparation for, during and after 
withdrawal.
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6.3 How are UK therapists already working with withdrawal?
Some UK psychological therapists are already 
directly involved in supporting people in 
withdrawal from prescribed psychiatric drugs 
either through working in one of the very few 
dedicated services (which together cover just 
three percent of the population8) or as individual 
therapists working independently. 
6.3.1 In dedicated services
Those working in dedicated services receive 
additional training about withdrawal from 
prescribed psychiatric drugs, including: 
■■ How to help people prepare to withdraw
■■ How to engage and achieve the support of the 
persons’ prescriber 
■■ How to support people during withdrawal 
including offering relevant information, 
signposting helpful coping strategies and 
supporting gradual tapering (although  
plans should always be overseen by a 
prescriber)
■■ How to judge what kinds of therapeutic 
intervention are helpful at each stage of 
withdrawal.
First, it is helpful to recognise that under the 
umbrella of those dependent on prescribed 
psychiatric drugs there are different groups of 
patients. Broadly speaking there are those: 
a. who are currently unaware they might be 
dependent and therefore need to be contacted 
proactively, and
b. those that know they are dependent and need 
support to withdraw through reactive services 
they can self-refer to.
The four existing dedicated services in the UK 
tend to be primarily aligned with one of these two 
groups:
a. Proactive services 
The two small multidisciplinary services which 
currently cater for patients in the first group are 
the:
■– Prescribed Medication Support Service (PMSS) 
covering six counties in North Wales,  
and the
■– Bridge ‘Addiction to Medicines’ Programme 
based in Bradford.
The PMSS
■■ works alongside local GPs and pharmacists 
to identify patients taking painkillers or 
benzodiazepines who are in need of a drug 
review for a variety of reasons e.g. prescribing 
is beyond current guidelines, newly pregnant 
women. Patients can self-refer but not many 
do.
■■ Patients are invited in for a holistic assessment 
of their needs with one of a small number of 
Prescribed Medication Therapists (a nurse/
counsellor hybrid role). 
■■ a plan is developed, usually including a 
personalised drug reducing regime, which is 
then signed off by the GP. 
■■ other appropriate support is drawn from a range 
of services, including a traditional primary care 
counselling service. 
The above model has been recommended, by the 
Welsh Government Petitions Committee,10 as one 
possible model upon which to base the national 
distribution of similar services.
The Bridge in Bradford operates on a similar basis, 
and again focuses on painkillers, benzodiazepines 
and Z-drugs.8
People who are taking antidepressants and 
antipsychotics, and who are prescribed beyond 
guidelines, are not currently proactively contacted 
by either of these services. 
b. Reactive services 
The other two dedicated services offer support 
to people within their vicinity who contact them 
directly for help. They are:
■– the Bristol and District Tranquiliser Project (BTP) 
and 
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■– REST (Mind in Camden), recently taken over by a 
large substance misuse service provider.*  
Both these services are staffed by a small number 
of counsellors trained in supporting withdrawal. 
Given that many people who contact these 
services report having had poor experiences 
with their doctors, meetings are offered in non-
medical settings. However, it remains important 
that prescribers are involved in the withdrawal 
process. Those using services take responsibility 
for contacting their GP and getting their support 
for an agreed tapering plan. If the person is a local 
resident, the service might offer group or one-to-
one counselling, with peer-to-peer support offered 
outside of meetings. 
The above dedicated prescribed drug dependence 
services rely on psychological therapists who have 
some additional knowledge of withdrawal, but 
only two services work directly with doctors. The 
reactive services offer training to local GP surgeries 
on a request basis, but the people using the service 
remain responsible for establishing contact with 
their prescriber. This mirrors the situation generally 
for psychological therapists who either work in 
a multi-disciplinary team, or independently of 
doctors, either in an agency or alone.
6.3.2 In independent practice 
A few therapists working independently with 
prescribed drug dependency and withdrawal 
have acquired substantial experience through 
working with this specific client group. They have 
considerable knowledge of the available literature, 
to which they may even have contributed via 
practice-based research. This knowledge is 
reflected in the ‘combined wisdom’ approach 
outlined in 6.1.
*  It is important to note that whilst there is excellent work being done in substance misuse teams who are often working with people 
dependent on a mixture of prescribed and non-prescribed drugs, the majority of people who are only dependent on prescribed drugs 
understandably do not identify themselves as ‘substance misusers’ – they have taken drugs as prescribed by their doctors and so 
attending a service focused on substance misuse is regarded by them as inappropriate. 
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6.4 Conclusion
Throughout this section it has been emphasised that 
it is not the role of the therapist to decide when drugs 
should be withdrawn, how this may be best achieved 
or what tapering protocols should be deployed. 
However, this does not mean that therapists cannot 
have a critical role to play in supporting the client 
during withdrawal. By using this guidance, therapists 
will be better informed about some of the possible 
variables impacting a client’s potential withdrawal 
experience. They may also be in a better position 
to communicate with other practitioners where 
appropriate (if the client does not wish to do so 
themselves), and to suggest that the client consults 
their prescriber in cases where adverse drug reactions 
arise before, during or after withdrawal.
Finally, if the therapist holds any particular concerns 
regarding how the prescriber may be understanding 
and managing an individual’s withdrawal, it may be 
advisable (again, if the client does not wish to do so 
themselves and with their consent) to communicate 
these formally to the prescriber. The ethical 
therapist, while practising within their own sphere 
of professional competence, will always be thinking 
about the importance of the relationship their client 
has with their prescriber, assessing any ways in which 
that relationship can be supported in service of the 
client’s needs and wants. This has been covered in 
more detail together with ethical considerations, such 
as the importance of ‘informed choice’, in 3.2.5. 
This section reflects the current state of knowledge 
on what is helpful for psychological therapists to 
consider when working with clients withdrawing 
from, or preparing to withdraw from, psychiatric 
drugs. As withdrawal becomes better recognised 
throughout the mental health professions, it is 
hoped that appropriate and directed research will 
further add to this knowledge.
This guidance aims to empower and support 
conversations often already taking place 
between therapists and their clients. Therapists 
will need to decide for themselves whether, and 
to what extent, they wish to use this guidance 
in the context of their therapeutic work. These 
decisions will depend on their theoretical 
modality, practice setting and the individual 
needs of the client. The client’s agency, as 
always, should be supported and respected 
at all times. Clients should be encouraged to 
discuss withdrawal from prescribed psychiatric 
drugs with a knowledgeable prescriber who 
can give medical advice, oversee and manage 
any withdrawal process appropriately. While 
this guidance advocates the importance 
of informed client choice based on full 
information about potential benefits and risks, 
it does not advocate therapists telling their 
clients to take, not take, stay on or withdraw 
from psychiatric drugs. These matters should 
be left to the prescriber and client to decide.
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7. Patient voices – examples from real life 
 Dr Anne Guy (Ed.) 
The stories that follow have been offered by 
volunteers with the intention of helping therapists 
understand some possible experiences some 
people may have when taking or withdrawing 
from psychiatric drugs. These experiences are 
not presented as being representative, they are 
rather offered as examples that may illuminate 
some of the complexities involved. The people 
here are described as ‘patients’ as their stories are 
primarily about the impact of the drugs they were 
prescribed. Suggestions for further reading are 
provided at the end of the section.
Sarah’s story
I took an SSRI antidepressant for 17 years. The 
reasons I ended up staying on the drug for that long 
are threefold:
a. I was lied to and told I had a chemical imbalance 
in my brain, so, until I investigated and 
challenged this ‘diagnosis’, I believed I needed 
the drug.
b. Whenever I tried to stop taking it and went into 
withdrawal, I was told that the drug was not 
addictive so my symptoms were an indication of 
the extent of my illness.
c. The only place to get advice on tapering was 
from the internet. This was sporadic and 
inaccurate and so my tapering efforts constantly 
failed.
The withdrawal symptoms I experienced were, 
in the early days: nausea, vertigo, IBS, weight 
loss, muscle tension, brain zaps, palpitations and 
insomnia. Each time I tried to come off the drug by 
tapering more and more slowly, those withdrawal 
effects got stronger as key bodily systems were 
affected by the absence of the drug. 
As time went on my nervous system became more 
and more hyper vigilant as I felt unsafe, finding 
danger everywhere. I developed a number of phobic 
reactions to external and internal stimuli – e.g. a 
hot flush would be followed by a wave of fear. Each 
attempt at withdrawing sent me into a state of 
shock, in effect, to the point where I developed a 
movement disorder and symptoms of trauma. When 
I finally completely stopped the drug, it took four 
years for the majority of the symptoms to subside.
Peter’s story
I had a decade of mixing and matching anti-
psychotic, antidepressant and mood stabilising 
medications from my late teens to late twenties. 
During my early twenties the consultant 
psychiatrist I saw regularly had prescribed Largactil 
[editor’s note: an antipsychotic], he then withdrew 
it in favour of another medication when I said it 
wasn’t effective.
Firstly, I would say that the advice around 
withdrawing was sparse and effects that I might 
encounter never discussed. What ensued was a 
couple of weeks that I can only describe as ‘scary’ 
that saw me become extremely paranoid, have 
visual hallucinations and physical sensations.
My paranoia was based around the fact I was 
relaying information back to my consultant and on 
one occasion to an on-call duty psychiatrist that my 
wife had called because she was so worried. The 
information I relayed was dismissed as me ‘lying’ 
‘exaggerating’ and ‘making it up’.
I was explaining that in my peripheral vision I could 
see a dark figure and it seemed to be following 
me everywhere I was going, during this time I was 
experiencing repeated and extreme panic attacks. 
I was also getting repeated sensations in my brain, 
from temple to temple that I can only describe as 
electric shocks, these were extremely frightening, 
and I was convinced I was going to die.
My trust in the doctor and his profession was shaken 
at a time that I was very unwell, this eventually led to 
me taking a non-medication approach to my mental 
health, something that has proved successful as I 
look back on a decade of wellness but something my 
consultant did not support.
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Molly’s story
I was under the care of a psychiatrist in the 
community mental health team. I was taking a 
combination of Mirtazapine [editor’s note: an 
antidepressant] and Trazodone [editor’s note: 
an antidepressant which is also a sedative] with 
Zopiclone [editor’s note: a ‘Z’-drug, similar to a 
benzodiazepine, induces sleep] when I became 
tired of the side effects while the psychiatrist was 
on holiday and chose to stop taking the first two. 
Within a couple of days, I had started to become 
increasingly ‘up’ and became hypomanic nudging 
into mania with symptoms of psychosis two 
days later. I became convinced my psychiatrist 
and the mental health team were conspiring to 
have me sectioned and managed to persuade 
my psychiatrist to discharge me although I was 
exhibiting pressured speech. 
My therapist, who was separate from the mental 
health team but was funded by the CCG, was 
someone I confided in and who tried to get support 
from my psychiatrist by calling him directly. When 
we discussed it afterwards, he said he found the 
lack of support difficult to handle as he watched 
me spiraling out of control. 
In the end I ran away to Paris and ‘snapped out’ 
of the episode after putting my safety at risk 
several times. The therapist had to manage the 
repercussions in terms of the impact on my mental 
health but also rebuilding my trust in medication, 
which I was cautious about taking with a fear of 
withdrawal if I ever had to stop. 
Angela’s story
In 2015 I was advised by my GP to try 10mg 
of Nortriptyline [editor’s note: a tricyclic 
antidepressant] to see if it helped reduce the 
frequency of my migraines. It didn’t help so after 
three months I wanted to wean off and asked 
my GP for it in liquid form so that I could do it 
gradually. 
My GP refused saying the liquid was only licensed 
for elderly patients and suggested I cut the 10mg 
tablet in half for a week, then into quarters for a 
week, then a quarter every other day for a week 
and stop. I did this regime however when I stopped 
my nervous system went into chaos. 
I felt extremely anxious, depressed, angry and 
irrational and couldn’t eat or sleep. I went back to 
my GP and asked whether this was a reaction to 
stopping the medicine, but he said not on the low 
dose you were on! He suggested that I was having a 
relapse into an anxious state as I have had a history 
of anxiety due to PTSD although never to this 
extent before! 
He gave me 14 days prescription of 3.75mg 
Zopiclone sleeping tablet without warning about 
how addictive they were if used for more than a few 
nights at a time! After two weeks I hadn’t improved 
and was given another 14 days prescription of 
Zopiclone. By week four I had reached tolerance 
and needed to double the dose to sleep. The 
following day I had a bad reaction to the drug and 
my body became numb all over and I was having 
continuous, uncontrollable body jerking and finally 
I collapsed, and the paramedics were called. 
It was only then that I googled Zopiclone and read 
the many articles warning about the high risk 
of dependency and the department of health’s 
warning to all GPs that Zopiclone and other 
Benzos should not be taken for more than two 
weeks! To cut a long story short, I received no 
help or sympathy from my GP and had to plan 
my own escape from the hell I found myself in. 
The only help I could find was the Bristol drug 
project helpline and the one in Camden. I used 
the Ashton manual and tried reducing 10% of 
Zopiclone but the withdrawal symptoms were so 
bad that I couldn’t get out of bed. The helplines 
and the Ashton manual recommended swapping to 
Valium, which has a longer half-life, compared with 
Zopiclone’s very short half-life and would be easier 
to wean off. I made the swap and started weaning 
off at 10% every two weeks but still had horrendous 
withdrawal symptoms, I became housebound 
and couldn’t work or drive for five months due to 
shaking most of the time. It was the worst time of 
my life and has taken me a couple of years to get 
my life back on track.
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Majid’s story
I have been a service user and carer for over 15 
years. Initially my diagnoses was depression and 
anxiety and I was treated with venlafaxine [editor’s 
note: an SNRI antidepressant]. 
Over the years my illness was then changed to 
personality disorder with severe depression. Over 
10 years I have never seen the same consultant 
twice, therefore, no one knew how I was doing.  
The side effects made me deteriorate with little 
sleep. I would be mentally exhausted and sleep 
on benches in the park or on settees when visiting 
family. I was soon banned going to houses due 
to me not looking after myself and sleeping 
everywhere.
The medications made me put on weight and I 
was outgrowing my clothes. I can remember that I 
found walking up three steps a struggle and would 
be out of breath. I would often feel dizzy and faint, 
(and thought this was normal). Yet I was told by the 
team to carry on taking the medicines.
I took venlafaxine for 10 years and tried to come 
off them twice but was advised to stay on them 
by a locum psychiatrist and a support worker. The 
medicine in the long-run made me more alert and 
I would often be awake till 5am in the morning, 
which ruined my relationship with my family.
When I eventually saw a psychologist, she told me 
that I needed ‘tweaking up’ and would attend my 
psychiatric appointment. The problem was identified 
that I would say I am fine (because we were told in 
group therapy to be positive and I had no insight into 
my illness – 10 years made it a normality). 
My psychologist argued my case, but the 
psychiatrist was saying that I was not taking my 
medication! (Not true and this was the first time 
he saw me but looked at history notes) that is why 
I was behaving manic. After another appointment 
with the psychiatrist and psychologist he changed 
my tablets to mirtazapine. I had no tapering of the 
other drug just a straight swap and had to endure 
sweating sleeplessness, panic attacks, anxiety 
attacks, paranoia and I could not trust anyone in 
my family.
I was later told the side effects of venlafaxine had 
made me manic. I am now on a different medication 
but still have issues with people and have flashbacks 
of how I was. I am more relaxed with this medication 
but would like to come off them so I can concentrate 
and do more things, because the medications make 
me tired and forgetful. Since I am calm, the family is 
calm and not alert.
Medicines are dangerous if not checked upon and 
can make you do stupid things which you have no 
control over. Venlafaxine was making me suicidal. 
Thank Allah I am off them and in more control of 
my life. Due to this I have lost my benefits and had 
housing eviction letters because I was not filling in 
the forms on time (poor concentration/sleep).
I am now diagnosed with general anxiety and 
depression. Not personality disorder or Bipolar 
which they were thinking of labelling me. It’s 
amazing what medicines can do to you.
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Suggestions for further reading
i.  International survey into withdrawal from 
psychiatric drugs1 
In Sep 2017 the All-Party Parliamentary Group 
for Prescribed Drug Dependence, in conjunction 
with researchers at the University of Roehampton, 
undertook one of the largest direct-to-consumer 
international surveys of its kind into withdrawal 
from psychiatric drugs (antidepressants, 
antipsychotics and benzodiazepines). There were 
approximately 1,700 respondents, 319 of whom 
were taking antidepressants living in the UK. 
This report summarises both the quantitative 
and qualitative data on those in the UK taking 
antidepressants (319) who reported their 
withdrawal experience.
ii. Petition submissions – Scotland & Wales
One hundred and fifty-eight personal accounts of 
people impacted by prescribed drug dependence 
and withdrawal (specifically for antidepressants 
and benzodiazepines) were submitted in response 
to two petitions lodged with parliamentary 
Petitions Committees in Scotland2 and Wales3 in 
2017. These submissions have also been analysed 
and summarised in a report.4
References
1. Davies, J., Pauli, R. & Montagu, L. (2018). Antidepressant 
withdrawal: A survey of patients’ experience (an APPG for PDD 
Report).
2.  Scottish Petition PE01651 http://www.parliament.scot/
GettingInvolved/Petitions/PE01651. 
3.  Welsh Petition reference P-05-784 http://www.senedd.
assembly.wales/ieIssueDetails.aspx?IId=19952&Opt=3. 
4.  Guy, A., Brown, M. & Lewis, S. (2018). The patient voice: An 
analysis of personal accounts of prescribed drug dependence 
and withdrawal submitted to petitions in Scotland and Wales 
(an APPG for PDD Report).
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Appendix A – Resources 
Withdrawal Support Sites
The Ashton Manual  
Research information and protocol for the 
treatment of withdrawal 
benzo.org.uk/manual/
Battle Against Tranquilisers 
Support for withdrawal from benzodiazepines, 




Online support for benzodiazepine withdrawal 
benzobuddies.org
Benzo.org 
Articles, information, expert medical documents, 
news stories and personal accounts on 
benzodiazepine withdrawal 
benzo.org.uk
Bloom in Wellness 
Free info or membership at nominal monthly fee for 
benzodiazepine and anti-depressant withdrawal 
baylissa.com
British Psychological Society 
Understanding psychosis and schizophrenia 
https://www.bps.org.uk/what-psychology/
understanding-psychosis-and-schizophrenia
Coming Off Psych Drugs: A Meeting of Minds 
A film by Daniel Mackler 
bit.ly/1UcVqNh
The Council for Evidence Based Psychiatry 
Providing evidence of the potentially harmful 
effects of psychiatric drugs to the people and 
institutions in the UK that can make a difference 
cepuk.org
Icarus Project and Freedom Centre 





Lehmann, P. (Ed), (2004). Coming off psychiatric 
drugs: Successful withdrawal from neuroleptics, 
antidepressants, lithium, carbamazepine and 
tranquilizers. Berlin: Peter Lehmann Publishing. 
Mad in America 








Information on coming off of antidepressants 
nhs.uk/conditions/antidepressants/dosage/
Nice Guidelines  
British National Formulary – Guidance, advice and 
information for health, public health and social 





Antidepressant and benzodiazepine withdrawal 
support 
http://www.recovery-road.org
Royal College of Psychiatrists 




This is owned and operated by Data Based 
Medicine Americas Ltd. (DBM), based in Toronto, 
Canada. It is run by a group of high-profile medical 
experts with international reputations in early 
drug-side-effect detection and risk mitigation, 
pharmacovigilance, and patient-centered care. 





Online forum providing peer support for tapering 
and withdrawal syndrome 
survivingantidepressants.org/
The Withdrawal Project 
Support for tapering off psychiatric medication 
withdrawal.theinnercompass.org
Tapering strips
For general information about tapering strips and 
how then can be legally ordered from the UK see: 
http://www.taperingstrip.org




Dedicated services currently 
offering support in the UK
Bristol & District Tranquiliser Project 
Support for withdrawal from tranquilisers and 
antidepressants 
btpinfo.org.uk
The Bridge Project, Bradford: New Directions 
‘Addiction to Medicines’ service (painkillers, 
benzodiazepines and Z-drugs) 
https://thebridgeproject.org.uk
The Prescribed Medication Support Service 




NHS (2012). Liberating the NHS: No decision about 





Coping tools for use during 
withdrawal – introductory links
The Withdrawal Project 









Anthony, Wen & Howard, Matthew & Garland, 
Eric & McGovern, Tricia & Lazar, Michael. (2017). 
Mindfulness treatment for substance misuse: A 
systematic review and meta-analysis. Journal 
of Substance Abuse Treatment, 75. 10.1016/j.
jsat.2017.01.008.




NHS (2018). Guide to mindfulness. Available online: 
https://www.nhs.uk/conditions/stress-anxiety-
depression/mindfulness/
Positive self-support and self-talk
Battles, M. (2019). Self talk determines your success. 
Available online:  
https://www.lifehack.org/504756/self-talk-
determines-your-success-15-tips




Scott, E. (2019). Reduce stress and improve your life 
with positive self talk. Available online: 
https://www.verywellmind.com/how-to-use-
positive-self-talk-for-stress-relief-3144816





Boyes, A. (2016). Breathing techniques for anxiety. 
Psychology Today. Available online: 
https://www.psychologytoday.com/us/blog/in-
practice/201607/breathing-techniques-anxiety 
Human Givens Institute (2012). 7–11 breathing: 
How does deep breathing make you feel more 
relaxed? Available online: https://www.hgi.org.uk/
resources/delve-our-extensive-library/resources-
and-techniques/7-11-breathing-how-does-deep 
Emotional freedom technique (EFT) aka 
“tapping”
It’s suggested that this is ideally learned from an 
EFT practitioner, although there are some You Tube 
videos from its founder, Gary Craig, which describe 
its use e.g. EFT Intro  
https://www.youtube.com/watch?v=5r4kVp1yf5E
Grounding
Get self help (2018). Grounding techniques for 
coping with flashbacks and distress. Available 
online: https://www.getselfhelp.co.uk/flashbacks.
htm
Taibbi, R. (2019). Upset? 10 grounding techniques 
first-aid for when you feel stressed, angry, 




Villines, Z. (2017). What is the best type of 




Inner Compass, Guided Meditation Resources, 
Available online: https://withdrawal.
theinnercompass.org/coping/guided-meditation





Good Therapy, Self-compassion, Available online: 
https://www.goodtherapy.org/learn-about-
therapy/issues/self-compassion
Neff, K. & Germer, C. (2018). The mindful self-
compassion workbook. Guilford Press, New York.
Keeping a diary
Mind (2013). ‘Self-care for anxiety’ encourages 




Scott, E. (2019). A ‘how to’ guide on keeping a diary. 
Available online:  
https://www.verywellmind.com/journaling-a-great-
tool-for-coping-with-anxiety-3144672
Bipolar UK, Mood Diary (a template for tracking 
medications and feelings). Available online:  
https://www.bipolaruk.org/FAQs/mood-diary
Visualisation
Okhai, F. (2003). The power of deep relaxation and 






Beck, A.T. (1985). Anxiety disorders & phobias. NY: 
Harper & Row





Drug classes and their uses – summary table
Drug class Subtypes Examples Common uses




Depression, anxiety disorders, 
obsessive compulsive disorder, 
post-traumatic stress disorder, 
bulimia nervosa
■■ SNRIs ■■ Venlafaxine
■■ Duloxetine
Depression, anxiety disorders
■■ Other ■■ Mirtazapine Depression
■■ Tricyclic antidepressants ■■ Amitriptyline
■■ Lofepramine
Depression, chronic pain 
(amitriptyline)





Psychotic disorders, acute 
mania, sedation








■■ Benzodiazepines ■■ Diazepam
■■ Lorazepam 
■■ Chlordiazepoxide
Anxiety, sedation, alcohol 
withdrawal




■■ Pregabalin and 
gabapentin
Anxiety, chronic pain
Mood stabilisers ■■ Lithium Bipolar affective disorder
■■ Drugs used in epilepsy ■■ Sodium valproate
■■ Carbamazapine 
■■ Lamotrigine
Bipolar affective disorder, 
epilepsy
■■ Some antipsychotics ■■ Olanzapine Bipolar affective disorder
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